{
  "symbol": "PRPO",
  "company_name": "Precipio Inc",
  "ir_website": "https://www.precipiodx.com/investors/",
  "structured_data": [
    {
      "section_name": "Press Releases",
      "links": [
        {
          "title": "Press Releases",
          "url": "https://www.precipiodx.com/investors/press-releases/",
          "content": "[Skip to content](#main)\n\n[ ![Precipio](https://www.precipiodx.com/wp-content/uploads/2022/07/logo.png) ![Precipio](https://www.precipiodx.com/wp-content/uploads/2022/07/logo.png) ](https://www.precipiodx.com/ \"Precipio - Expect More from the start.\")\n\n  * [ ](#)\n\n\n\n\n  * [About Us](https://www.precipiodx.com/about/)\n    * [Our Culture](https://www.precipiodx.com/about/culture/)\n    * [News](https://www.precipiodx.com/about/news/)\n    * [Careers](https://www.precipiodx.com/about/careers/)\n    * [Scientific Advisors](https://www.precipiodx.com/about/scientific-advisors/)\n    * [Management Team](https://www.precipiodx.com/about/management-team/)\n    * [Board of Directors](https://www.precipiodx.com/about/board-of-directors/)\n  * [Products](https://www.precipiodx.com/products/)\n    * [Molecular Kits](https://www.precipiodx.com/products/molecular-kits/)\n      * [MPN Panel](https://www.precipiodx.com/products/bloodhound-mpn-panel/)\n      * [BCR-ABL1 Panel](https://www.precipiodx.com/products/bloodhound-bcr-abl1-molecular-panel/)\n      * [ABL1 Resistance Panel](https://www.precipiodx.com/products/bloodhound-abl1-resistance-panel/)\n      * [AML Panel](https://www.precipiodx.com/products/molecular-kits/acute-myeloid-leukemia-panel/)\n      * [CLL Panel](https://www.precipiodx.com/products/molecular-kits/cll-panel/)\n      * [Cytopenia Panel](https://www.precipiodx.com/products/molecular-kits/cytopenia-panel/)\n    * [IV-Cell Cytogenetics Media](https://www.precipiodx.com/products/iv-cell-cytogenetics-media/)\n  * [Clinical Services](https://www.precipiodx.com/clinical-services/)\n    * [Hematopathology Services](https://www.precipiodx.com/clinical-services/blood-cancer-testing/)\n    * [Sample Reports](https://www.precipiodx.com/sample-report/)\n    * [Proprietary Technologies](https://www.precipiodx.com/clinical-services/proprietary-technologies/)\n    * [Meet Our Hematopathologists](https://www.precipiodx.com/clinical-services/meet-our-pathologists/)\n  * [Resources](https://www.precipiodx.com/resources/)\n    * [FAQs](https://www.precipiodx.com/resources/faqs/)\n    * [Brochures](https://www.precipiodx.com/resources/brochures/)\n    * [Case Studies](https://www.precipiodx.com/resources/case-studies/)\n    * [Sample Reports](https://www.precipiodx.com/sample-report/)\n    * [Instructions For Use](https://www.precipiodx.com/resources/ifus/)\n    * [Instructions For Use – Non U.S. CE](https://www.precipiodx.com/resources/instructions-for-use-non-us-ce/)\n  * [Investors](https://www.precipiodx.com/investors/)\n    * [Press Releases](https://www.precipiodx.com/investors/press-releases/)\n    * [Media](https://www.precipiodx.com/investors/media/)\n    * [SEC Filings](https://www.precipiodx.com/investors/sec-filings/)\n    * [Subscription](https://www.precipiodx.com/investors/subscription/)\n    * [Investor FAQs](https://www.precipiodx.com/investors/investor-faqs/)\n    * [Corporate Governance](https://www.precipiodx.com/investors/corporate-governance/)\n    * [Business Update Calls](https://www.precipiodx.com/investors/business-update-calls/)\n  * [Contact](https://www.precipiodx.com/contact/)\n  * [My Account](https://www.precipiodx.com/login/)\n    * [![Login Icon](https://www.precipiodx.com/wp-content/uploads/2022/07/login-svgrepo-com.svg)CaseVu](https://www.casevu-lis.precipiodx.com/)\n    * [![Login Icon](https://www.precipiodx.com/wp-content/uploads/2022/07/login-svgrepo-com.svg)Shop](https://www.precipiodx.com/my-account/)\n    * [![Login Icon](https://www.precipiodx.com/wp-content/uploads/2022/07/login-svgrepo-com.svg)Patient Bill Pay](https://www.precipiodx.com/billing/)\n  * [ $0.00 **0** ](https://www.precipiodx.com/cart/ \"Cart\")\n\nCart\n\n  * [](#)\n    * Search for:\n\n\n\n\n  * [ **0** ](https://www.precipiodx.com/cart/ \"Cart\")\n\n\n\n# Press Releases\n\n[ ![Precipio Press Release](https://www.precipiodx.com/wp-content/uploads/2022/08/PressRelease-300x158.png) ](https://www.precipiodx.com/precipio-announces-q3-2024-shareholder-update-call/)\n\n#####  [Precipio Announces Q3-2024 Shareholder Update Call](https://www.precipiodx.com/precipio-announces-q3-2024-shareholder-update-call/)\n\nNovember 6, 2024\n\nConference Call to be held on November 18, 2024, at 5:00 PM EST NEW HAVEN, CT, (November 6, 2024) – Specialty cancer diagnostics company Precipio, Inc. (NASDAQ: PRPO), [...] \n\n[ Read More ](https://www.precipiodx.com/precipio-announces-q3-2024-shareholder-update-call/)\n\n[ ![Precipio Press Release](https://www.precipiodx.com/wp-content/uploads/2022/08/PressRelease-300x158.png) ](https://www.precipiodx.com/precipio-expands-bloodhound-mpn-panel-by-adding-calr-mutation-subtyping/)\n\n#####  [Precipio Expands Bloodhound™ MPN Panel by Adding CALR Mutation Subtyping](https://www.precipiodx.com/precipio-expands-bloodhound-mpn-panel-by-adding-calr-mutation-subtyping/)\n\nOctober 8, 2024\n\nThe unique assay enables laboratories to provide clinicians with more informed treatment decisions for their patients NEW HAVEN, CT, (October 8th, 2024) – Specialty cancer diagnostics [...] \n\n[ Read More ](https://www.precipiodx.com/precipio-expands-bloodhound-mpn-panel-by-adding-calr-mutation-subtyping/)\n\n[ ![Precipio Press Release](https://www.precipiodx.com/wp-content/uploads/2022/08/PressRelease-300x158.png) ](https://www.precipiodx.com/precipio-announces-employee-stock-option-plan-repricing/)\n\n#####  [Precipio Announces Employee Stock Option Plan Repricing](https://www.precipiodx.com/precipio-announces-employee-stock-option-plan-repricing/)\n\nSeptember 6, 2024\n\nManagement lays out rationale and impact to shareholders below NEW HAVEN, CT, (September 6th, 2024) – Specialty cancer diagnostics company Precipio, Inc. (NASDAQ: PRPO) announces the Company’s repricing [...] \n\n[ Read More ](https://www.precipiodx.com/precipio-announces-employee-stock-option-plan-repricing/)\n\n[ ![Precipio Press Release](https://www.precipiodx.com/wp-content/uploads/2022/08/PressRelease-300x158.png) ](https://www.precipiodx.com/precipio-announces-q2-2024-shareholder-update-call/)\n\n#####  [Precipio Announces Q2-2024 Shareholder Update Call](https://www.precipiodx.com/precipio-announces-q2-2024-shareholder-update-call/)\n\nAugust 15, 2024\n\nConference Call to be held on August 19, 2024 at 5:00 PM EST NEW HAVEN, CT, (August 15, 2024) – Specialty cancer diagnostics company Precipio, Inc. (NASDAQ: PRPO), [...] \n\n[ Read More ](https://www.precipiodx.com/precipio-announces-q2-2024-shareholder-update-call/)\n\n[ ![Precipio Press Release](https://www.precipiodx.com/wp-content/uploads/2022/08/PressRelease-300x158.png) ](https://www.precipiodx.com/precipio-reports-0-3m-cash-generated-by-operations-unaudited-in-q2-2024-as-the-company-advances-towards-breakeven/)\n\n#####  [Precipio Reports $0.3M cash generated by operations (unaudited) in Q2-2024, as the company advances towards breakeven](https://www.precipiodx.com/precipio-reports-0-3m-cash-generated-by-operations-unaudited-in-q2-2024-as-the-company-advances-towards-breakeven/)\n\nJuly 25, 2024\n\nCompany’s continued growth and improved cash position alleviates the need for capital raise in the foreseeable future NEW HAVEN, CT, Globenewswire – (July 25, 2024) – [...] \n\n[ Read More ](https://www.precipiodx.com/precipio-reports-0-3m-cash-generated-by-operations-unaudited-in-q2-2024-as-the-company-advances-towards-breakeven/)\n\n[ ![Precipio Press Release](https://www.precipiodx.com/wp-content/uploads/2022/08/PressRelease-300x158.png) ](https://www.precipiodx.com/precipio-reports-4-4m-for-q2-2024-unaudited-revenues-a-leap-of-30-from-q1-2024/)\n\n#####  [Precipio Reports $4.4M for Q2-2024 (unaudited) Revenues, a leap of 30% from Q1-2024](https://www.precipiodx.com/precipio-reports-4-4m-for-q2-2024-unaudited-revenues-a-leap-of-30-from-q1-2024/)\n\nJuly 17, 2024\n\nPathology Revenues in June exceed breakeven target and continue growth trend NEW HAVEN, CT, Globenewswire – (July 17, 2024) – Specialty cancer diagnostics company Precipio, Inc. [...] \n\n[ Read More ](https://www.precipiodx.com/precipio-reports-4-4m-for-q2-2024-unaudited-revenues-a-leap-of-30-from-q1-2024/)\n\n[ ![Precipio Press Release](https://www.precipiodx.com/wp-content/uploads/2022/08/PressRelease-300x158.png) ](https://www.precipiodx.com/precipio-inc-announces-adjournment-of-annual-meeting-of-stockholders/)\n\n#####  [Precipio, Inc. Announces Adjournment of Annual Meeting of Stockholders](https://www.precipiodx.com/precipio-inc-announces-adjournment-of-annual-meeting-of-stockholders/)\n\nJune 13, 2024\n\nNew Shareholders Meeting Date: Friday, June 21 at 9 a.m. Eastern Time. NEW HAVEN, CT, (June 13, 2024) Specialty diagnostics company Precipio, Inc. (NASDAQ: PRPO), today [...] \n\n[ Read More ](https://www.precipiodx.com/precipio-inc-announces-adjournment-of-annual-meeting-of-stockholders/)\n\n[ ![Precipio Press Release](https://www.precipiodx.com/wp-content/uploads/2022/08/PressRelease-300x158.png) ](https://www.precipiodx.com/precipio-is-requesting-shareholders-brokers-vote-today-to-avoid-costly-adjournment-and-rescheduling-of-annual-shareholders-meeting/)\n\n#####  [Precipio is requesting Shareholders/Brokers vote today to avoid costly adjournment and rescheduling of Annual Shareholders Meeting](https://www.precipiodx.com/precipio-is-requesting-shareholders-brokers-vote-today-to-avoid-costly-adjournment-and-rescheduling-of-annual-shareholders-meeting/)\n\nJune 12, 2024\n\nThe cost of a rescheduled shareholder meeting could reach $100,000 NEW HAVEN, CT, (June 12th, 2024) – Management of specialty cancer diagnostics company Precipio, Inc. (NASDAQ: PRPO) is [...] \n\n[ Read More ](https://www.precipiodx.com/precipio-is-requesting-shareholders-brokers-vote-today-to-avoid-costly-adjournment-and-rescheduling-of-annual-shareholders-meeting/)\n\n[ ![Precipio Press Release](https://www.precipiodx.com/wp-content/uploads/2022/08/PressRelease-300x158.png) ](https://www.precipiodx.com/precipio-provides-status-update-on-current-business-matters/)\n\n#####  [Precipio Provides Status Update on Current Business Matters](https://www.precipiodx.com/precipio-provides-status-update-on-current-business-matters/)\n\nJune 12, 2024\n\nNEW HAVEN, CT, (June 12th, 2024) – Management of specialty cancer diagnostics company Precipio, Inc. (NASDAQ: PRPO) provides the following update to its shareholders on various business matters [...] \n\n[ Read More ](https://www.precipiodx.com/precipio-provides-status-update-on-current-business-matters/)\n\n[ ![Precipio Press Release](https://www.precipiodx.com/wp-content/uploads/2022/08/PressRelease-300x158.png) ](https://www.precipiodx.com/precipio-secures-a-short-term-500k-credit-facility/)\n\n#####  [Precipio Secures a short-term $500K Credit Facility](https://www.precipiodx.com/precipio-secures-a-short-term-500k-credit-facility/)\n\nMay 6, 2024\n\nLoan will supplement any temporary cashflow deficit related to cash collections delay due to Change Healthcare cybersecurity attack NEW HAVEN, CT, (May 6th, 2024) – Specialty [...] \n\n[ Read More ](https://www.precipiodx.com/precipio-secures-a-short-term-500k-credit-facility/)\n\n[ ![Precipio Press Release](https://www.precipiodx.com/wp-content/uploads/2022/08/PressRelease-300x158.png) ](https://www.precipiodx.com/precipio-announces-year-end-2023-shareholder-update-call/)\n\n#####  [Precipio Announces Year end 2023 Shareholder Update Call](https://www.precipiodx.com/precipio-announces-year-end-2023-shareholder-update-call/)\n\nMarch 25, 2024\n\nConference Call to be held on April 1st, 2024 at 5:00 PM EST NEW HAVEN, CT, (March 25th, 2024) – Specialty cancer diagnostics company Precipio, Inc. (NASDAQ: PRPO), [...] \n\n[ Read More ](https://www.precipiodx.com/precipio-announces-year-end-2023-shareholder-update-call/)\n\n[ ![Precipio Press Release](https://www.precipiodx.com/wp-content/uploads/2022/08/PressRelease-300x158.png) ](https://www.precipiodx.com/precipio-to-report-15-2m-for-fy-2023-unaudited-revenues-an-increase-of-60-yoy/)\n\n#####  [Precipio to Report $15.2M for FY-2023 (unaudited) Revenues, an increase of 60% YoY](https://www.precipiodx.com/precipio-to-report-15-2m-for-fy-2023-unaudited-revenues-an-increase-of-60-yoy/)\n\nFebruary 13, 2024\n\nCompany continues to make strides towards breakeven NEW HAVEN, CT, Globenewswire – (February 13, 2024) – Specialty cancer diagnostics company Precipio, Inc. (NASDAQ: PRPO), announces that [...] \n\n[ Read More ](https://www.precipiodx.com/precipio-to-report-15-2m-for-fy-2023-unaudited-revenues-an-increase-of-60-yoy/)\n\n[ ![Precipio Press Release](https://www.precipiodx.com/wp-content/uploads/2022/08/PressRelease-300x158.png) ](https://www.precipiodx.com/precipio-and-cardinal-health-sign-distribution-agreement-for-its-hemescreen-portfolio-of-molecular-assays-for-cancer/)\n\n#####  [Precipio and Cardinal Health Sign Distribution Agreement for its HemeScreen® Portfolio of Molecular assays for Cancer](https://www.precipiodx.com/precipio-and-cardinal-health-sign-distribution-agreement-for-its-hemescreen-portfolio-of-molecular-assays-for-cancer/)\n\nFebruary 6, 2024\n\nNEW HAVEN, CT, Globenewswire – (February 6, 2024) – Specialty cancer diagnostics company Precipio, Inc. (NASDAQ: PRPO) announces it has entered into a distribution agreement with [...] \n\n[ Read More ](https://www.precipiodx.com/precipio-and-cardinal-health-sign-distribution-agreement-for-its-hemescreen-portfolio-of-molecular-assays-for-cancer/)\n\n[ ![Precipio Press Release](https://www.precipiodx.com/wp-content/uploads/2022/08/PressRelease-300x158.png) ](https://www.precipiodx.com/precipios-q4-2023-cash-burn-from-operations-unaudited-drops-below-100k-for-the-full-quarter/)\n\n#####  [Precipio’s Q4-2023 Cash Burn From Operations (unaudited) drops below $100K for the full quarter](https://www.precipiodx.com/precipios-q4-2023-cash-burn-from-operations-unaudited-drops-below-100k-for-the-full-quarter/)\n\nJanuary 23, 2024\n\nResults clearly demonstrate the business’s ability to reach breakeven in the near future NEW HAVEN, CT, Globenewswire – (January 23, 2024) – Specialty cancer diagnostics company [...] \n\n[ Read More ](https://www.precipiodx.com/precipios-q4-2023-cash-burn-from-operations-unaudited-drops-below-100k-for-the-full-quarter/)\n\n[ ![Precipio Press Release](https://www.precipiodx.com/wp-content/uploads/2022/08/PressRelease-300x158.png) ](https://www.precipiodx.com/precipio-signs-distribution-agreement-for-iv-cell-and-hemescreen-in-japan/)\n\n#####  [Precipio Signs Distribution Agreement For IV-Cell® and HemeScreen® in Japan](https://www.precipiodx.com/precipio-signs-distribution-agreement-for-iv-cell-and-hemescreen-in-japan/)\n\nJanuary 17, 2024\n\nFirst order for IV-Cell placed by Major Japanese Laboratory NEW HAVEN, CT, Globenewswire – (January 17, 2024) – Specialty cancer diagnostics company Precipio, Inc. (NASDAQ: PRPO) [...] \n\n[ Read More ](https://www.precipiodx.com/precipio-signs-distribution-agreement-for-iv-cell-and-hemescreen-in-japan/)\n\n[ ![Precipio Press Release](https://www.precipiodx.com/wp-content/uploads/2022/08/PressRelease-300x158.png) ](https://www.precipiodx.com/precipio-announces-christina-valauri-joins-the-board-of-directors/)\n\n#####  [Precipio Announces Christina Valauri joins the Board of Directors](https://www.precipiodx.com/precipio-announces-christina-valauri-joins-the-board-of-directors/)\n\nJanuary 2, 2024\n\nDouglas Fisher, MD will step down as Director, and remain as a board observer NEW HAVEN, CT, Globenewswire – (January 2, 2024) – Specialty cancer diagnostics [...] \n\n[ Read More ](https://www.precipiodx.com/precipio-announces-christina-valauri-joins-the-board-of-directors/)\n\n[ ![Precipio Press Release](https://www.precipiodx.com/wp-content/uploads/2022/08/PressRelease-300x158.png) ](https://www.precipiodx.com/precipio-management-shares-thoughts-on-2023-and-looks-ahead-to-2024/)\n\n#####  [Precipio Management Shares Thoughts on 2023, and Looks Ahead To 2024](https://www.precipiodx.com/precipio-management-shares-thoughts-on-2023-and-looks-ahead-to-2024/)\n\nDecember 14, 2023\n\nNEW HAVEN, CT, Globenewswire – (December 14, 2023) – Management of specialty cancer diagnostics company Precipio, Inc. (NASDAQ: PRPO) shares thoughts and reflections looking back at [...] \n\n[ Read More ](https://www.precipiodx.com/precipio-management-shares-thoughts-on-2023-and-looks-ahead-to-2024/)\n\n[ ![Precipio Press Release](https://www.precipiodx.com/wp-content/uploads/2022/08/PressRelease-300x158.png) ](https://www.precipiodx.com/precipio-announces-q3-2023-shareholder-update-call/)\n\n#####  [Precipio Announces Q3-2023 Shareholder Update Call](https://www.precipiodx.com/precipio-announces-q3-2023-shareholder-update-call/)\n\nNovember 16, 2023\n\nConference Call to be held on November 20th, 2023 at 5:00 PM EST NEW HAVEN, CT, (November 16th, 2023) – Specialty cancer diagnostics company Precipio, Inc. (NASDAQ: PRPO), [...] \n\n[ Read More ](https://www.precipiodx.com/precipio-announces-q3-2023-shareholder-update-call/)\n\n[ ![Precipio Press Release](https://www.precipiodx.com/wp-content/uploads/2022/08/PressRelease-300x158.png) ](https://www.precipiodx.com/precipio-to-report-4-5m-q3-2023-revenues-double-from-q3-2022/)\n\n#####  [Precipio to Report $4.5M Q3-2023 Revenues, Double From Q3-2022](https://www.precipiodx.com/precipio-to-report-4-5m-q3-2023-revenues-double-from-q3-2022/)\n\nOctober 18, 2023\n\n28% Revenue Increase is Major Step toward Company Breakeven NEW HAVEN, CT, Globenewswire – (October 18, 2023) – Specialty cancer diagnostics company Precipio, Inc. (NASDAQ: PRPO), [...] \n\n[ Read More ](https://www.precipiodx.com/precipio-to-report-4-5m-q3-2023-revenues-double-from-q3-2022/)\n\n[ ![Precipio Press Release](https://www.precipiodx.com/wp-content/uploads/2022/08/PressRelease-300x158.png) ](https://www.precipiodx.com/precipios-q3-cash-burn-from-operations-unaudited-declines-59-yoy-from-2-5m-in-q3-2022-to-approximately-1m-in-q3-2023/)\n\n#####  [Precipio’s Q3 Cash Burn From Operations (unaudited) Declines 59% YoY, from $2.5M in Q3-2022 to approximately $1M in Q3-2023](https://www.precipiodx.com/precipios-q3-cash-burn-from-operations-unaudited-declines-59-yoy-from-2-5m-in-q3-2022-to-approximately-1m-in-q3-2023/)\n\nOctober 3, 2023\n\nCompany anticipates current cash levels sufficient to reach breakeven NEW HAVEN, CT, Globenewswire – (October 3rd, 2023) – Specialty cancer diagnostics company Precipio, Inc. (NASDAQ: PRPO), [...] \n\n[ Read More ](https://www.precipiodx.com/precipios-q3-cash-burn-from-operations-unaudited-declines-59-yoy-from-2-5m-in-q3-2022-to-approximately-1m-in-q3-2023/)\n\n[ ![Precipio Press Release](https://www.precipiodx.com/wp-content/uploads/2022/08/PressRelease-300x158.png) ](https://www.precipiodx.com/precipio-continues-to-sign-new-hemescreen-customers/)\n\n#####  [Precipio Continues to Sign New HemeScreen™ Customers](https://www.precipiodx.com/precipio-continues-to-sign-new-hemescreen-customers/)\n\nSeptember 28, 2023\n\nNew customer orders received in Q3 exceed $1M annualized revenue NEW HAVEN, CT, Globenewswire – (September 28th, 2023) – Specialty cancer diagnostics company Precipio, Inc. (NASDAQ: PRPO) announced [...] \n\n[ Read More ](https://www.precipiodx.com/precipio-continues-to-sign-new-hemescreen-customers/)\n\n[ ![Precipio Press Release](https://www.precipiodx.com/wp-content/uploads/2022/08/PressRelease-300x158.png) ](https://www.precipiodx.com/precipio-reduces-product-revenue-result-needed-for-cash-flow-breakeven/)\n\n#####  [Precipio Reduces Product Revenue Result Needed for Cash Flow Breakeven](https://www.precipiodx.com/precipio-reduces-product-revenue-result-needed-for-cash-flow-breakeven/)\n\nSeptember 25, 2023\n\nHigher pathology revenues and lower cost structure drive down product revenue breakeven point from $8M to $6M NEW HAVEN, CT, Globenewswire – (September 25th, 2023) – [...] \n\n[ Read More ](https://www.precipiodx.com/precipio-reduces-product-revenue-result-needed-for-cash-flow-breakeven/)\n\n[ ![Precipio Press Release](https://www.precipiodx.com/wp-content/uploads/2022/08/PressRelease-300x158.png) ](https://www.precipiodx.com/precipio-takes-final-step-towards-regaining-nasdaq-compliance-2/)\n\n#####  [Precipio Takes Final Step Towards Regaining Nasdaq Compliance](https://www.precipiodx.com/precipio-takes-final-step-towards-regaining-nasdaq-compliance-2/)\n\nSeptember 21, 2023\n\nCompany announces 1-for-20 reverse stock split NEW HAVEN, CT – (September 21, 2023) – Specialty cancer diagnostics company Precipio, Inc. (NASDAQ: PRPO) today announced that [...] \n\n[ Read More ](https://www.precipiodx.com/precipio-takes-final-step-towards-regaining-nasdaq-compliance-2/)\n\n[ ![Precipio Press Release](https://www.precipiodx.com/wp-content/uploads/2022/08/PressRelease-300x158.png) ](https://www.precipiodx.com/precipios-pathology-division-exceeds-breakeven-revenues-in-august-four-months-ahead-of-plan/)\n\n#####  [Precipio’s Pathology Division Exceeds Breakeven Revenues in August, Four Months Ahead of Plan](https://www.precipiodx.com/precipios-pathology-division-exceeds-breakeven-revenues-in-august-four-months-ahead-of-plan/)\n\nSeptember 13, 2023\n\nCompany continues to make strides towards profitability NEW HAVEN, CT, Globenewswire – (September 13, 2023) – Specialty cancer diagnostics company Precipio, Inc. (NASDAQ: PRPO), announces its [...] \n\n[ Read More ](https://www.precipiodx.com/precipios-pathology-division-exceeds-breakeven-revenues-in-august-four-months-ahead-of-plan/)\n\n[ ![Precipio Press Release](https://www.precipiodx.com/wp-content/uploads/2022/08/PressRelease-300x158.png) ](https://www.precipiodx.com/precipio-announces-q2-2023-shareholder-update-call/)\n\n#####  [Precipio Announces Q2-2023 Shareholder Update Call](https://www.precipiodx.com/precipio-announces-q2-2023-shareholder-update-call/)\n\nAugust 10, 2023\n\nConference Call to be held on August 17, 2023 at 5:00 PM EST NEW HAVEN, CT, (August 10th, 2023) – Specialty cancer diagnostics company Precipio, Inc. (NASDAQ: PRPO), [...] \n\n[ Read More ](https://www.precipiodx.com/precipio-announces-q2-2023-shareholder-update-call/)\n\n[ ![Precipio Press Release](https://www.precipiodx.com/wp-content/uploads/2022/08/PressRelease-300x158.png) ](https://www.precipiodx.com/precipio-launches-its-much-anticipated-quantitative-bcr-abl-2-0-panel/)\n\n#####  [Precipio Launches Its Much-Anticipated Quantitative BCR-ABL 2.0 Panel](https://www.precipiodx.com/precipio-launches-its-much-anticipated-quantitative-bcr-abl-2-0-panel/)\n\nAugust 8, 2023\n\nAdvanced panel already generating six-figure pre-orders NEW HAVEN, CT, Globenewswire – (August 8, 2023) – Specialty cancer diagnostics company Precipio, Inc. (NASDAQ: PRPO), announces the launch [...] \n\n[ Read More ](https://www.precipiodx.com/precipio-launches-its-much-anticipated-quantitative-bcr-abl-2-0-panel/)\n\n[ ![Precipio Press Release](https://www.precipiodx.com/wp-content/uploads/2022/08/PressRelease-300x158.png) ](https://www.precipiodx.com/precipios-operational-efficiency-measures-continue-to-reduce-cash-burn-and-move-the-company-towards-breakeven/)\n\n#####  [Precipio’s Operational Efficiency Measures Continue To Reduce Cash Burn And Move The Company Towards Breakeven](https://www.precipiodx.com/precipios-operational-efficiency-measures-continue-to-reduce-cash-burn-and-move-the-company-towards-breakeven/)\n\nAugust 3, 2023\n\nRevenue growth and customer pipeline advance the Company towards breakeven NEW HAVEN, CT, Globenewswire – (August 3, 2023) – Specialty cancer diagnostics company Precipio, Inc. (NASDAQ: [...] \n\n[ Read More ](https://www.precipiodx.com/precipios-operational-efficiency-measures-continue-to-reduce-cash-burn-and-move-the-company-towards-breakeven/)\n\n[ ![Precipio Press Release](https://www.precipiodx.com/wp-content/uploads/2022/08/PressRelease-300x158.png) ](https://www.precipiodx.com/precipio-unaudited-q2-2023-revenues-show-combined-increase-of-25-over-q1-2023/)\n\n#####  [Precipio Unaudited Q2-2023 Revenues Show combined increase of 25% over Q1-2023](https://www.precipiodx.com/precipio-unaudited-q2-2023-revenues-show-combined-increase-of-25-over-q1-2023/)\n\nAugust 1, 2023\n\nRevenue growth and customer pipeline advance the Company towards breakeven NEW HAVEN, CT, Globenewswire – (August 1, 2023) – Specialty cancer diagnostics company Precipio, Inc. (NASDAQ: [...] \n\n[ Read More ](https://www.precipiodx.com/precipio-unaudited-q2-2023-revenues-show-combined-increase-of-25-over-q1-2023/)\n\n[ ![Precipio Press Release](https://www.precipiodx.com/wp-content/uploads/2022/08/PressRelease-300x158.png) ](https://www.precipiodx.com/precipio-enters-into-collaboration-with-prestigious-new-york-based-institution-to-develop-revolutionary-brain-tumor-panel-using-hemescreen-technology/)\n\n#####  [Precipio Enters into Collaboration with Prestigious New York-based Institution to Develop Revolutionary Brain Tumor Panel using HemeScreen® Technology](https://www.precipiodx.com/precipio-enters-into-collaboration-with-prestigious-new-york-based-institution-to-develop-revolutionary-brain-tumor-panel-using-hemescreen-technology/)\n\nJune 13, 2023\n\nNew panel will enable rapid, precise genetic profiling of patients with deadly disease NEW HAVEN, CT, (June 13th, 2023) – Specialty cancer diagnostics company Precipio, Inc. (NASDAQ: PRPO), [...] \n\n[ Read More ](https://www.precipiodx.com/precipio-enters-into-collaboration-with-prestigious-new-york-based-institution-to-develop-revolutionary-brain-tumor-panel-using-hemescreen-technology/)\n\n[ ![Precipio Press Release](https://www.precipiodx.com/wp-content/uploads/2022/08/PressRelease-300x158.png) ](https://www.precipiodx.com/precipio-inc-announces-pricing-of-2-million-registered-direct-offering-and-concurrent-private-placement/)\n\n#####  [Precipio, Inc. Announces Pricing of $2 Million Registered Direct Offering and Concurrent Private Placement](https://www.precipiodx.com/precipio-inc-announces-pricing-of-2-million-registered-direct-offering-and-concurrent-private-placement/)\n\nJune 8, 2023\n\nNEW HAVEN, CT, (June 8th, 2023) – Specialty cancer diagnostics company Precipio, Inc. (NASDAQ: PRPO), today announced it has entered into securities purchase agreements with certain institutional investors [...] \n\n[ Read More ](https://www.precipiodx.com/precipio-inc-announces-pricing-of-2-million-registered-direct-offering-and-concurrent-private-placement/)\n\n[ ![Precipio Press Release](https://www.precipiodx.com/wp-content/uploads/2022/08/PressRelease-300x158.png) ](https://www.precipiodx.com/projected-cash-burn-reduced-by-1-5-million-annually-from-three-operational-efficiency-projects/)\n\n#####  [Projected cash burn reduced by $1.5 million annually from Three Operational Efficiency Projects](https://www.precipiodx.com/projected-cash-burn-reduced-by-1-5-million-annually-from-three-operational-efficiency-projects/)\n\nJune 7, 2023\n\nIndependent of revenue growth, these Projects expected to decrease cash burn by 25% in Q3 NEW HAVEN, CT, (June 7th, 2023) – Specialty cancer diagnostics company Precipio, [...] \n\n[ Read More ](https://www.precipiodx.com/projected-cash-burn-reduced-by-1-5-million-annually-from-three-operational-efficiency-projects/)\n\n[ ![Precipio Press Release](https://www.precipiodx.com/wp-content/uploads/2022/08/PressRelease-300x158.png) ](https://www.precipiodx.com/precipio-shares-growth-catalysts-for-hemescreen/)\n\n#####  [Precipio Shares Growth Catalysts For HemeScreen](https://www.precipiodx.com/precipio-shares-growth-catalysts-for-hemescreen/)\n\nMay 17, 2023\n\nQ1 Results and catalysts show promising growth trajectory NEW HAVEN, CT, (May 17th, 2023) – Specialty cancer diagnostics company Precipio, Inc. (NASDAQ: PRPO), will be discussing on today’s [...] \n\n[ Read More ](https://www.precipiodx.com/precipio-shares-growth-catalysts-for-hemescreen/)\n\n[ ![Precipio Press Release](https://www.precipiodx.com/wp-content/uploads/2022/08/PressRelease-300x158.png) ](https://www.precipiodx.com/precipio-announces-q1-2023-shareholder-update-call/)\n\n#####  [Precipio Announces Q1-2023 Shareholder Update Call](https://www.precipiodx.com/precipio-announces-q1-2023-shareholder-update-call/)\n\nMay 15, 2023\n\nConference Call to be held on May 17, 2023 at 5:00 PM EST NEW HAVEN, CT, (May 15th, 2023) – Specialty cancer diagnostics company Precipio, Inc. (NASDAQ: PRPO), [...] \n\n[ Read More ](https://www.precipiodx.com/precipio-announces-q1-2023-shareholder-update-call/)\n\n[ ![Precipio Press Release](https://www.precipiodx.com/wp-content/uploads/2022/08/PressRelease-300x158.png) ](https://www.precipiodx.com/precipio-adds-substantial-pathology-customer-to-its-diagnostic-services-division/)\n\n#####  [Precipio Adds Substantial Pathology Customer to its Diagnostic Services Division](https://www.precipiodx.com/precipio-adds-substantial-pathology-customer-to-its-diagnostic-services-division/)\n\nMay 4, 2023\n\nCustomer’s pathology services annual revenues expected to exceed $1.5M NEW HAVEN, CT, Globenewswire – (May 4th, 2023) – Specialty cancer diagnostics company Precipio, Inc. (NASDAQ: PRPO) announces another [...] \n\n[ Read More ](https://www.precipiodx.com/precipio-adds-substantial-pathology-customer-to-its-diagnostic-services-division/)\n\n[ ![Precipio Press Release](https://www.precipiodx.com/wp-content/uploads/2022/08/PressRelease-300x158.png) ](https://www.precipiodx.com/precipio-signs-another-hemescreen-customer/)\n\n#####  [Precipio Signs Another HemeScreen™ Customer](https://www.precipiodx.com/precipio-signs-another-hemescreen-customer/)\n\nMay 4, 2023\n\nCustomer’s revenues expected at $750K at full capacity NEW HAVEN, CT, Globenewswire – (May 4th, 2023) – Specialty cancer diagnostics company Precipio, Inc. (NASDAQ: PRPO) announces another agreement [...] \n\n[ Read More ](https://www.precipiodx.com/precipio-signs-another-hemescreen-customer/)\n\n[ ![Precipio Press Release](https://www.precipiodx.com/wp-content/uploads/2022/08/PressRelease-300x158.png) ](https://www.precipiodx.com/precipio-granted-180-day-extension-from-nasdaq-to-regain-compliance/)\n\n#####  [Precipio Granted 180-day Extension From NASDAQ To Regain Compliance](https://www.precipiodx.com/precipio-granted-180-day-extension-from-nasdaq-to-regain-compliance/)\n\nApril 27, 2023\n\nExtension will enable the Company to execute on its growth and advance toward breakeven NEW HAVEN, CT, Globenewswire – (April 27th, 2023) – Specialty cancer diagnostics [...] \n\n[ Read More ](https://www.precipiodx.com/precipio-granted-180-day-extension-from-nasdaq-to-regain-compliance/)\n\n[ ![Precipio Press Release](https://www.precipiodx.com/wp-content/uploads/2022/08/PressRelease-300x158.png) ](https://www.precipiodx.com/precipio-unaudited-q1-2023-product-revenues-exceed-the-two-prior-quarters-q3q4-of-2022-combined/)\n\n#####  [Precipio Unaudited Q1-2023 Product Revenues Exceed The Two Prior Quarters (Q3+Q4 of 2022) Combined](https://www.precipiodx.com/precipio-unaudited-q1-2023-product-revenues-exceed-the-two-prior-quarters-q3q4-of-2022-combined/)\n\nApril 19, 2023\n\nQ1-2023 product revenues approximately $0.76M exceeded the $0.66M combined revenue of Q3+Q4 2022 NEW HAVEN, CT, Globenewswire – (April 19th, 2023) – Specialty cancer diagnostics company [...] \n\n[ Read More ](https://www.precipiodx.com/precipio-unaudited-q1-2023-product-revenues-exceed-the-two-prior-quarters-q3q4-of-2022-combined/)\n\n[ ![Precipio Press Release](https://www.precipiodx.com/wp-content/uploads/2022/08/PressRelease-300x158.png) ](https://www.precipiodx.com/precipio-announces-2022-fourth-quarter-and-year-end-shareholder-update-call/)\n\n#####  [Precipio Announces 2022 Fourth Quarter and Year-End Shareholder Update Call](https://www.precipiodx.com/precipio-announces-2022-fourth-quarter-and-year-end-shareholder-update-call/)\n\nMarch 28, 2023\n\nConference Call to be held on Monday, April 3rd, 2023 at 5:00 PM EST NEW HAVEN, CT, Globenewswire – (March 28th, 2023) – Specialty cancer diagnostics [...] \n\n[ Read More ](https://www.precipiodx.com/precipio-announces-2022-fourth-quarter-and-year-end-shareholder-update-call/)\n\n[ ![Precipio Press Release](https://www.precipiodx.com/wp-content/uploads/2022/08/PressRelease-300x158.png) ](https://www.precipiodx.com/precipio-ships-first-iv-cell-order-to-major-us-healthcare-system/)\n\n#####  [Precipio Ships First IV-Cell® Order to Major US Healthcare System](https://www.precipiodx.com/precipio-ships-first-iv-cell-order-to-major-us-healthcare-system/)\n\nMarch 21, 2023\n\nProducts Division revenues begin to diversify beyond HemeScreen® NEW HAVEN, CT, Globenewswire – (March 21st, 2023) – Specialty cancer diagnostics company Precipio, Inc. (NASDAQ: PRPO) delivered its first [...] \n\n[ Read More ](https://www.precipiodx.com/precipio-ships-first-iv-cell-order-to-major-us-healthcare-system/)\n\n[ ![Precipio Press Release](https://www.precipiodx.com/wp-content/uploads/2022/08/PressRelease-300x158.png) ](https://www.precipiodx.com/precipio-continues-to-sign-up-and-onboard-hemescreen-customers/)\n\n#####  [Precipio continues to sign up and onboard HemeScreen™ customers](https://www.precipiodx.com/precipio-continues-to-sign-up-and-onboard-hemescreen-customers/)\n\nMarch 7, 2023\n\nConversion from sales funnels developed with distribution partners alongside direct sales points to continued accelerated growth NEW HAVEN, CT, Globenewswire – (March 7th, 2023) – Specialty [...] \n\n[ Read More ](https://www.precipiodx.com/precipio-continues-to-sign-up-and-onboard-hemescreen-customers/)\n\n[ ![Precipio Press Release](https://www.precipiodx.com/wp-content/uploads/2022/08/PressRelease-300x158.png) ](https://www.precipiodx.com/thermofisher-salesforce-votes-precipios-hemescreen-as-best-new-product/)\n\n#####  [Precipio’s HemeScreen® Selected as 2022 Best New Product](https://www.precipiodx.com/thermofisher-salesforce-votes-precipios-hemescreen-as-best-new-product/)\n\nFebruary 14, 2023\n\nHemeScreen® Technology and Product Line were recognized by Fisher Healthcare during recent National Sales Meeting “We are privileged to have Fisher Healthcare as a distribution [...] \n\n[ Read More ](https://www.precipiodx.com/thermofisher-salesforce-votes-precipios-hemescreen-as-best-new-product/)\n\n[ ![Precipio Press Release](https://www.precipiodx.com/wp-content/uploads/2022/08/PressRelease-300x158.png) ](https://www.precipiodx.com/precipio-signs-another-major-hemescreen-customer/)\n\n#####  [Precipio Signs Another Major HemeScreen™ Customer](https://www.precipiodx.com/precipio-signs-another-major-hemescreen-customer/)\n\nJanuary 11, 2023\n\nCustomer’s initial annual revenue expected at $650K, $2.0M revenue at full capacity NEW HAVEN, CT, Globenewswire – (January 11th, 2023) – Specialty cancer diagnostics company Precipio, Inc. (NASDAQ: [...] \n\n[ Read More ](https://www.precipiodx.com/precipio-signs-another-major-hemescreen-customer/)\n\n[ ![Precipio Press Release](https://www.precipiodx.com/wp-content/uploads/2022/08/PressRelease-300x158.png) ](https://www.precipiodx.com/precipio-signs-additional-major-hemescreen-customer/)\n\n#####  [Precipio Signs Additional Major HemeScreen™ Customer](https://www.precipiodx.com/precipio-signs-additional-major-hemescreen-customer/)\n\nDecember 6, 2022\n\nCustomer to begin gradually onboarding panels in Q1-2023, potential $1.2M revenue at full capacity NEW HAVEN, CT, Globenewswire – (December 6th, 2022) – Specialty cancer diagnostics [...] \n\n[ Read More ](https://www.precipiodx.com/precipio-signs-additional-major-hemescreen-customer/)\n\n[ ![Precipio Press Release](https://www.precipiodx.com/wp-content/uploads/2022/08/PressRelease-300x158.png) ](https://www.precipiodx.com/precipio-presents-poster-on-hemescreen-study-at-association-of-molecular-pathology-amp-2022-annual-conference/)\n\n#####  [Precipio Presents Poster on HemeScreen® Study at Association of Molecular Pathology (AMP) 2022 Annual Conference](https://www.precipiodx.com/precipio-presents-poster-on-hemescreen-study-at-association-of-molecular-pathology-amp-2022-annual-conference/)\n\nNovember 7, 2022\n\nPoster presents findings of a study of ~1000 patient samples demonstrating superior accuracy for HemeScreen™ MPN Assay NEW HAVEN, CT, Globenewswire – (November 7th, 2022) – [...] \n\n[ Read More ](https://www.precipiodx.com/precipio-presents-poster-on-hemescreen-study-at-association-of-molecular-pathology-amp-2022-annual-conference/)\n\n[ ![Precipio Press Release](https://www.precipiodx.com/wp-content/uploads/2022/08/PressRelease-300x158.png) ](https://www.precipiodx.com/precipio-announces-third-quarter-shareholder-update-call/)\n\n#####  [Precipio Announces Third Quarter Shareholder Update Call](https://www.precipiodx.com/precipio-announces-third-quarter-shareholder-update-call/)\n\nNovember 2, 2022\n\nConference Call to be held on Monday, November 14th, 2022 at 5:00 PM ET NEW HAVEN, CT, Globenewswire – (November 2nd, 2022) – Specialty cancer diagnostics [...] \n\n[ Read More ](https://www.precipiodx.com/precipio-announces-third-quarter-shareholder-update-call/)\n\n[ ![Precipio Press Release](https://www.precipiodx.com/wp-content/uploads/2022/08/PressRelease-300x158.png) ](https://www.precipiodx.com/precipio-signs-agreement-with-another-major-us-healthcare-distributor-for-hemescreen/)\n\n#####  [Precipio Signs Agreement with Another Major US Healthcare Distributor for HemeScreen™](https://www.precipiodx.com/precipio-signs-agreement-with-another-major-us-healthcare-distributor-for-hemescreen/)\n\nSeptember 15, 2022\n\nAdding customer segment exceeding $100M in market potential NEW HAVEN, CT, Globenewswire – (September 15th, 2022) – Specialty cancer diagnostics company Precipio, Inc. (NASDAQ: PRPO), has signed a [...] \n\n[ Read More ](https://www.precipiodx.com/precipio-signs-agreement-with-another-major-us-healthcare-distributor-for-hemescreen/)\n\n[ ![Precipio Press Release](https://www.precipiodx.com/wp-content/uploads/2022/08/PressRelease-300x158.png) ](https://www.precipiodx.com/sharon-robins-joins-precipios-products-division-as-senior-director-of-laboratory-hospital-sales/)\n\n#####  [Sharon Robins Joins Precipio’s Products Division As Senior Director Of Laboratory & Hospital Sales](https://www.precipiodx.com/sharon-robins-joins-precipios-products-division-as-senior-director-of-laboratory-hospital-sales/)\n\nAugust 24, 2022\n\nPrecipio continues to build strong team in anticipation of substantial growth in the next 12 months NEW HAVEN, CT, Globenewswire – (August 24th, 2022) – Specialty [...] \n\n[ Read More ](https://www.precipiodx.com/sharon-robins-joins-precipios-products-division-as-senior-director-of-laboratory-hospital-sales/)\n\n[ ![Precipio Press Release](https://www.precipiodx.com/wp-content/uploads/2022/08/PressRelease-300x158.png) ](https://www.precipiodx.com/precipio-launches-new-1-step-technology-for-all-hemescreen-assays/)\n\n#####  [Precipio Launches New 1-Step Technology For All HemeScreen Assays](https://www.precipiodx.com/precipio-launches-new-1-step-technology-for-all-hemescreen-assays/)\n\nAugust 16, 2022\n\nNew technology enables same day test results by eliminating extra confirmation step NEW HAVEN, CT, Globenewswire – (August 16th, 2022) – Specialty cancer diagnostics company Precipio, Inc. (NASDAQ: [...] \n\n[ Read More ](https://www.precipiodx.com/precipio-launches-new-1-step-technology-for-all-hemescreen-assays/)\n\n[ ![Precipio Press Release](https://www.precipiodx.com/wp-content/uploads/2022/08/PressRelease-300x158.png) ](https://www.precipiodx.com/toni-ann-mills-joins-precipios-products-division-to-lead-channel-partner-training-learning-development/)\n\n#####  [Toni-Ann Mills Joins Precipio’s Products Division To Lead Channel Partner Training, Learning & Development](https://www.precipiodx.com/toni-ann-mills-joins-precipios-products-division-to-lead-channel-partner-training-learning-development/)\n\nAugust 10, 2022\n\nPrecipio prepares to launch a nationwide HemeScreen sales effort of 250+ sales reps from AmerisourceBergen, ThermoFisher, and other distributors NEW HAVEN, CT, Globenewswire – (August [...] \n\n[ Read More ](https://www.precipiodx.com/toni-ann-mills-joins-precipios-products-division-to-lead-channel-partner-training-learning-development/)\n\n[ ![Precipio Press Release](https://www.precipiodx.com/wp-content/uploads/2022/08/PressRelease-300x158.png) ](https://www.precipiodx.com/precipio-announces-second-quarter-shareholder-update-call/)\n\n#####  [Precipio Announces Second Quarter Shareholder Update Call](https://www.precipiodx.com/precipio-announces-second-quarter-shareholder-update-call/)\n\nAugust 8, 2022\n\nConference Call to be held on Monday, August 15th, 2022 at 5:00 PM EST NEW HAVEN, CT, Globenewswire – (August 8th, 2022) – Specialty cancer diagnostics [...] \n\n[ Read More ](https://www.precipiodx.com/precipio-announces-second-quarter-shareholder-update-call/)\n\n[ ![Precipio Press Release](https://www.precipiodx.com/wp-content/uploads/2022/08/PressRelease-300x158.png) ](https://www.precipiodx.com/precipio-to-distribute-hemescreen-through-fisher-healthcare-channel/)\n\n#####  [Precipio To Distribute HemeScreen® Through Fisher Healthcare Channel](https://www.precipiodx.com/precipio-to-distribute-hemescreen-through-fisher-healthcare-channel/)\n\nJuly 20, 2022\n\nAgreement Enhances Precipio’s Product Reach to US Laboratories NEW HAVEN, CT – (Globe Newswire) – (July 20th, 2022) – Specialty cancer diagnostics company Precipio, Inc. (NASDAQ: PRPO), today [...] \n\n[ Read More ](https://www.precipiodx.com/precipio-to-distribute-hemescreen-through-fisher-healthcare-channel/)\n\n[ ![Precipio Press Release](https://www.precipiodx.com/wp-content/uploads/2022/08/PressRelease-300x158.png) ](https://www.precipiodx.com/precipio-requests-that-all-stockholders-that-have-not-yet-voted-proceed-to-cast-their-vote/)\n\n#####  [Precipio Requests That All Stockholders That Have Not Yet Voted, Proceed To Cast Their Vote](https://www.precipiodx.com/precipio-requests-that-all-stockholders-that-have-not-yet-voted-proceed-to-cast-their-vote/)\n\nJune 14, 2022\n\nMeeting Adjourned, new meeting set for July 5th at 10am EDT NEW HAVEN, CT – (June 14th, 2022) – Specialty diagnostics company Precipio, Inc. (NASDAQ: PRPO), announced today [...] \n\n[ Read More ](https://www.precipiodx.com/precipio-requests-that-all-stockholders-that-have-not-yet-voted-proceed-to-cast-their-vote/)\n\n[ ![Precipio Press Release](https://www.precipiodx.com/wp-content/uploads/2022/08/PressRelease-300x158.png) ](https://www.precipiodx.com/keith-meadors-joins-precipio-to-lead-its-products-division/)\n\n#####  [Keith Meadors Joins Precipio To Lead Its Products Division](https://www.precipiodx.com/keith-meadors-joins-precipio-to-lead-its-products-division/)\n\nJune 13, 2022\n\nSeasoned, experienced industry executive with a track record of managing 9-figure revenue sales organizations NEW HAVEN, CT – (Globenewswire) – (June 13th, 2022) – Specialty cancer [...] \n\n[ Read More ](https://www.precipiodx.com/keith-meadors-joins-precipio-to-lead-its-products-division/)\n\n[ ![Precipio Press Release](https://www.precipiodx.com/wp-content/uploads/2022/08/PressRelease-300x158.png) ](https://www.precipiodx.com/precipio-receives-ce-ivd-certification-to-market-multiple-hemescreen-panels-in-europe/)\n\n#####  [Precipio Receives CE-IVD Certification To Market Multiple HemeScreen® Panels In Europe](https://www.precipiodx.com/precipio-receives-ce-ivd-certification-to-market-multiple-hemescreen-panels-in-europe/)\n\nMay 24, 2022\n\nThis Regulatory Approval Opens the Company’s Reach to the European Market NEW HAVEN, CT – (Globenewswire) – (May 24th, 2022) – Specialty cancer diagnostics company Precipio, Inc. (NASDAQ: [...] \n\n[ Read More ](https://www.precipiodx.com/precipio-receives-ce-ivd-certification-to-market-multiple-hemescreen-panels-in-europe/)\n\n[ ![Precipio Press Release](https://www.precipiodx.com/wp-content/uploads/2022/08/PressRelease-300x158.png) ](https://www.precipiodx.com/precipio-signs-first-iv-cell-customer-agreement/)\n\n#####  [Precipio Signs First IV-Cell Customer Agreement](https://www.precipiodx.com/precipio-signs-first-iv-cell-customer-agreement/)\n\nMay 10, 2022\n\nLaboratory operating both HemeScreen® & IV-Cell® demonstrates significant cross-sell potential NEW HAVEN, CT – (Globenewswire) – (May 10th, 2022) – Specialty cancer diagnostics company Precipio, Inc. (NASDAQ: PRPO), [...] \n\n[ Read More ](https://www.precipiodx.com/precipio-signs-first-iv-cell-customer-agreement/)\n\n[ ![Precipio Press Release](https://www.precipiodx.com/wp-content/uploads/2022/08/PressRelease-300x158.png) ](https://www.precipiodx.com/precipio-customer-american-oncology-network-aon-selected-to-present-hemescreen-technology-case-study-at-industry-leading-clinical-laboratory-conference/)\n\n#####  [Precipio Customer American Oncology Network (AON) Selected To Present HemeScreen® Technology Case Study At Industry Leading Clinical Laboratory Conference](https://www.precipiodx.com/precipio-customer-american-oncology-network-aon-selected-to-present-hemescreen-technology-case-study-at-industry-leading-clinical-laboratory-conference/)\n\nApril 26, 2022\n\nNEW HAVEN, CT – (Apr 26th, 2022) – Specialty cancer diagnostics company Precipio, Inc. (NASDAQ: PRPO), is excited to announce its participation and the presentation of HemeScreen, its [...] \n\n[ Read More ](https://www.precipiodx.com/precipio-customer-american-oncology-network-aon-selected-to-present-hemescreen-technology-case-study-at-industry-leading-clinical-laboratory-conference/)\n\n[ ![Precipio Press Release](https://www.precipiodx.com/wp-content/uploads/2022/08/PressRelease-300x158.png) ](https://www.precipiodx.com/precipio-announces-2021-fourth-quarter-and-year-end-shareholder-update-call/)\n\n#####  [Precipio Announces 2021 Fourth Quarter And Year-End Shareholder Update Call](https://www.precipiodx.com/precipio-announces-2021-fourth-quarter-and-year-end-shareholder-update-call/)\n\nMarch 22, 2022\n\nConference Call to be held on Monday, April 4th, 2022 at 5:00 PM EST NEW HAVEN, CT, Globenewswire – (Mar 22nd, 2022) – Specialty cancer diagnostics [...] \n\n[ Read More ](https://www.precipiodx.com/precipio-announces-2021-fourth-quarter-and-year-end-shareholder-update-call/)\n\n[ ![Precipio Press Release](https://www.precipiodx.com/wp-content/uploads/2022/08/PressRelease-300x158.png) ](https://www.precipiodx.com/precipio-inc-announces-the-resignation-of-its-chief-financial-officer-and-appointment-of-interim-cfo/)\n\n#####  [Precipio Inc. Announces The Resignation Of Its Chief Financial Officer And Appointment Of Interim CFO](https://www.precipiodx.com/precipio-inc-announces-the-resignation-of-its-chief-financial-officer-and-appointment-of-interim-cfo/)\n\nMarch 21, 2022\n\nNEW HAVEN, CT, (Mar 21st, 2022) – Specialty cancer diagnostics company Precipio, Inc. (NASDAQ: PRPO), today announced that Mr. Carl Iberger, Precipio’s CFO for the past five years, [...] \n\n[ Read More ](https://www.precipiodx.com/precipio-inc-announces-the-resignation-of-its-chief-financial-officer-and-appointment-of-interim-cfo/)\n\n[ ![Precipio Press Release](https://www.precipiodx.com/wp-content/uploads/2022/08/PressRelease-300x158.png) ](https://www.precipiodx.com/precipio-releases-year-end-2021-preliminary-unaudited-results-and-outlook-for-2022/)\n\n#####  [Precipio Releases Year-End 2021 Preliminary Unaudited Results And Outlook For 2022](https://www.precipiodx.com/precipio-releases-year-end-2021-preliminary-unaudited-results-and-outlook-for-2022/)\n\nFebruary 24, 2022\n\nNEW HAVEN, CT, (Feb 24th, 2022) – Specialty cancer diagnostics company Precipio, Inc. (NASDAQ: PRPO), today announced its unaudited and preliminary results for 2021. The Company anticipates posting [...] \n\n[ Read More ](https://www.precipiodx.com/precipio-releases-year-end-2021-preliminary-unaudited-results-and-outlook-for-2022/)\n\n[ ![Precipio Press Release](https://www.precipiodx.com/wp-content/uploads/2022/08/PressRelease-300x158.png) ](https://www.precipiodx.com/new-york-state-approves-precipios-hemescreen-for-pol-clinical-use/)\n\n#####  [New York State Approves Precipio’s HemeScreen For POL Clinical Use](https://www.precipiodx.com/new-york-state-approves-precipios-hemescreen-for-pol-clinical-use/)\n\nNovember 18, 2021\n\nNew York Cancer & Blood POL will commence the use of HemeScreen in its laboratory NEW HAVEN, CT, (Nov 18th, 2021) – Specialty cancer diagnostics company Precipio, [...] \n\n[ Read More ](https://www.precipiodx.com/new-york-state-approves-precipios-hemescreen-for-pol-clinical-use/)\n\n[ ![Precipio Press Release](https://www.precipiodx.com/wp-content/uploads/2022/08/PressRelease-300x158.png) ](https://www.precipiodx.com/precipio-announces-q3-2021-and-year-end-shareholder-update-call/)\n\n#####  [Precipio Announces Q3-2021 And Year-End Shareholder Update Call](https://www.precipiodx.com/precipio-announces-q3-2021-and-year-end-shareholder-update-call/)\n\nNovember 1, 2021\n\nConference Call to be held on Monday, November 15th, 2021 at 5:00 PM EST NEW HAVEN, CT, (Nov 1st, 2021) – Specialty cancer diagnostics company Precipio, Inc. (NASDAQ: [...] \n\n[ Read More ](https://www.precipiodx.com/precipio-announces-q3-2021-and-year-end-shareholder-update-call/)\n\n[ ![Precipio Press Release](https://www.precipiodx.com/wp-content/uploads/2022/08/PressRelease-300x158.png) ](https://www.precipiodx.com/american-oncology-network-partners-with-precipio-to-bring-hemescreen-into-aons-laboratory/)\n\n#####  [American Oncology Network Partners With Precipio To Bring HemeScreen® Into AON’s Laboratory](https://www.precipiodx.com/american-oncology-network-partners-with-precipio-to-bring-hemescreen-into-aons-laboratory/)\n\nAugust 26, 2021\n\nHemeScreen Assays will enable AON to deliver rapid patient diagnostics for hematologic malignancies through advanced molecular screening technology New Haven, CT, and Fort Myers, FL [...] \n\n[ Read More ](https://www.precipiodx.com/american-oncology-network-partners-with-precipio-to-bring-hemescreen-into-aons-laboratory/)\n\n[ ![Precipio Press Release](https://www.precipiodx.com/wp-content/uploads/2022/08/PressRelease-300x158.png) ](https://www.precipiodx.com/precipio-reschedules-q2-2021-shareholder-update-call/)\n\n#####  [Precipio Reschedules Q2-2021 Shareholder Update Call](https://www.precipiodx.com/precipio-reschedules-q2-2021-shareholder-update-call/)\n\nAugust 20, 2021\n\nDue to a schedule conflict, the call is moved to Thursday August 26th at 5:00PM EST NEW HAVEN, CT, (Aug 20th, 2021) – Specialty cancer diagnostics [...] \n\n[ Read More ](https://www.precipiodx.com/precipio-reschedules-q2-2021-shareholder-update-call/)\n\n[ ![Precipio Press Release](https://www.precipiodx.com/wp-content/uploads/2022/08/PressRelease-300x158.png) ](https://www.precipiodx.com/precipio-announces-q2-2021-and-year-end-shareholder-update-call/)\n\n#####  [Precipio Announces Q2-2021 And Year-End Shareholder Update Call](https://www.precipiodx.com/precipio-announces-q2-2021-and-year-end-shareholder-update-call/)\n\nAugust 12, 2021\n\nConference Call to be held on Monday, August 23rd, 2021 at 5:00 PM EST NEW HAVEN, CT, (Aug 12th, 2021) – Specialty cancer diagnostics company Precipio, Inc. (NASDAQ: [...] \n\n[ Read More ](https://www.precipiodx.com/precipio-announces-q2-2021-and-year-end-shareholder-update-call/)\n\n[ ![Precipio Press Release](https://www.precipiodx.com/wp-content/uploads/2022/08/PressRelease-300x158.png) ](https://www.precipiodx.com/precipio-announces-preliminary-unaudited-q2-2021-revenues-of-2-3m/)\n\n#####  [Precipio Announces Preliminary Unaudited Q2-2021 Revenues Of $2.3M](https://www.precipiodx.com/precipio-announces-preliminary-unaudited-q2-2021-revenues-of-2-3m/)\n\nJuly 28, 2021\n\nIncrease of 65% YoY, and 29% from Q1-2021 due to strong Pathology Growth and HemeScreen NEW HAVEN, CT, (Jul 28th, 2021) – Specialty diagnostics company Precipio, Inc. (NASDAQ: [...] \n\n[ Read More ](https://www.precipiodx.com/precipio-announces-preliminary-unaudited-q2-2021-revenues-of-2-3m/)\n\n[ ![Precipio Press Release](https://www.precipiodx.com/wp-content/uploads/2022/08/PressRelease-300x158.png) ](https://www.precipiodx.com/precipio-terminates-its-equity-line/)\n\n#####  [Precipio Terminates Its Equity Line](https://www.precipiodx.com/precipio-terminates-its-equity-line/)\n\nJune 15, 2021\n\nNEW HAVEN, CT, (Jun 15th, 2021) – Specialty diagnostics company Precipio, Inc. (NASDAQ: PRPO), announces that as part of management’s review of its current financing arrangements, it has [...] \n\n[ Read More ](https://www.precipiodx.com/precipio-terminates-its-equity-line/)\n\n[ ![Precipio Press Release](https://www.precipiodx.com/wp-content/uploads/2022/08/PressRelease-300x158.png) ](https://www.precipiodx.com/precipio-launches-hemescreen-anemia-panel-a-one-of-its-kind-testing-tool/)\n\n#####  [Precipio Launches HemeScreen® Anemia Panel, A One-Of-Its-Kind Testing Tool](https://www.precipiodx.com/precipio-launches-hemescreen-anemia-panel-a-one-of-its-kind-testing-tool/)\n\nJune 8, 2021\n\nLaboratories can use this rapid, cost effective test to distinguish malignancy-driven anemia from other causes NEW HAVEN, CT, (June 8th, 2021) – Specialty diagnostics company Precipio, Inc. (NASDAQ: [...] \n\n[ Read More ](https://www.precipiodx.com/precipio-launches-hemescreen-anemia-panel-a-one-of-its-kind-testing-tool/)\n\n[ ![Precipio Press Release](https://www.precipiodx.com/wp-content/uploads/2022/08/PressRelease-300x158.png) ](https://www.precipiodx.com/precipio-announces-q1-2021-and-year-end-shareholder-update-call/)\n\n#####  [Precipio Announces Q1-2021 And Year-End Shareholder Update Call](https://www.precipiodx.com/precipio-announces-q1-2021-and-year-end-shareholder-update-call/)\n\nMay 14, 2021\n\nConference Call to be held on Thursday, May 20th, 2021 at 5:00 PM EST NEW HAVEN, CT, (May 14th, 2021) – Specialty cancer diagnostics company Precipio, Inc. (NASDAQ: [...] \n\n[ Read More ](https://www.precipiodx.com/precipio-announces-q1-2021-and-year-end-shareholder-update-call/)\n\n[ ![Precipio Press Release](https://www.precipiodx.com/wp-content/uploads/2022/08/PressRelease-300x158.png) ](https://www.precipiodx.com/precipio-launches-new-hemescreen-panel-for-aml-with-an-unparalleled-4-hour-turnaround-time/)\n\n#####  [Precipio Launches New HemeScreen Panel For AML, With An Unparalleled 4-Hour Turnaround-Time](https://www.precipiodx.com/precipio-launches-new-hemescreen-panel-for-aml-with-an-unparalleled-4-hour-turnaround-time/)\n\nMay 10, 2021\n\nPhysician Office Laboratory (POL) Customers will be able to immediately integrate this important test into their current operations NEW HAVEN, CT, (May 10th, 2021) – Specialty [...] \n\n[ Read More ](https://www.precipiodx.com/precipio-launches-new-hemescreen-panel-for-aml-with-an-unparalleled-4-hour-turnaround-time/)\n\n[ ![Precipio Press Release](https://www.precipiodx.com/wp-content/uploads/2022/08/PressRelease-300x158.png) ](https://www.precipiodx.com/precipio-launches-its-rapid-covid-19-antibody-test-on-amazon-platform/)\n\n#####  [Precipio Launches Its Rapid COVID-19 Antibody Test On Amazon Platform](https://www.precipiodx.com/precipio-launches-its-rapid-covid-19-antibody-test-on-amazon-platform/)\n\nMay 3, 2021\n\nNirmidas’ test is available to POC healthcare providers with an Amazon business account NEW HAVEN, CT, (May 3rd, 2021) – Specialty diagnostics company Precipio, Inc. (NASDAQ: PRPO), announced [...] \n\n[ Read More ](https://www.precipiodx.com/precipio-launches-its-rapid-covid-19-antibody-test-on-amazon-platform/)\n\n[ ![Precipio Press Release](https://www.precipiodx.com/wp-content/uploads/2022/08/PressRelease-300x158.png) ](https://www.precipiodx.com/current-signed-customers-expected-to-generate-1m-annualized-reported-revenues-from-precipios-hemescreen-pol-offering-by-q4-2021/)\n\n#####  [Current Signed Customers Expected To Generate $1M Annualized Reported Revenues From Precipio’s HemeScreen POL Offering By Q4-2021](https://www.precipiodx.com/current-signed-customers-expected-to-generate-1m-annualized-reported-revenues-from-precipios-hemescreen-pol-offering-by-q4-2021/)\n\nApril 26, 2021\n\nPrecipio reaffirms forecast that product revenues will reach approximately 50% of pathology revenue by the fourth quarter of 2021 NEW HAVEN, CT, (April 26th, 2021) – [...] \n\n[ Read More ](https://www.precipiodx.com/current-signed-customers-expected-to-generate-1m-annualized-reported-revenues-from-precipios-hemescreen-pol-offering-by-q4-2021/)\n\n[ ![Precipio Press Release](https://www.precipiodx.com/wp-content/uploads/2022/08/PressRelease-300x158.png) ](https://www.precipiodx.com/precipio-enters-into-an-at-the-market-atm-financing-arrangement/)\n\n#####  [Precipio Enters Into An At-The -Market (ATM) Financing Arrangement](https://www.precipiodx.com/precipio-enters-into-an-at-the-market-atm-financing-arrangement/)\n\nApril 5, 2021\n\nNEW HAVEN, CT, (April 5th, 2021) – Specialty cancer diagnostics company Precipio, Inc. (NASDAQ: PRPO), announces a new “At-The-Market” (ATM) financing arrangement that improves its financing flexibility. As [...] \n\n[ Read More ](https://www.precipiodx.com/precipio-enters-into-an-at-the-market-atm-financing-arrangement/)\n\n[ ![Precipio Press Release](https://www.precipiodx.com/wp-content/uploads/2022/08/PressRelease-300x158.png) ](https://www.precipiodx.com/precipio-announces-95-annual-growth-yoy-and-180-quarterly-growth-yoy/)\n\n#####  [Precipio Announces 95% Annual Growth YoY And 180% Quarterly Growth YoY](https://www.precipiodx.com/precipio-announces-95-annual-growth-yoy-and-180-quarterly-growth-yoy/)\n\nMarch 30, 2021\n\nHemeScreen projected to rapidly become a material revenue contributor in 2021 NEW HAVEN, CT, (March 30th, 2021) – Specialty cancer diagnostics company Precipio, Inc. (NASDAQ: PRPO), announced its [...] \n\n[ Read More ](https://www.precipiodx.com/precipio-announces-95-annual-growth-yoy-and-180-quarterly-growth-yoy/)\n\n[ ![Precipio Press Release](https://www.precipiodx.com/wp-content/uploads/2022/08/PressRelease-300x158.png) ](https://www.precipiodx.com/precipio-announces-q4-2020-and-year-end-shareholder-update-call/)\n\n#####  [Precipio Announces Q4-2020 And Year-End Shareholder Update Call](https://www.precipiodx.com/precipio-announces-q4-2020-and-year-end-shareholder-update-call/)\n\nMarch 18, 2021\n\nConference Call to be held on Wednesday, March 31st, 2021 at 5:00 PM EST NEW HAVEN, CT, (March 18th, 2021) – Specialty cancer diagnostics company Precipio, Inc. (NASDAQ: [...] \n\n[ Read More ](https://www.precipiodx.com/precipio-announces-q4-2020-and-year-end-shareholder-update-call/)\n\n[ ![Precipio Press Release](https://www.precipiodx.com/wp-content/uploads/2022/08/PressRelease-300x158.png) ](https://www.precipiodx.com/mr-ron-andrews-joins-precipios-board-of-directors/)\n\n#####  [Mr. Ron Andrews Joins Precipio’s Board Of Directors](https://www.precipiodx.com/mr-ron-andrews-joins-precipios-board-of-directors/)\n\nMarch 3, 2021\n\nCompany Strengthens Depth of Expertise in Products Industry NEW HAVEN, CT, (March 3rd, 2021) – Specialty cancer diagnostics company Precipio, Inc. (NASDAQ: PRPO) announces that Mr. Ron Andrews has joined the [...] \n\n[ Read More ](https://www.precipiodx.com/mr-ron-andrews-joins-precipios-board-of-directors/)\n\n[ ![Precipio Press Release](https://www.precipiodx.com/wp-content/uploads/2022/08/PressRelease-300x158.png) ](https://www.precipiodx.com/mr-richard-sandberg-is-appointed-chairman-of-precipios-board-of-directors/)\n\n#####  [Mr. Richard Sandberg Is Appointed Chairman Of Precipio’s Board Of Directors](https://www.precipiodx.com/mr-richard-sandberg-is-appointed-chairman-of-precipios-board-of-directors/)\n\nMarch 3, 2021\n\nNEW HAVEN, CT, (March 3rd, 2021) – Specialty cancer diagnostics company Precipio, Inc. (NASDAQ: PRPO) announces the appointment of Mr. Richard Sandberg as Chairman of the Board of Directors. [...] \n\n[ Read More ](https://www.precipiodx.com/mr-richard-sandberg-is-appointed-chairman-of-precipios-board-of-directors/)\n\n[ ![Precipio Press Release](https://www.precipiodx.com/wp-content/uploads/2022/08/PressRelease-300x158.png) ](https://www.precipiodx.com/precipio-launches-covid-19-antibody-testing-at-point-of-care/)\n\n#####  [Precipio Launches COVID-19 Antibody Testing At Point-Of-Care](https://www.precipiodx.com/precipio-launches-covid-19-antibody-testing-at-point-of-care/)\n\nJanuary 28, 2021\n\nFollowing the receipt of FDA EUA by Nirmidas, Precipio begins market roll out to POC NEW HAVEN, CT, (January 28th, 2021) – Specialty cancer diagnostics company Precipio, [...] \n\n[ Read More ](https://www.precipiodx.com/precipio-launches-covid-19-antibody-testing-at-point-of-care/)\n\n[ ![Precipio Press Release](https://www.precipiodx.com/wp-content/uploads/2022/08/PressRelease-300x158.png) ](https://www.precipiodx.com/precipio-signs-hemescreen-deals-with-two-leading-oncology-groups/)\n\n#####  [Precipio Signs HemeScreen™ Deals With Two Leading Oncology Groups](https://www.precipiodx.com/precipio-signs-hemescreen-deals-with-two-leading-oncology-groups/)\n\nJanuary 20, 2021\n\nPartnership with ION Solutions expected to accelerate sales NEW HAVEN, CT, (January 20th, 2021) – Specialty cancer diagnostics company Precipio, Inc. (NASDAQ: PRPO), has signed agreements with two [...] \n\n[ Read More ](https://www.precipiodx.com/precipio-signs-hemescreen-deals-with-two-leading-oncology-groups/)\n\n[ ![Precipio Press Release](https://www.precipiodx.com/wp-content/uploads/2022/08/PressRelease-300x158.png) ](https://www.precipiodx.com/precipio-signs-sales-marketing-agreement-for-hemescreen-with-major-oncology-distributor/)\n\n#####  [Precipio Signs Sales & Marketing Agreement For HemeScreen™ With Major Oncology Distributor](https://www.precipiodx.com/precipio-signs-sales-marketing-agreement-for-hemescreen-with-major-oncology-distributor/)\n\nDecember 10, 2020\n\nThousands of Oncology Practices will gain access to HemeScreen POL program NEW HAVEN, CT, (December 10th, 2020) – Specialty cancer diagnostics company Precipio, Inc. (NASDAQ: PRPO), has entered [...] \n\n[ Read More ](https://www.precipiodx.com/precipio-signs-sales-marketing-agreement-for-hemescreen-with-major-oncology-distributor/)\n\n[ ![Precipio Press Release](https://www.precipiodx.com/wp-content/uploads/2022/08/PressRelease-300x158.png) ](https://www.precipiodx.com/precipio-announces-q3-2020-shareholder-update-call/)\n\n#####  [Precipio Announces Q3-2020 Shareholder Update Call](https://www.precipiodx.com/precipio-announces-q3-2020-shareholder-update-call/)\n\nNovember 11, 2020\n\nConference Call to be held on Thursday, November 19th, 2020 at 5:00 PM EST NEW HAVEN, CT, (November 11th, 2020) – Specialty cancer diagnostics company Precipio, Inc. (NASDAQ: [...] \n\n[ Read More ](https://www.precipiodx.com/precipio-announces-q3-2020-shareholder-update-call/)\n\n[ ![Precipio Press Release](https://www.precipiodx.com/wp-content/uploads/2022/08/PressRelease-300x158.png) ](https://www.precipiodx.com/precipio-ads-biotec-launch-seven-beta-sites-for-iv-cell/)\n\n#####  [Precipio & ADS Biotec Launch Seven Beta Sites For IV-Cell™](https://www.precipiodx.com/precipio-ads-biotec-launch-seven-beta-sites-for-iv-cell/)\n\nOctober 6, 2020\n\nProminent Laboratories in US and Europe will begin testing the media NEW HAVEN, CT, (October 6th, 2020) – Specialty cancer diagnostics company Precipio, Inc. (NASDAQ: PRPO), along with [...] \n\n[ Read More ](https://www.precipiodx.com/precipio-ads-biotec-launch-seven-beta-sites-for-iv-cell/)\n\n[ ![Precipio Press Release](https://www.precipiodx.com/wp-content/uploads/2022/08/PressRelease-300x158.png) ](https://www.precipiodx.com/precipio-launches-its-proprietary-hemescreen-aml-acute-myeloid-leukemia-molecular-panel/)\n\n#####  [Precipio Launches Its Proprietary HemeScreen™ AML (Acute Myeloid Leukemia) Molecular Panel](https://www.precipiodx.com/precipio-launches-its-proprietary-hemescreen-aml-acute-myeloid-leukemia-molecular-panel/)\n\nSeptember 22, 2020\n\nPanel of clinically critical genes can yield same-day results outperforming major competitors NEW HAVEN, CT, (September 22nd, 2020) – Specialty cancer diagnostics company Precipio, Inc. (NASDAQ: PRPO), announced [...] \n\n[ Read More ](https://www.precipiodx.com/precipio-launches-its-proprietary-hemescreen-aml-acute-myeloid-leukemia-molecular-panel/)\n\n[ ![Precipio Press Release](https://www.precipiodx.com/wp-content/uploads/2022/08/PressRelease-300x158.png) ](https://www.precipiodx.com/precipio-announces-a-shareholder-call-to-discuss-its-covid-19-progress-and-future-plans/)\n\n#####  [Precipio Announces A Shareholder Call To Discuss Its COVID-19 Progress And Future Plans](https://www.precipiodx.com/precipio-announces-a-shareholder-call-to-discuss-its-covid-19-progress-and-future-plans/)\n\nSeptember 4, 2020\n\nIlan Danieli, Precipio CEO, will address questions from shareholders related to company COVID-19 strategy NEW HAVEN, CT, (September 4th, 2020) – Specialty cancer diagnostics company Precipio, Inc. (NASDAQ: [...] \n\n[ Read More ](https://www.precipiodx.com/precipio-announces-a-shareholder-call-to-discuss-its-covid-19-progress-and-future-plans/)\n\n[ ![Precipio Press Release](https://www.precipiodx.com/wp-content/uploads/2022/08/PressRelease-300x158.png) ](https://www.precipiodx.com/precipio-ads-biotec-sign-global-distribution-agreement-for-iv-cell/)\n\n#####  [Precipio & ADS Biotec Sign Global Distribution Agreement For IV-Cell™](https://www.precipiodx.com/precipio-ads-biotec-sign-global-distribution-agreement-for-iv-cell/)\n\nAugust 20, 2020\n\nPartnership is expected to accelerate product introduction to most major labs worldwide NEW HAVEN, CT, (August 20th, 2020) – Specialty cancer diagnostics company Precipio, Inc. (NASDAQ: PRPO), announced [...] \n\n[ Read More ](https://www.precipiodx.com/precipio-ads-biotec-sign-global-distribution-agreement-for-iv-cell/)\n\n[ ![Precipio Press Release](https://www.precipiodx.com/wp-content/uploads/2022/08/PressRelease-300x158.png) ](https://www.precipiodx.com/precipio-announces-q2-2020-corporate-update-call-for-shareholders/)\n\n#####  [Precipio Announces Q2-2020 Corporate Update Call For Shareholders](https://www.precipiodx.com/precipio-announces-q2-2020-corporate-update-call-for-shareholders/)\n\nAugust 7, 2020\n\nConference Call to be held on Monday, August 17th, 2020 at 5:00 PM EST NEW HAVEN, CT, (August 7th, 2020) – Specialty cancer diagnostics company Precipio, Inc. (NASDAQ: [...] \n\n[ Read More ](https://www.precipiodx.com/precipio-announces-q2-2020-corporate-update-call-for-shareholders/)\n\n[ ![Precipio Press Release](https://www.precipiodx.com/wp-content/uploads/2022/08/PressRelease-300x158.png) ](https://www.precipiodx.com/precipio-launches-covid-19-antibody-test-in-its-clia-laboratory/)\n\n#####  [Precipio Launches Covid-19 Antibody Test In Its CLIA Laboratory](https://www.precipiodx.com/precipio-launches-covid-19-antibody-test-in-its-clia-laboratory/)\n\nAugust 4, 2020\n\nTest initially offered to Precipio’s customer base, then expanding distribution reach NEW HAVEN, CT, (August 4th, 2020) – Specialty diagnostics company Precipio, Inc. (NASDAQ: PRPO), announced it has [...] \n\n[ Read More ](https://www.precipiodx.com/precipio-launches-covid-19-antibody-test-in-its-clia-laboratory/)\n\n#####  [Precipio Announces Commercial Launch Of Covid-19 Antibody Test](https://www.precipiodx.com/precipio-announces-commercial-launch-of-covid-19-antibody-test/)\n\nJuly 30, 2020\n\nTest received FDA EUA; commercialization begins NEW HAVEN, CT, (July 30th, 2020) – Specialty diagnostics company Precipio, Inc. (NASDAQ: PRPO), is announcing its COVID-19 strategy, and its intent [...] \n\n[ Read More ](https://www.precipiodx.com/precipio-announces-commercial-launch-of-covid-19-antibody-test/)\n\n[ ![Precipio Press Release](https://www.precipiodx.com/wp-content/uploads/2022/08/PressRelease-300x158.png) ](https://www.precipiodx.com/precipio-announces-q2-2020-unaudited-pathology-services-revenue-increased-approximately-50-over-q120/)\n\n#####  [Precipio Announces Q2-2020 Unaudited Pathology Services Revenue Increased Approximately 50% Over Q1’20](https://www.precipiodx.com/precipio-announces-q2-2020-unaudited-pathology-services-revenue-increased-approximately-50-over-q120/)\n\nJuly 22, 2020\n\nNEW HAVEN, CT, (July 22nd, 2020) – Specialty diagnostics company Precipio, Inc. (NASDAQ: PRPO), announced its preliminary unaudited revenues for its pathology services increased from $0.8M in Q1’20, [...] \n\n[ Read More ](https://www.precipiodx.com/precipio-announces-q2-2020-unaudited-pathology-services-revenue-increased-approximately-50-over-q120/)\n\n[ ![Precipio Press Release](https://www.precipiodx.com/wp-content/uploads/2022/08/PressRelease-300x158.png) ](https://www.precipiodx.com/precipio-regains-listing-compliance-with-nasdaq-minimum-bid-requirement/)\n\n#####  [Precipio Regains Listing Compliance With NASDAQ Minimum Bid Requirement](https://www.precipiodx.com/precipio-regains-listing-compliance-with-nasdaq-minimum-bid-requirement/)\n\nJuly 1, 2020\n\nNEW HAVEN, CT, (July 1st, 2020) – Specialty diagnostics company Precipio, Inc. (NASDAQ: PRPO), announced that it has regained compliance with the Nasdaq listing requirements. On June 29, [...] \n\n[ Read More ](https://www.precipiodx.com/precipio-regains-listing-compliance-with-nasdaq-minimum-bid-requirement/)\n\n[ ![Precipio Press Release](https://www.precipiodx.com/wp-content/uploads/2022/08/PressRelease-300x158.png) ](https://www.precipiodx.com/precipio-adds-another-hemescreen-customer/)\n\n#####  [Precipio Adds Another HemeScreen™ Customer](https://www.precipiodx.com/precipio-adds-another-hemescreen-customer/)\n\nJune 9, 2020\n\nNewly Created Reagent Rental Program Continues to Gain HemeScreen Adopters NEW HAVEN, CT, (June 9th, 2020) – Specialty diagnostics company Precipio, Inc. (NASDAQ: PRPO), announced that Cancer and Hematology [...] \n\n[ Read More ](https://www.precipiodx.com/precipio-adds-another-hemescreen-customer/)\n\n[ ![Precipio Press Release](https://www.precipiodx.com/wp-content/uploads/2022/08/PressRelease-300x158.png) ](https://www.precipiodx.com/q1-2020-reported-revenues-increase-77-over-q4-2019-to-1-2m/)\n\n#####  [Q1-2020 Reported Revenues Increase 77% Over Q4-2019 To $1.2M](https://www.precipiodx.com/q1-2020-reported-revenues-increase-77-over-q4-2019-to-1-2m/)\n\nMay 15, 2020\n\nPrecipio Pathology Sales Performance Metrics Demonstrate Growth in Customer Acquisition, Retention, and Total Case Volume NEW HAVEN, CT, (May 15th, 2020) – Specialty cancer diagnostics company Precipio, [...] \n\n[ Read More ](https://www.precipiodx.com/q1-2020-reported-revenues-increase-77-over-q4-2019-to-1-2m/)\n\n[ ![Precipio Press Release](https://www.precipiodx.com/wp-content/uploads/2022/08/PressRelease-300x158.png) ](https://www.precipiodx.com/precipio-announces-q1-2020-corporate-update-call-for-shareholders/)\n\n#####  [Precipio Announces Q1-2020 Corporate Update Call For Shareholders](https://www.precipiodx.com/precipio-announces-q1-2020-corporate-update-call-for-shareholders/)\n\nMay 12, 2020\n\nConference Call to be held on Tuesday, May 19th, 2020 at 5:00 PM EST NEW HAVEN, CT, (May 12th, 2020) – Specialty cancer diagnostics company Precipio, Inc. (NASDAQ: [...] \n\n[ Read More ](https://www.precipiodx.com/precipio-announces-q1-2020-corporate-update-call-for-shareholders/)\n\n[ ![Precipio Press Release](https://www.precipiodx.com/wp-content/uploads/2022/08/PressRelease-300x158.png) ](https://www.precipiodx.com/precipio-launches-new-hemescreen-reagent-rental-program/)\n\n#####  [Precipio Launches New HemeScreen™ Reagent Rental Program](https://www.precipiodx.com/precipio-launches-new-hemescreen-reagent-rental-program/)\n\nApril 6, 2020\n\nOncology Practices Improve Patient care and Increase Revenue & Profit NEW HAVEN, CT, (April 6th, 2020) – Specialty diagnostics company Precipio, Inc. (NASDAQ: PRPO), announced today that it [...] \n\n[ Read More ](https://www.precipiodx.com/precipio-launches-new-hemescreen-reagent-rental-program/)\n\n[ ![Precipio Press Release](https://www.precipiodx.com/wp-content/uploads/2022/08/PressRelease-300x158.png) ](https://www.precipiodx.com/company-update-during-the-covid-19-era/)\n\n#####  [Company Update During The COVID-19 Era](https://www.precipiodx.com/company-update-during-the-covid-19-era/)\n\nMarch 20, 2020\n\nLetter to the Shareholders from the CEO NEW HAVEN, CT, (March 20th, 2020) – Specialty diagnostics company Precipio, Inc. (NASDAQ: PRPO), released today the following letter to shareholders [...] \n\n[ Read More ](https://www.precipiodx.com/company-update-during-the-covid-19-era/)\n\n[ ![Precipio Press Release](https://www.precipiodx.com/wp-content/uploads/2022/08/PressRelease-300x158.png) ](https://www.precipiodx.com/precipio-completes-the-transaction-with-poplar-healthcares-oncometrix-hematopathology-division/)\n\n#####  [Precipio Completes The Transaction With Poplar Healthcare’s Oncometrix Hematopathology Division](https://www.precipiodx.com/precipio-completes-the-transaction-with-poplar-healthcares-oncometrix-hematopathology-division/)\n\nMarch 16, 2020\n\nCustomer base and sales team transition to Precipio, Doubling Revenues NEW HAVEN, CT, (March 16th, 2020) – Specialty diagnostics company Precipio, Inc. (NASDAQ: PRPO), announced today that it [...] \n\n[ Read More ](https://www.precipiodx.com/precipio-completes-the-transaction-with-poplar-healthcares-oncometrix-hematopathology-division/)\n\n[ ![Precipio Press Release](https://www.precipiodx.com/wp-content/uploads/2022/08/PressRelease-300x158.png) ](https://www.precipiodx.com/precipio-achieves-impressive-initial-results-of-artificial-intelligence-decision-support-tool/)\n\n#####  [Precipio Achieves Impressive Initial Results Of Artificial Intelligence Decision-Support Tool](https://www.precipiodx.com/precipio-achieves-impressive-initial-results-of-artificial-intelligence-decision-support-tool/)\n\nFebruary 26, 2020\n\nGroundbreaking clinical and economic impact to be generated NEW HAVEN, CT, (February 26th, 2020) – Specialty diagnostics company Precipio, Inc. (NASDAQ: PRPO), announced today that preliminary results from [...] \n\n[ Read More ](https://www.precipiodx.com/precipio-achieves-impressive-initial-results-of-artificial-intelligence-decision-support-tool/)\n\n[ ![Precipio Press Release](https://www.precipiodx.com/wp-content/uploads/2022/08/PressRelease-300x158.png) ](https://www.precipiodx.com/precipio-in-advanced-discussions-with-poplar-healthcare-towards-a-multi-faceted-strategic-partnership/)\n\n#####  [Precipio In Advanced Discussions With Poplar Healthcare Towards A Multi-Faceted Strategic Partnership](https://www.precipiodx.com/precipio-in-advanced-discussions-with-poplar-healthcare-towards-a-multi-faceted-strategic-partnership/)\n\nFebruary 18, 2020\n\nNEW HAVEN, CT, (February 18th, 2020) – Specialty diagnostics company Precipio, Inc. (NASDAQ: PRPO), announced today that it is in advanced discussions with Poplar Healthcare to establish a strategic partnership [...] \n\n[ Read More ](https://www.precipiodx.com/precipio-in-advanced-discussions-with-poplar-healthcare-towards-a-multi-faceted-strategic-partnership/)\n\n[ ![Precipio Press Release](https://www.precipiodx.com/wp-content/uploads/2022/08/PressRelease-300x158.png) ](https://www.precipiodx.com/precipio-provides-clarification-to-amendment-no-1-to-form-s-1-filing/)\n\n#####  [Precipio Provides Clarification To Amendment No.1 To Form S-1 Filing](https://www.precipiodx.com/precipio-provides-clarification-to-amendment-no-1-to-form-s-1-filing/)\n\nJanuary 28, 2020\n\nNEW HAVEN, CT, (January 28th, 2020) – The management team of specialty diagnostics company Precipio, Inc. (NASDAQ: PRPO), would like to provide an explanation on the recent Amendment [...] \n\n[ Read More ](https://www.precipiodx.com/precipio-provides-clarification-to-amendment-no-1-to-form-s-1-filing/)\n\n[ ![Precipio Press Release](https://www.precipiodx.com/wp-content/uploads/2022/08/PressRelease-300x158.png) ](https://www.precipiodx.com/precipio-provides-clarification-to-recent-s-1-filing/)\n\n#####  [Precipio Provides Clarification To Recent S-1 Filing](https://www.precipiodx.com/precipio-provides-clarification-to-recent-s-1-filing/)\n\nJanuary 15, 2020\n\nNEW HAVEN, CT, (January 15th, 2020) – The management team of specialty diagnostics company Precipio, Inc. (NASDAQ: PRPO), would like to provide several clarification points related to the [...] \n\n[ Read More ](https://www.precipiodx.com/precipio-provides-clarification-to-recent-s-1-filing/)\n\n[ ![Precipio Press Release](https://www.precipiodx.com/wp-content/uploads/2022/08/PressRelease-300x158.png) ](https://www.precipiodx.com/precipio-announces-shareholder-update-call-to-kick-off-2020/)\n\n#####  [Precipio Announces Shareholder Update Call To Kick Off 2020](https://www.precipiodx.com/precipio-announces-shareholder-update-call-to-kick-off-2020/)\n\nJanuary 13, 2020\n\nNEW HAVEN, CT, (January 13th, 2020) – Specialty diagnostics company Precipio, Inc. (NASDAQ: PRPO), announced that on Monday, January 20th at 5pm it will conduct a shareholder update [...] \n\n[ Read More ](https://www.precipiodx.com/precipio-announces-shareholder-update-call-to-kick-off-2020/)\n\n[ ![Precipio Press Release](https://www.precipiodx.com/wp-content/uploads/2022/08/PressRelease-300x158.png) ](https://www.precipiodx.com/precipio-announces-first-iv-cell-commercial-order-from-northwell-health/)\n\n#####  [Precipio Announces First IV-Cell™ Commercial Order From Northwell Health](https://www.precipiodx.com/precipio-announces-first-iv-cell-commercial-order-from-northwell-health/)\n\nDecember 17, 2019\n\nLargest healthcare provider in New York becomes the first IV-Cell customer NEW HAVEN, CT, (December 17th, 2019) – Specialty cancer diagnostics company Precipio, Inc. (NASDAQ: PRPO), today announced [...] \n\n[ Read More ](https://www.precipiodx.com/precipio-announces-first-iv-cell-commercial-order-from-northwell-health/)\n\n[ ![Precipio Press Release](https://www.precipiodx.com/wp-content/uploads/2022/08/PressRelease-300x158.png) ](https://www.precipiodx.com/precipio-announces-the-resignation-of-samuel-riccitelli-and-the-introduction-of-richard-sandberg-to-its-board-of-directors/)\n\n#####  [Precipio Announces The Resignation Of Samuel Riccitelli And The Introduction Of Richard Sandberg To Its Board Of Directors](https://www.precipiodx.com/precipio-announces-the-resignation-of-samuel-riccitelli-and-the-introduction-of-richard-sandberg-to-its-board-of-directors/)\n\nDecember 4, 2019\n\nDouglas Fisher, MD will assume the role of interim Chairman of the Board NEW HAVEN, CT, (December 4th, 2019) – Specialty diagnostics company Precipio, Inc. (NASDAQ: PRPO), announced [...] \n\n[ Read More ](https://www.precipiodx.com/precipio-announces-the-resignation-of-samuel-riccitelli-and-the-introduction-of-richard-sandberg-to-its-board-of-directors/)\n\n#####  [Precipio Wins $750,000 Pharma Project](https://www.precipiodx.com/precipio-wins-750000-pharma-project/)\n\nNovember 14, 2019\n\nTesting and revenues will begin in Q4 and continue into Q1-2020 NEW HAVEN, CT, (November 14th, 2019) – Specialty diagnostics company Precipio, Inc. (NASDAQ: PRPO), announced a substantial [...] \n\n[ Read More ](https://www.precipiodx.com/precipio-wins-750000-pharma-project/)\n\n[ ![Precipio Press Release](https://www.precipiodx.com/wp-content/uploads/2022/08/PressRelease-300x158.png) ](https://www.precipiodx.com/precipio-reports-superior-performance-for-iv-cell-in-side-by-side-analysis-conducted-by-two-major-external-laboratories/)\n\n#####  [Precipio Reports Superior Performance For IV-Cell™ In Side-By-Side Analysis Conducted By Two Major External Laboratories](https://www.precipiodx.com/precipio-reports-superior-performance-for-iv-cell-in-side-by-side-analysis-conducted-by-two-major-external-laboratories/)\n\nNovember 14, 2019\n\nTesting yielded substantially better operational and clinical results, including the identification of a Leukemia missed when using a competing media NEW HAVEN, CT, (November 14th, 2019) – Specialty [...] \n\n[ Read More ](https://www.precipiodx.com/precipio-reports-superior-performance-for-iv-cell-in-side-by-side-analysis-conducted-by-two-major-external-laboratories/)\n\n[ ![Precipio Press Release](https://www.precipiodx.com/wp-content/uploads/2022/08/PressRelease-300x158.png) ](https://www.precipiodx.com/precipio-announces-q3-2019-corporate-update-call-for-shareholders/)\n\n#####  [Precipio Announces Q3-2019 Corporate Update Call For Shareholders](https://www.precipiodx.com/precipio-announces-q3-2019-corporate-update-call-for-shareholders/)\n\nNovember 4, 2019\n\nConference Call to be held on Wednesday, November 13th, 2019 at 5:30 PM EST NEW HAVEN, CT, (November 4th, 2019) – Specialty cancer diagnostics company Precipio, Inc. (NASDAQ: [...] \n\n[ Read More ](https://www.precipiodx.com/precipio-announces-q3-2019-corporate-update-call-for-shareholders/)\n\n[ ![Precipio Press Release](https://www.precipiodx.com/wp-content/uploads/2022/08/PressRelease-300x158.png) ](https://www.precipiodx.com/partners-healthcare-and-precipio-enter-into-pathology-services-agreement/)\n\n#####  [Partners HealthCare And Precipio Enter Into Pathology Services Agreement](https://www.precipiodx.com/partners-healthcare-and-precipio-enter-into-pathology-services-agreement/)\n\nOctober 9, 2019\n\nContinued Expansion of Academic Expertise Platform NEW HAVEN, CT, (October 9th, 2019) – Specialty diagnostics company Precipio, Inc. (NASDAQ: PRPO), announced today a further expansion of its cancer [...] \n\n[ Read More ](https://www.precipiodx.com/partners-healthcare-and-precipio-enter-into-pathology-services-agreement/)\n\n[ ![Precipio Press Release](https://www.precipiodx.com/wp-content/uploads/2022/08/PressRelease-300x158.png) ](https://www.precipiodx.com/precipio-announces-shareholder-update-call-on-commercial-progress/)\n\n#####  [Precipio Announces Shareholder Update Call On Commercial Progress](https://www.precipiodx.com/precipio-announces-shareholder-update-call-on-commercial-progress/)\n\nOctober 2, 2019\n\nConference call to be held Thursday October 10th at 5:00PM EST NEW HAVEN, CT, (October 2nd, 2019) – Specialty diagnostics company Precipio, Inc. (NASDAQ: PRPO), will hold a [...] \n\n[ Read More ](https://www.precipiodx.com/precipio-announces-shareholder-update-call-on-commercial-progress/)\n\n[ ![Precipio Press Release](https://www.precipiodx.com/wp-content/uploads/2022/08/PressRelease-300x158.png) ](https://www.precipiodx.com/clinical-validations-for-iv-cell-and-hemescreen-completed/)\n\n#####  [Clinical Validations For IV-Cell™ And HemeScreen™ Completed](https://www.precipiodx.com/clinical-validations-for-iv-cell-and-hemescreen-completed/)\n\nSeptember 26, 2019\n\nOrders expected from several major labs both domestically and internationally NEW HAVEN, CT, (September 26th, 2019) – Specialty diagnostics company Precipio, Inc. (NASDAQ: PRPO), announced that as it [...] \n\n[ Read More ](https://www.precipiodx.com/clinical-validations-for-iv-cell-and-hemescreen-completed/)\n\n[ ![Precipio Press Release](https://www.precipiodx.com/wp-content/uploads/2022/08/PressRelease-300x158.png) ](https://www.precipiodx.com/precipio-and-university-of-pennsylvania-enter-into-joint-collaboration-agreement-for-pathology-diagnostics/)\n\n#####  [Precipio And University Of Pennsylvania Enter Into Joint Collaboration Agreement For Pathology Diagnostics](https://www.precipiodx.com/precipio-and-university-of-pennsylvania-enter-into-joint-collaboration-agreement-for-pathology-diagnostics/)\n\nSeptember 5, 2019\n\nFirst cases already diagnosed and reported by Penn expert pathologists NEW HAVEN, CT, (September 5th, 2019) – Specialty diagnostics company Precipio, Inc. (NASDAQ: PRPO), announced today a major [...] \n\n[ Read More ](https://www.precipiodx.com/precipio-and-university-of-pennsylvania-enter-into-joint-collaboration-agreement-for-pathology-diagnostics/)\n\n[ ![Precipio Press Release](https://www.precipiodx.com/wp-content/uploads/2022/08/PressRelease-300x158.png) ](https://www.precipiodx.com/precipio-pathology-sales-metrics-demonstrate-continuous-improvement-in-q2-2019/)\n\n#####  [Precipio Pathology Sales Metrics Demonstrate Continuous Improvement In Q2 2019](https://www.precipiodx.com/precipio-pathology-sales-metrics-demonstrate-continuous-improvement-in-q2-2019/)\n\nAugust 13, 2019\n\nThree key metrics indicate growth over prior Quarter and same Quarter of 2018 NEW HAVEN, CT, (August 13th, 2019) – Specialty cancer diagnostics company Precipio, Inc. (NASDAQ: PRPO), [...] \n\n[ Read More ](https://www.precipiodx.com/precipio-pathology-sales-metrics-demonstrate-continuous-improvement-in-q2-2019/)\n\n[ ![Precipio Press Release](https://www.precipiodx.com/wp-content/uploads/2022/08/PressRelease-300x158.png) ](https://www.precipiodx.com/precipio-announces-q2-2019-corporate-update-call-for-shareholders/)\n\n#####  [Precipio Announces Q2-2019 Corporate Update Call For Shareholders](https://www.precipiodx.com/precipio-announces-q2-2019-corporate-update-call-for-shareholders/)\n\nAugust 13, 2019\n\nConference Call to be held on Wednesday, August 21st, 2019 at 5:00 PM EST NEW HAVEN, CT, (August 13, 2019) – Specialty cancer diagnostics company Precipio, Inc. (NASDAQ: [...] \n\n[ Read More ](https://www.precipiodx.com/precipio-announces-q2-2019-corporate-update-call-for-shareholders/)\n\n[ ![Precipio Press Release](https://www.precipiodx.com/wp-content/uploads/2022/08/PressRelease-300x158.png) ](https://www.precipiodx.com/global-expansion-efforts-begin-yielding-results/)\n\n#####  [Global Expansion Efforts Begin Yielding Results](https://www.precipiodx.com/global-expansion-efforts-begin-yielding-results/)\n\nJuly 22, 2019\n\nAsia is the first Key Geographic Focal Point NEW HAVEN, CT, (July 22nd, 2019) – Specialty diagnostics company Precipio, Inc. (NASDAQ: PRPO), announced today that in conjunction with [...] \n\n[ Read More ](https://www.precipiodx.com/global-expansion-efforts-begin-yielding-results/)\n\n[ ![Precipio Press Release](https://www.precipiodx.com/wp-content/uploads/2022/08/PressRelease-300x158.png) ](https://www.precipiodx.com/precipio-and-h3-biomedicine-sign-second-development-agreement/)\n\n#####  [Precipio And H3 Biomedicine Sign Second Development Agreement](https://www.precipiodx.com/precipio-and-h3-biomedicine-sign-second-development-agreement/)\n\nJune 25, 2019\n\nCompanies to create a panel amplifying targeted regions of key cancer genes NEW HAVEN, CT, (June 25th, 2019) – Specialty diagnostics company Precipio, Inc. (NASDAQ: PRPO), announced the [...] \n\n[ Read More ](https://www.precipiodx.com/precipio-and-h3-biomedicine-sign-second-development-agreement/)\n\n[ ![Precipio Press Release](https://www.precipiodx.com/wp-content/uploads/2022/08/PressRelease-300x158.png) ](https://www.precipiodx.com/precipio-ceo-provides-update-letter-to-shareholders/)\n\n#####  [Precipio CEO Provides Update Letter To Shareholders](https://www.precipiodx.com/precipio-ceo-provides-update-letter-to-shareholders/)\n\nJune 17, 2019\n\nNEW HAVEN, CT, (June 17th, 2019) – Specialty diagnostics company Precipio, Inc. (NASDAQ: PRPO), provides an update to its shareholders. Dear Investors: We are all aware of the [...] \n\n[ Read More ](https://www.precipiodx.com/precipio-ceo-provides-update-letter-to-shareholders/)\n\n[ ![Precipio Press Release](https://www.precipiodx.com/wp-content/uploads/2022/08/PressRelease-300x158.png) ](https://www.precipiodx.com/precipio-signs-exclusive-manufacturing-agreement-for-iv-cell/)\n\n#####  [Precipio Signs Exclusive Manufacturing Agreement For IV-Cell™](https://www.precipiodx.com/precipio-signs-exclusive-manufacturing-agreement-for-iv-cell/)\n\nJune 4, 2019\n\nNEW HAVEN, CT, (June 4th, 2019) – Specialty diagnostics company Precipio, Inc. (NASDAQ: PRPO), announced that it has entered into an exclusive subcontracting manufacturing agreement with diagnostics manufacturing [...] \n\n[ Read More ](https://www.precipiodx.com/precipio-signs-exclusive-manufacturing-agreement-for-iv-cell/)\n\n[ ![Precipio Press Release](https://www.precipiodx.com/wp-content/uploads/2022/08/PressRelease-300x158.png) ](https://www.precipiodx.com/precipio-pathology-sales-performance-metrics-demonstrate-substantial-improvement-in-q1-2019/)\n\n#####  [Precipio Pathology Sales Performance Metrics Demonstrate Substantial Improvement In Q1-2019](https://www.precipiodx.com/precipio-pathology-sales-performance-metrics-demonstrate-substantial-improvement-in-q1-2019/)\n\nMay 30, 2019\n\nThree key metrics are leading indicators of continuous revenue growth NEW HAVEN, CT, (May 30th, 2019) – Specialty diagnostics company Precipio, Inc. (NASDAQ: PRPO), today provides shareholders with [...] \n\n[ Read More ](https://www.precipiodx.com/precipio-pathology-sales-performance-metrics-demonstrate-substantial-improvement-in-q1-2019/)\n\n[ ![Precipio Press Release](https://www.precipiodx.com/wp-content/uploads/2022/08/PressRelease-300x158.png) ](https://www.precipiodx.com/precipio-ceo-enrolls-in-long-term-stock-purchase-plan/)\n\n#####  [Precipio CEO Enrolls In Long Term Stock Purchase Plan](https://www.precipiodx.com/precipio-ceo-enrolls-in-long-term-stock-purchase-plan/)\n\nMay 23, 2019\n\nNEW HAVEN, CT, (May 23, 2019) – Specialty diagnostics company Precipio, Inc. (NASDAQ: PRPO), announced today that, as previously stated, Ilan Danieli, Precipio’s CEO, has enrolled in a [...] \n\n[ Read More ](https://www.precipiodx.com/precipio-ceo-enrolls-in-long-term-stock-purchase-plan/)\n\n[ ![Precipio Press Release](https://www.precipiodx.com/wp-content/uploads/2022/08/PressRelease-300x158.png) ](https://www.precipiodx.com/precipio-regains-nasdaq-listing-compliance/)\n\n#####  [Precipio Regains Nasdaq Listing Compliance](https://www.precipiodx.com/precipio-regains-nasdaq-listing-compliance/)\n\nMay 15, 2019\n\nNEW HAVEN, CT, (May 15, 2019) – Specialty diagnostics company Precipio, Inc. (NASDAQ: PRPO), announced that on May 15, 2019 the Company received a letter from Nasdaq informing [...] \n\n[ Read More ](https://www.precipiodx.com/precipio-regains-nasdaq-listing-compliance/)\n\n[ ![Precipio Press Release](https://www.precipiodx.com/wp-content/uploads/2022/08/PressRelease-300x158.png) ](https://www.precipiodx.com/precipio-conducts-iv-cell-validation-trial-with-a-prominent-laboratory/)\n\n#####  [Precipio Conducts IV-Cell™ Validation Trial With A Prominent Laboratory](https://www.precipiodx.com/precipio-conducts-iv-cell-validation-trial-with-a-prominent-laboratory/)\n\nMay 6, 2019\n\nNEW HAVEN, CT, (May 06, 2019) – Specialty diagnostics company Precipio, Inc. (NASDAQ: PRPO), announced that it is in the process of completing a trial of its Proprietary [...] \n\n[ Read More ](https://www.precipiodx.com/precipio-conducts-iv-cell-validation-trial-with-a-prominent-laboratory/)\n\n[ ![Precipio Press Release](https://www.precipiodx.com/wp-content/uploads/2022/08/PressRelease-300x158.png) ](https://www.precipiodx.com/precipio-successfully-completes-nasdaq-hearing-process/)\n\n#####  [Precipio Successfully Completes Nasdaq Hearing Process](https://www.precipiodx.com/precipio-successfully-completes-nasdaq-hearing-process/)\n\nMay 3, 2019\n\nCompany is expected to regain listing compliance upon completion of the remaining 10-day requirement NEW HAVEN, CT, (May 03, 2019) – Specialty diagnostics company Precipio, Inc. (NASDAQ: PRPO), [...] \n\n[ Read More ](https://www.precipiodx.com/precipio-successfully-completes-nasdaq-hearing-process/)\n\n[ ![Precipio Press Release](https://www.precipiodx.com/wp-content/uploads/2022/08/PressRelease-300x158.png) ](https://www.precipiodx.com/precipio-reminder-of-corporate-update-shareholder-call/)\n\n#####  [Precipio Reminder Of Corporate Update Shareholder Call](https://www.precipiodx.com/precipio-reminder-of-corporate-update-shareholder-call/)\n\nMay 1, 2019\n\nConference Call to be held Monday May 6th, 2019 at 5:00pm Eastern Time NEW HAVEN, CT, (May 01, 2019) – Specialty diagnostics company Precipio, Inc. (NASDAQ: PRPO), will [...] \n\n[ Read More ](https://www.precipiodx.com/precipio-reminder-of-corporate-update-shareholder-call/)\n\n[ ![Precipio Press Release](https://www.precipiodx.com/wp-content/uploads/2022/08/PressRelease-300x158.png) ](https://www.precipiodx.com/precipio-signs-first-major-international-services-contract/)\n\n#####  [Precipio Signs First Major International Services Contract](https://www.precipiodx.com/precipio-signs-first-major-international-services-contract/)\n\nApril 29, 2019\n\nContract expected to generate over $1.5M in revenues annually NEW HAVEN, CT, (April 29, 2019) – Specialty cancer diagnostics company Precipio, Inc. (NASDAQ: PRPO) today announced that it has [...] \n\n[ Read More ](https://www.precipiodx.com/precipio-signs-first-major-international-services-contract/)\n\n[ ![Precipio Press Release](https://www.precipiodx.com/wp-content/uploads/2022/08/PressRelease-300x158.png) ](https://www.precipiodx.com/precipio-takes-final-step-towards-regaining-nasdaq-compliance/)\n\n#####  [Precipio Takes Final Step Towards Regaining Nasdaq Compliance](https://www.precipiodx.com/precipio-takes-final-step-towards-regaining-nasdaq-compliance/)\n\nApril 26, 2019\n\nCompany announces 1-for-15 reverse stock split NEW HAVEN, CT, (April 26, 2019) – Specialty cancer diagnostics company Precipio, Inc. (NASDAQ: PRPO) today announced that it has implemented a 1-for-15 [...] \n\n[ Read More ](https://www.precipiodx.com/precipio-takes-final-step-towards-regaining-nasdaq-compliance/)\n\n[ ![Precipio Press Release](https://www.precipiodx.com/wp-content/uploads/2022/08/PressRelease-300x158.png) ](https://www.precipiodx.com/precipio-launches-global-expansion-strategy/)\n\n#####  [Precipio Launches Global Expansion Strategy](https://www.precipiodx.com/precipio-launches-global-expansion-strategy/)\n\nApril 24, 2019\n\nPrecipio to capitalize on powerful data and expertise to grow business globally NEW HAVEN, CT, (April 24, 2019) – Specialty diagnostics company Precipio, Inc. (NASDAQ: PRPO) announces the launch [...] \n\n[ Read More ](https://www.precipiodx.com/precipio-launches-global-expansion-strategy/)\n\n[ ![Precipio Press Release](https://www.precipiodx.com/wp-content/uploads/2022/08/PressRelease-300x158.png) ](https://www.precipiodx.com/mr-ori-karev-joins-precipio-executive-team-as-chief-strategy-officer/)\n\n#####  [Mr. Ori Karev Joins Precipio Executive Team As Chief Strategy Officer](https://www.precipiodx.com/mr-ori-karev-joins-precipio-executive-team-as-chief-strategy-officer/)\n\nApril 18, 2019\n\nPrecipio to expand its reach globally NEW HAVEN, CT, (April 18, 2019) – Specialty diagnostics company Precipio, Inc. (NASDAQ: PRPO) announced today that Mr. Ori Karev has joined the [...] \n\n[ Read More ](https://www.precipiodx.com/mr-ori-karev-joins-precipio-executive-team-as-chief-strategy-officer/)\n\n[ ![Precipio Press Release](https://www.precipiodx.com/wp-content/uploads/2022/08/PressRelease-300x158.png) ](https://www.precipiodx.com/precipio-announces-2018-year-end-corporate-update-call-for-shareholders/)\n\n#####  [Precipio Announces 2018 Year-End Corporate Update Call For Shareholders](https://www.precipiodx.com/precipio-announces-2018-year-end-corporate-update-call-for-shareholders/)\n\nApril 15, 2019\n\nConference Call to Be Held On Monday, May 6th, 2019 at 5:00 PM ET NEW HAVEN, CT, (April 15th, 2019) – Specialty cancer diagnostics company Precipio, Inc. (NASDAQ: [...] \n\n[ Read More ](https://www.precipiodx.com/precipio-announces-2018-year-end-corporate-update-call-for-shareholders/)\n\n[ ![Precipio Press Release](https://www.precipiodx.com/wp-content/uploads/2022/08/PressRelease-300x158.png) ](https://www.precipiodx.com/precipio-identifies-manufacturer-for-its-iv-cell-media/)\n\n#####  [Precipio Identifies Manufacturer For Its IV-Cell Media](https://www.precipiodx.com/precipio-identifies-manufacturer-for-its-iv-cell-media/)\n\nApril 9, 2019\n\nManufacturing Partner enables Precipio to address customer demand and plans for global distribution NEW HAVEN, CT, (April 9th, 2019) – Specialty diagnostics company Precipio, Inc. (NASDAQ: PRPO) announced today [...] \n\n[ Read More ](https://www.precipiodx.com/precipio-identifies-manufacturer-for-its-iv-cell-media/)\n\n[ ![Precipio Press Release](https://www.precipiodx.com/wp-content/uploads/2022/08/PressRelease-300x158.png) ](https://www.precipiodx.com/precipios-hemescreen-adopted-by-methodist-health/)\n\n#####  [Precipio’s HemeScreen™ Adopted By Methodist Health](https://www.precipiodx.com/precipios-hemescreen-adopted-by-methodist-health/)\n\nApril 3, 2019\n\nNew Molecular Screening Assay Technology Gains Traction NEW HAVEN, CT, (April 3, 2019) – Specialty diagnostics company Precipio, Inc. (NASDAQ: PRPO), announced today that Methodist Hospital, located in Memphis, [...] \n\n[ Read More ](https://www.precipiodx.com/precipios-hemescreen-adopted-by-methodist-health/)\n\n[ ![Precipio Press Release](https://www.precipiodx.com/wp-content/uploads/2022/08/PressRelease-300x158.png) ](https://www.precipiodx.com/precipio-ceo-issues-shareholder-update-letter/)\n\n#####  [Precipio CEO Issues Shareholder Update Letter](https://www.precipiodx.com/precipio-ceo-issues-shareholder-update-letter/)\n\nMarch 11, 2019\n\nNEW HAVEN, CT, (March 11th, 2019) – Specialty cancer diagnostics company Precipio, Inc. (NASDAQ: PRPO), issues the following letter from CEO Ilan Danieli. Dear Shareholders, Following our recent [...] \n\n[ Read More ](https://www.precipiodx.com/precipio-ceo-issues-shareholder-update-letter/)\n\n[ ![Precipio Press Release](https://www.precipiodx.com/wp-content/uploads/2022/08/PressRelease-300x158.png) ](https://www.precipiodx.com/precipio-provides-corporate-update-shareholder-call/)\n\n#####  [Precipio Provides Corporate Update Shareholder Call](https://www.precipiodx.com/precipio-provides-corporate-update-shareholder-call/)\n\nFebruary 18, 2019\n\nConference Call to be held Thursday February 21st, 2019 at 4:30pm Eastern Time NEW HAVEN, CT, (February 18th, 2019) – Specialty cancer diagnostics company Precipio, Inc. (NASDAQ: PRPO),will [...] \n\n[ Read More ](https://www.precipiodx.com/precipio-provides-corporate-update-shareholder-call/)\n\n[ ![Precipio Press Release](https://www.precipiodx.com/wp-content/uploads/2022/08/PressRelease-300x158.png) ](https://www.precipiodx.com/precipio-2018-revenues-increase-66-over-2017-company-takes-substantial-cost-cutting-measures-towards-profitability/)\n\n#####  [Precipio 2018 Revenues Increase 66% Over 2017; Company Takes Substantial Cost-Cutting Measures Towards Profitability](https://www.precipiodx.com/precipio-2018-revenues-increase-66-over-2017-company-takes-substantial-cost-cutting-measures-towards-profitability/)\n\nFebruary 14, 2019\n\nShareholder call scheduled for February 21st at 4:30PM EST NEW HAVEN, CT, (February 14th, 2019) – Specialty cancer diagnostics company Precipio, Inc. (NASDAQ: PRPO),announced today its preliminary unaudited [...] \n\n[ Read More ](https://www.precipiodx.com/precipio-2018-revenues-increase-66-over-2017-company-takes-substantial-cost-cutting-measures-towards-profitability/)\n\n[ ![Precipio Press Release](https://www.precipiodx.com/wp-content/uploads/2022/08/PressRelease-300x158.png) ](https://www.precipiodx.com/makati-medical-center-in-the-philippines-adopts-precipios-ice-cold-pcr-mutation-enrichment-technology-for-liquid-biopsies/)\n\n#####  [Makati Medical Center In The Philippines Adopts Precipio’s ICE COLD-PCR Mutation Enrichment Technology For Liquid Biopsies](https://www.precipiodx.com/makati-medical-center-in-the-philippines-adopts-precipios-ice-cold-pcr-mutation-enrichment-technology-for-liquid-biopsies/)\n\nJanuary 15, 2019\n\nOne of Nation’s Premier Hospitals to Become Central Laboratory for Liquid Biopsies NEW HAVEN, CT, (January 15th, 2019) – Specialty cancer diagnostics company Precipio, Inc. (NASDAQ: PRPO) announced that Makati [...] \n\n[ Read More ](https://www.precipiodx.com/makati-medical-center-in-the-philippines-adopts-precipios-ice-cold-pcr-mutation-enrichment-technology-for-liquid-biopsies/)\n\n[ ![Precipio Press Release](https://www.precipiodx.com/wp-content/uploads/2022/08/PressRelease-300x158.png) ](https://www.precipiodx.com/precipio-announces-first-us-government-customer-for-ice-cold-pcr-mutation-enrichment-technology/)\n\n#####  [Precipio Announces First US Government Customer For ICE COLD-PCR™ Mutation Enrichment Technology](https://www.precipiodx.com/precipio-announces-first-us-government-customer-for-ice-cold-pcr-mutation-enrichment-technology/)\n\nJanuary 10, 2019\n\nDepartment of Defense Approves Precipio as a Vendor for its Liquid Biopsy Testing NEW HAVEN, CT, (January 10th, 2019) – Specialty cancer diagnostics company Precipio, Inc. (NASDAQ: PRPO), [...] \n\n[ Read More ](https://www.precipiodx.com/precipio-announces-first-us-government-customer-for-ice-cold-pcr-mutation-enrichment-technology/)\n\n[ ![Precipio Press Release](https://www.precipiodx.com/wp-content/uploads/2022/08/PressRelease-300x158.png) ](https://www.precipiodx.com/precipio-files-patent-for-hemescreen-its-novel-molecular-assay/)\n\n#####  [Precipio Files Patent For HemeScreen™, Its Novel Molecular Assay](https://www.precipiodx.com/precipio-files-patent-for-hemescreen-its-novel-molecular-assay/)\n\nJanuary 8, 2019\n\nCommercialization of assay underway with both in-house testing and hospital sales NEW HAVEN, CT, (January 8th, 2019) – Specialty diagnostics company Precipio, Inc. (NASDAQ: PRPO), today announced the [...] \n\n[ Read More ](https://www.precipiodx.com/precipio-files-patent-for-hemescreen-its-novel-molecular-assay/)\n\n[ ![Precipio Press Release](https://www.precipiodx.com/wp-content/uploads/2022/08/PressRelease-300x158.png) ](https://www.precipiodx.com/precipio-reports-strong-mid-quarter-growth/)\n\n#####  [Precipio Reports Strong Mid-Quarter Growth](https://www.precipiodx.com/precipio-reports-strong-mid-quarter-growth/)\n\nDecember 12, 2018\n\nKey Metrics Indicate Continued Growth QoQ for Fourth Quarter 2018 NEW HAVEN, CT, (December 12th, 2018) – Specialty diagnostics company Precipio, Inc. (NASDAQ: PRPO), announced today that based [...] \n\n[ Read More ](https://www.precipiodx.com/precipio-reports-strong-mid-quarter-growth/)\n\n[ ![Precipio Press Release](https://www.precipiodx.com/wp-content/uploads/2022/08/PressRelease-300x158.png) ](https://www.precipiodx.com/precipio-announces-1-2-million-securities-purchase-agreement-with-participation-from-members-of-its-board-of-directors-and-other-investors/)\n\n#####  [Precipio Announces $1.2 Million Securities Purchase Agreement With Participation From Members Of Its Board Of Directors, And Other Investors](https://www.precipiodx.com/precipio-announces-1-2-million-securities-purchase-agreement-with-participation-from-members-of-its-board-of-directors-and-other-investors/)\n\nDecember 4, 2018\n\nNEW HAVEN, CT, (December 4th, 2018) – Specialty diagnostics company Precipio, Inc. (NASDAQ: PRPO), announced today that it has entered into a $1.2 million Securities Purchase Agreement with [...] \n\n[ Read More ](https://www.precipiodx.com/precipio-announces-1-2-million-securities-purchase-agreement-with-participation-from-members-of-its-board-of-directors-and-other-investors/)\n\n[ ![Precipio Press Release](https://www.precipiodx.com/wp-content/uploads/2022/08/PressRelease-300x158.png) ](https://www.precipiodx.com/precipio-announces-third-quarter-2018-corporate-update-call-for-shareholders/)\n\n#####  [Precipio Announces Third Quarter 2018 Corporate Update Call For Shareholders](https://www.precipiodx.com/precipio-announces-third-quarter-2018-corporate-update-call-for-shareholders/)\n\nNovember 19, 2018\n\nConference Call to Be Held Monday, November 19, 2018 at 5:00 PM ET NEW HAVEN, CT, (November 15th, 2018) – Specialty diagnostics company Precipio, Inc. (NASDAQ: PRPO) will be [...] \n\n[ Read More ](https://www.precipiodx.com/precipio-announces-third-quarter-2018-corporate-update-call-for-shareholders/)\n\n[ ![Precipio Press Release](https://www.precipiodx.com/wp-content/uploads/2022/08/PressRelease-300x158.png) ](https://www.precipiodx.com/proxy-and-special-shareholder-meeting-letter-from-ceo/)\n\n#####  [Proxy And Special Shareholder Meeting Letter From CEO](https://www.precipiodx.com/proxy-and-special-shareholder-meeting-letter-from-ceo/)\n\nNovember 16, 2018\n\nCEO to share a few thoughts in advance of the upcoming shareholder call on Monday, November 19th at 5PM EST NEW HAVEN, CT, (November 16th, [...] \n\n[ Read More ](https://www.precipiodx.com/proxy-and-special-shareholder-meeting-letter-from-ceo/)\n\n[ ![Precipio Press Release](https://www.precipiodx.com/wp-content/uploads/2022/08/PressRelease-300x158.png) ](https://www.precipiodx.com/webinar-to-highlight-technology-underlying-precipios-ice-cold-pcr-on-november-20-2018/)\n\n#####  [Webinar To Highlight Technology Underlying Precipio’s ICE COLD-PCR On November 20, 2018](https://www.precipiodx.com/webinar-to-highlight-technology-underlying-precipios-ice-cold-pcr-on-november-20-2018/)\n\nNovember 14, 2018\n\nCurrent Status, Existing and Future Applications of COLD-PCR for Cancer and Prenatal Diagnosis to Be Presented NEW HAVEN, CT, (November 14th, 2018) – Specialty diagnostics company Precipio, [...] \n\n[ Read More ](https://www.precipiodx.com/webinar-to-highlight-technology-underlying-precipios-ice-cold-pcr-on-november-20-2018/)\n\n[ ![Precipio Press Release](https://www.precipiodx.com/wp-content/uploads/2022/08/PressRelease-300x158.png) ](https://www.precipiodx.com/precipio-and-perkinelmer-collaborate-to-provide-solutions-for-liquid-biopsy-testing-workflows/)\n\n#####  [Precipio And PerkinElmer Collaborate To Provide Solutions For Liquid Biopsy Testing Workflows](https://www.precipiodx.com/precipio-and-perkinelmer-collaborate-to-provide-solutions-for-liquid-biopsy-testing-workflows/)\n\nNovember 1, 2018\n\nPrecipio ICE COLD-PCR™ reagents will be sold with PerkinElmer DNA/RNA extraction and isolation products NEW HAVEN, CT, (November 1st, 2018) – Specialty cancer diagnostics company Precipio, Inc. (NASDAQ: [...] \n\n[ Read More ](https://www.precipiodx.com/precipio-and-perkinelmer-collaborate-to-provide-solutions-for-liquid-biopsy-testing-workflows/)\n\n[ ![Precipio Press Release](https://www.precipiodx.com/wp-content/uploads/2022/08/PressRelease-300x158.png) ](https://www.precipiodx.com/precipio-expands-ice-cold-pcr-menu-for-breast-colon-and-endometrial-cancers/)\n\n#####  [Precipio Expands ICE COLD-PCR™ Menu For Breast, Colon And Endometrial Cancers](https://www.precipiodx.com/precipio-expands-ice-cold-pcr-menu-for-breast-colon-and-endometrial-cancers/)\n\nOctober 23, 2018\n\nUltra-sensitive assays for PIK3CA exons 9 & 20 detect mutations that impact critical therapeutic decisions NEW HAVEN, CT, (October 23rd, 2018) – Precipio, Inc. (NASDAQ: PRPO), announced today [...] \n\n[ Read More ](https://www.precipiodx.com/precipio-expands-ice-cold-pcr-menu-for-breast-colon-and-endometrial-cancers/)\n\n[ ![Precipio Press Release](https://www.precipiodx.com/wp-content/uploads/2022/08/PressRelease-300x158.png) ](https://www.precipiodx.com/innovation-behind-precipios-ice-cold-pcr-platform-spotlighted-in-media/)\n\n#####  [Innovation Behind Precipio’s ICE-COLD PCR™ Platform Spotlighted In Media](https://www.precipiodx.com/innovation-behind-precipios-ice-cold-pcr-platform-spotlighted-in-media/)\n\nOctober 18, 2018\n\nArticles Highlight Scientific and Economic Advantages Provided by Precipio’s Technology NEW HAVEN, CT, (October 18th, 2018) – The scientific and economic advantages of the proprietary, ultra-sensitive [...] \n\n[ Read More ](https://www.precipiodx.com/innovation-behind-precipios-ice-cold-pcr-platform-spotlighted-in-media/)\n\n[ ![Precipio Press Release](https://www.precipiodx.com/wp-content/uploads/2022/08/PressRelease-300x158.png) ](https://www.precipiodx.com/precipio-launches-hemescreen-a-disruptive-proprietary-molecular-test-for-hematologic-cancers/)\n\n#####  [Precipio Launches HemeScreen™, A Disruptive, Proprietary Molecular Test For Hematologic Cancers](https://www.precipiodx.com/precipio-launches-hemescreen-a-disruptive-proprietary-molecular-test-for-hematologic-cancers/)\n\nOctober 3, 2018\n\nImpacts a $100M annual US laboratory market by reducing testing costs through a simple, screening assay NEW HAVEN, CT, (October 3rd, 2018) – Specialty cancer diagnostics [...] \n\n[ Read More ](https://www.precipiodx.com/precipio-launches-hemescreen-a-disruptive-proprietary-molecular-test-for-hematologic-cancers/)\n\n[ ![Precipio Press Release](https://www.precipiodx.com/wp-content/uploads/2022/08/PressRelease-300x158.png) ](https://www.precipiodx.com/precipio-granted-180-day-nasdaq-extension-to-regain-compliance/)\n\n#####  [Precipio Granted 180 Day NASDAQ Extension To Regain Compliance](https://www.precipiodx.com/precipio-granted-180-day-nasdaq-extension-to-regain-compliance/)\n\nSeptember 27, 2018\n\nEnables Company to execute on strategic and commercial initiatives with the goal of meeting the minimum $1.00 price target NEW HAVEN, CT, (September 27th, 2018) – [...] \n\n[ Read More ](https://www.precipiodx.com/precipio-granted-180-day-nasdaq-extension-to-regain-compliance/)\n\n[ ![Precipio Press Release](https://www.precipiodx.com/wp-content/uploads/2022/08/PressRelease-300x158.png) ](https://www.precipiodx.com/precipio-expands-ice-cold-pcr-lung-cancer-mutation-detection-offering/)\n\n#####  [Precipio Expands ICE-COLD PCR™ Lung Cancer Mutation Detection Offering](https://www.precipiodx.com/precipio-expands-ice-cold-pcr-lung-cancer-mutation-detection-offering/)\n\nSeptember 20, 2018\n\nNew reagent examines most relevant EGFR exons that impact therapeutic decisions for lung cancer patients NEW HAVEN, CT, (September 20th, 2018) – Specialty cancer diagnostics company Precipio, [...] \n\n[ Read More ](https://www.precipiodx.com/precipio-expands-ice-cold-pcr-lung-cancer-mutation-detection-offering/)\n\n[ ![Precipio Press Release](https://www.precipiodx.com/wp-content/uploads/2022/08/PressRelease-300x158.png) ](https://www.precipiodx.com/precipio-announces-third-quarter-2018-revenues-estimated-at-2-4-times-year-over-year-q3-2017/)\n\n#####  [Precipio Announces Third Quarter 2018 Revenues Estimated At 2.4 Times Year-Over-Year Q3-2017](https://www.precipiodx.com/precipio-announces-third-quarter-2018-revenues-estimated-at-2-4-times-year-over-year-q3-2017/)\n\nSeptember 16, 2018\n\nFourth consecutive Quarter of Triple-Digit YoY Quarterly Growth; Triple YTD Revenues Over Same Period Last Year NEW HAVEN, CT, (October 16th, 2018) – Specialty cancer diagnostics [...] \n\n[ Read More ](https://www.precipiodx.com/precipio-announces-third-quarter-2018-revenues-estimated-at-2-4-times-year-over-year-q3-2017/)\n\n[ ![Precipio Press Release](https://www.precipiodx.com/wp-content/uploads/2022/08/PressRelease-300x158.png) ](https://www.precipiodx.com/precipio-reminds-investors-of-conference-call-with-management-for-corporate-update-and-second-quarter-results/)\n\n#####  [Precipio Reminds Investors Of Conference Call With Management For Corporate Update And Second Quarter Results](https://www.precipiodx.com/precipio-reminds-investors-of-conference-call-with-management-for-corporate-update-and-second-quarter-results/)\n\nAugust 22, 2018\n\nProvides participation details for Thursday, August 23 call NEW HAVEN, CT, (August 22nd, 2018) – Specialty cancer diagnostics company Precipio, Inc. (NASDAQ: PRPO), wishes to remind investors and [...] \n\n[ Read More ](https://www.precipiodx.com/precipio-reminds-investors-of-conference-call-with-management-for-corporate-update-and-second-quarter-results/)\n\n[ ![Precipio Press Release](https://www.precipiodx.com/wp-content/uploads/2022/08/PressRelease-300x158.png) ](https://www.precipiodx.com/precipio-announces-second-quarter-2018-financial-results-and-provides-corporate-update/)\n\n#####  [Precipio Announces Second Quarter 2018 Financial Results And Provides Corporate Update](https://www.precipiodx.com/precipio-announces-second-quarter-2018-financial-results-and-provides-corporate-update/)\n\nAugust 17, 2018\n\nConference call with management to be held Thursday August 23, 2018 at 09:00 Eastern Time NEW HAVEN, CT, (August 17th, 2018) – Specialty cancer diagnostics company Precipio, [...] \n\n[ Read More ](https://www.precipiodx.com/precipio-announces-second-quarter-2018-financial-results-and-provides-corporate-update/)\n\n[ ![Precipio Press Release](https://www.precipiodx.com/wp-content/uploads/2022/08/PressRelease-300x158.png) ](https://www.precipiodx.com/precipio-appoints-new-board-member-to-replace-departing-director/)\n\n#####  [Precipio Appoints New Board Member To Replace Departing Director](https://www.precipiodx.com/precipio-appoints-new-board-member-to-replace-departing-director/)\n\nAugust 9, 2018\n\nKathy LaPorte brings 30-year track record of VC success financing and operating innovative biopharma, diagnostics and healthcare companies NEW HAVEN, CT, (August 09th, 2018) – Specialty [...] \n\n[ Read More ](https://www.precipiodx.com/precipio-appoints-new-board-member-to-replace-departing-director/)\n\n[ ![Precipio Press Release](https://www.precipiodx.com/wp-content/uploads/2022/08/PressRelease-300x158.png) ](https://www.precipiodx.com/precipio-announces-213-year-over-year-revenue-growth-in-preliminary-q2-2018-results/)\n\n#####  [Precipio Announces 213% Year-Over-Year Revenue Growth In Preliminary Q2-2018 Results](https://www.precipiodx.com/precipio-announces-213-year-over-year-revenue-growth-in-preliminary-q2-2018-results/)\n\nJuly 18, 2018\n\nThird consecutive quarter of triple-digit YoY Quarterly growth NEW HAVEN, CT, (July 18th, 2018) – Specialty cancer diagnostics company Precipio, Inc. (NASDAQ: PRPO), today announced preliminary second quarter [...] \n\n[ Read More ](https://www.precipiodx.com/precipio-announces-213-year-over-year-revenue-growth-in-preliminary-q2-2018-results/)\n\n[ ![Precipio Press Release](https://www.precipiodx.com/wp-content/uploads/2022/08/PressRelease-300x158.png) ](https://www.precipiodx.com/precipio-and-nucleai-partner-to-develop-artificial-intelligence-powered-hemepath-solution/)\n\n#####  [Precipio And Nucleai Partner To Develop Artificial Intelligence-Powered Hemepath Solution](https://www.precipiodx.com/precipio-and-nucleai-partner-to-develop-artificial-intelligence-powered-hemepath-solution/)\n\nJune 26, 2018\n\nSystem will support Hematopathologists in accurately identifying abnormalities to ensure diagnostic accuracy NEW HAVEN, CT, (June 26th, 2018) – Precipio, Inc. (NASDAQ: PRPO), announced today an agreement with [...] \n\n[ Read More ](https://www.precipiodx.com/precipio-and-nucleai-partner-to-develop-artificial-intelligence-powered-hemepath-solution/)\n\n[ ![Precipio Press Release](https://www.precipiodx.com/wp-content/uploads/2022/08/PressRelease-300x158.png) ](https://www.precipiodx.com/precipio-updates-commercial-pipeline-for-its-ice-cold-pcr-liquid-biopsy-technology/)\n\n#####  [Precipio Updates Commercial Pipeline For Its ICE-COLD PCR™ Liquid Biopsy Technology](https://www.precipiodx.com/precipio-updates-commercial-pipeline-for-its-ice-cold-pcr-liquid-biopsy-technology/)\n\nJune 19, 2018\n\nTrials underway at five laboratories and two diagnostic equipment companies NEW HAVEN, CT, (June 19th, 2018) – Precipio, Inc. (NASDAQ: PRPO), today detailed its pipeline of high-volume potential [...] \n\n[ Read More ](https://www.precipiodx.com/precipio-updates-commercial-pipeline-for-its-ice-cold-pcr-liquid-biopsy-technology/)\n\n[ ![Precipio Press Release](https://www.precipiodx.com/wp-content/uploads/2022/08/PressRelease-300x158.png) ](https://www.precipiodx.com/precipio-inc-announces-adjournment-of-annual-meeting-of-shareholders/)\n\n#####  [Precipio Inc. Announces Adjournment Of Annual Meeting Of Shareholders](https://www.precipiodx.com/precipio-inc-announces-adjournment-of-annual-meeting-of-shareholders/)\n\nJune 15, 2018\n\nNEW HAVEN, CT, (June 15th, 2018) – Specialty cancer diagnostics company Precipio, Inc. (NASDAQ: PRPO), announced today that the Company’s 2018 Annual Meeting of Shareholders, originally scheduled for [...] \n\n[ Read More ](https://www.precipiodx.com/precipio-inc-announces-adjournment-of-annual-meeting-of-shareholders/)\n\n[ ![Precipio Press Release](https://www.precipiodx.com/wp-content/uploads/2022/08/PressRelease-300x158.png) ](https://www.precipiodx.com/precipio-reminds-shareholders-to-vote-before-the-annual-general-meeting-on-june-15-2018-2/)\n\n#####  [Precipio Reminds Shareholders To Vote Before The Annual General Meeting On June 15, 2018](https://www.precipiodx.com/precipio-reminds-shareholders-to-vote-before-the-annual-general-meeting-on-june-15-2018-2/)\n\nJune 14, 2018\n\nNEW HAVEN, CT, (June 14th, 2018) – Specialty cancer diagnostics company Precipio, Inc. (NASDAQ: PRPO), today reminded its shareholders to vote on proposals 1-6 in accordance with the [...] \n\n[ Read More ](https://www.precipiodx.com/precipio-reminds-shareholders-to-vote-before-the-annual-general-meeting-on-june-15-2018-2/)\n\n[ ![Precipio Press Release](https://www.precipiodx.com/wp-content/uploads/2022/08/PressRelease-300x158.png) ](https://www.precipiodx.com/precipio-reminds-shareholders-to-vote-before-the-annual-general-meeting-on-june-15-2018/)\n\n#####  [Precipio Reminds Shareholders To Vote Before The Annual General Meeting On June 15, 2018](https://www.precipiodx.com/precipio-reminds-shareholders-to-vote-before-the-annual-general-meeting-on-june-15-2018/)\n\nJune 12, 2018\n\nNEW HAVEN, CT, (June 12th, 2018) – Specialty cancer diagnostics company Precipio, Inc. (NASDAQ: PRPO), today reminded its shareholders to vote on proposals 1-6 in accordance with the [...] \n\n[ Read More ](https://www.precipiodx.com/precipio-reminds-shareholders-to-vote-before-the-annual-general-meeting-on-june-15-2018/)\n\n[ ![Precipio Press Release](https://www.precipiodx.com/wp-content/uploads/2022/08/PressRelease-300x158.png) ](https://www.precipiodx.com/precipio-strengthens-patent-portfolio-with-expanded-reagent-claims-for-its-liquid-biopsy-enabling-dna-mutation-enrichment-technology/)\n\n#####  [Precipio Strengthens Patent Portfolio With Expanded Reagent Claims For Its Liquid Biopsy Enabling DNA Mutation Enrichment Technology](https://www.precipiodx.com/precipio-strengthens-patent-portfolio-with-expanded-reagent-claims-for-its-liquid-biopsy-enabling-dna-mutation-enrichment-technology/)\n\nJune 6, 2018\n\nNEW HAVEN, CT, (June 06th, 2018) – Specialty cancer diagnostics company Precipio, Inc. (NASDAQ: PRPO), today announced the award of US patent No. 9,957,556 entitled FULL COLD-PCR ENRICHMENT [...] \n\n[ Read More ](https://www.precipiodx.com/precipio-strengthens-patent-portfolio-with-expanded-reagent-claims-for-its-liquid-biopsy-enabling-dna-mutation-enrichment-technology/)\n\n[ ![Precipio Press Release](https://www.precipiodx.com/wp-content/uploads/2022/08/PressRelease-300x158.png) ](https://www.precipiodx.com/precipio-launches-liquid-biopsy-dna-enrichment-sales-in-europe-with-first-order/)\n\n#####  [Precipio Launches Liquid Biopsy DNA Enrichment Sales In Europe With First Order](https://www.precipiodx.com/precipio-launches-liquid-biopsy-dna-enrichment-sales-in-europe-with-first-order/)\n\nMay 24, 2018\n\n$10 million annual Europe market anticipated with $1 million annual addressable sales potential from local Italy partner/i> NEW HAVEN, CT, (May 24th, 2018) – Specialty cancer [...] \n\n[ Read More ](https://www.precipiodx.com/precipio-launches-liquid-biopsy-dna-enrichment-sales-in-europe-with-first-order/)\n\n#####  [Potential Sequential Revenue Run-Rate Growth Of 30% Over Q1, Based On Preliminary April Results](https://www.precipiodx.com/potential-sequential-revenue-run-rate-growth-of-30-over-q1-based-on-preliminary-april-results/)\n\nMay 22, 2018\n\nRevenue growth accelerating as new sales initiatives and expanded team gain traction NEW HAVEN, CT, (May 22nd, 2018) – Specialty cancer diagnostics company Precipio, Inc. (NASDAQ: PRPO), today [...] \n\n[ Read More ](https://www.precipiodx.com/potential-sequential-revenue-run-rate-growth-of-30-over-q1-based-on-preliminary-april-results/)\n\n[ ![Precipio Press Release](https://www.precipiodx.com/wp-content/uploads/2022/08/PressRelease-300x158.png) ](https://www.precipiodx.com/precipio-launches-ice-cold-pcr-liquid-biopsy-reagent-for-pancreatic-cancer/)\n\n#####  [Precipio Launches ICE COLD-PCR™ Liquid Biopsy Reagent For Pancreatic Cancer](https://www.precipiodx.com/precipio-launches-ice-cold-pcr-liquid-biopsy-reagent-for-pancreatic-cancer/)\n\nMay 17, 2018\n\nUltra-sensitive enrichment reagent enables development of low cost detection tests, allowing optimized patient treatment NEW HAVEN, CT, (May 17th, 2018) – Specialty cancer diagnostics company Precipio, Inc. (NASDAQ: [...] \n\n[ Read More ](https://www.precipiodx.com/precipio-launches-ice-cold-pcr-liquid-biopsy-reagent-for-pancreatic-cancer/)\n\n[ ![Precipio Press Release](https://www.precipiodx.com/wp-content/uploads/2022/08/PressRelease-300x158.png) ](https://www.precipiodx.com/precipio-announces-preliminary-q1-2018-year-over-year-revenue-increase-of-286/)\n\n#####  [Precipio Announces Preliminary Q1 2018 Year-Over-Year Revenue Increase Of 286%](https://www.precipiodx.com/precipio-announces-preliminary-q1-2018-year-over-year-revenue-increase-of-286/)\n\nMay 14, 2018\n\nGrowth resulting from commercial team reorganization, product and service cross-selling, and increased business stabilization NEW HAVEN, CT, (May 14th, 2018) – Specialty cancer diagnostics company Precipio, Inc. (NASDAQ: [...] \n\n[ Read More ](https://www.precipiodx.com/precipio-announces-preliminary-q1-2018-year-over-year-revenue-increase-of-286/)\n\n[ ![Precipio Press Release](https://www.precipiodx.com/wp-content/uploads/2022/08/PressRelease-300x158.png) ](https://www.precipiodx.com/precipio-announces-participation-details-for-upcoming-shareholder-conference-call/)\n\n#####  [Precipio Announces Participation Details For Upcoming Shareholder Conference Call](https://www.precipiodx.com/precipio-announces-participation-details-for-upcoming-shareholder-conference-call/)\n\nApril 26, 2018\n\nNEW HAVEN, CT, (April 26th, 2018) – Specialty cancer diagnostics company Precipio, Inc. (NASDAQ: PRPO), provides details of its previously announced upcoming shareholder conference call scheduled for Monday [...] \n\n[ Read More ](https://www.precipiodx.com/precipio-announces-participation-details-for-upcoming-shareholder-conference-call/)\n\n[ ![Precipio Press Release](https://www.precipiodx.com/wp-content/uploads/2022/08/PressRelease-300x158.png) ](https://www.precipiodx.com/precipio-completes-a-3m-convertible-debt-facility/)\n\n#####  [Precipio Completes A $3M Convertible Debt Facility](https://www.precipiodx.com/precipio-completes-a-3m-convertible-debt-facility/)\n\nApril 23, 2018\n\nManagement focuses on growth opportunities NEW HAVEN, CT, (April 23rd, 2018) – Specialty cancer diagnostics company Precipio, Inc. (NASDAQ: PRPO), announced today that it entered into a convertible [...] \n\n[ Read More ](https://www.precipiodx.com/precipio-completes-a-3m-convertible-debt-facility/)\n\n[ ![Precipio Press Release](https://www.precipiodx.com/wp-content/uploads/2022/08/PressRelease-300x158.png) ](https://www.precipiodx.com/precipio-in-strategic-partnership-discussions-for-proprietary-cytogenetics-media-iv-cell/)\n\n#####  [Precipio In Strategic Partnership Discussions For Proprietary Cytogenetics Media IV-Cell](https://www.precipiodx.com/precipio-in-strategic-partnership-discussions-for-proprietary-cytogenetics-media-iv-cell/)\n\nApril 18, 2018\n\nNEW HAVEN, CT, (April 18th, 2018) – Specialty cancer diagnostics company Precipio, Inc. (NASDAQ: PRPO), announced today it is in active licensing discussions with several potential partners regarding [...] \n\n[ Read More ](https://www.precipiodx.com/precipio-in-strategic-partnership-discussions-for-proprietary-cytogenetics-media-iv-cell/)\n\n[ ![Precipio Press Release](https://www.precipiodx.com/wp-content/uploads/2022/08/PressRelease-300x158.png) ](https://www.precipiodx.com/precipio-releases-its-2017-10-k-files-a-form-s-1-and-hosts-fourth-quarter-and-full-year-update-call/)\n\n#####  [Precipio Releases Its 2017 10-K, Files A Form S-1, And Hosts Fourth Quarter And Full Year Update Call](https://www.precipiodx.com/precipio-releases-its-2017-10-k-files-a-form-s-1-and-hosts-fourth-quarter-and-full-year-update-call/)\n\nApril 17, 2018\n\nManagement to provide strategic business update to shareholders NEW HAVEN, CT, (April 17th, 2018) – Specialty cancer diagnostics company Precipio, Inc. (NASDAQ: PRPO), announced today that on April [...] \n\n[ Read More ](https://www.precipiodx.com/precipio-releases-its-2017-10-k-files-a-form-s-1-and-hosts-fourth-quarter-and-full-year-update-call/)\n\n[ ![Precipio Press Release](https://www.precipiodx.com/wp-content/uploads/2022/08/PressRelease-300x158.png) ](https://www.precipiodx.com/precipio-launches-ice-cold-pcr-research-access-program-for-cancer-centers/)\n\n#####  [Precipio Launches ICE COLD-PCR™ Research Access Program For Cancer Centers](https://www.precipiodx.com/precipio-launches-ice-cold-pcr-research-access-program-for-cancer-centers/)\n\nApril 11, 2018\n\nComplimentary Precipio ICE COLD PCR™ reagents now available to advance body of research and accelerate market expansion NEW HAVEN, CT, (April 11th, 2018) – Specialty cancer [...] \n\n[ Read More ](https://www.precipiodx.com/precipio-launches-ice-cold-pcr-research-access-program-for-cancer-centers/)\n\n[ ![Precipio Press Release](https://www.precipiodx.com/wp-content/uploads/2022/08/PressRelease-300x158.png) ](https://www.precipiodx.com/important-jama-article-underscores-superiority-of-precipios-liquid-biopsy-core-technology/)\n\n#####  [Important JAMA Article Underscores Superiority Of Precipio’s Liquid Biopsy Core Technology](https://www.precipiodx.com/important-jama-article-underscores-superiority-of-precipios-liquid-biopsy-core-technology/)\n\nApril 3, 2018\n\nStudy cites major accuracy flaws in predominant liquid biopsy platforms offered by competitors NEW HAVEN, CT, (April 03rd, 2018) – Specialty cancer diagnostics company Precipio, Inc. (NASDAQ: PRPO), [...] \n\n[ Read More ](https://www.precipiodx.com/important-jama-article-underscores-superiority-of-precipios-liquid-biopsy-core-technology/)\n\n#####  [Precipio Files Patent For Non-Invasive Cell Capture Device For Gynecological Cancer Detection](https://www.precipiodx.com/precipio-files-patent-for-non-invasive-cell-capture-device-for-gynecological-cancer-detection/)\n\nMarch 28, 2018\n\nIn collaboration with Yale, feminine panty liner designed to remove obstacles to early detection NEW HAVEN, CT, (March 28th, 2018) – Specialty cancer diagnostics company Precipio, Inc. (NASDAQ: [...] \n\n[ Read More ](https://www.precipiodx.com/precipio-files-patent-for-non-invasive-cell-capture-device-for-gynecological-cancer-detection/)\n\n[ ![Precipio Press Release](https://www.precipiodx.com/wp-content/uploads/2022/08/PressRelease-300x158.png) ](https://www.precipiodx.com/precipio-enters-india-liquid-biopsy-market-with-adoption-by-leading-laboratory/)\n\n#####  [Precipio Enters India Liquid Biopsy Market With Adoption By Leading Laboratory](https://www.precipiodx.com/precipio-enters-india-liquid-biopsy-market-with-adoption-by-leading-laboratory/)\n\nMarch 26, 2018\n\nCORE Diagnostics to transition to Precipio’s price competitive ICE COLD-PCR™ platform NEW HAVEN, CT, (March 26th, 2018) – Specialty cancer diagnostics company Precipio, Inc. (NASDAQ: PRPO), today announced [...] \n\n[ Read More ](https://www.precipiodx.com/precipio-enters-india-liquid-biopsy-market-with-adoption-by-leading-laboratory/)\n\n[ ![Precipio Press Release](https://www.precipiodx.com/wp-content/uploads/2022/08/PressRelease-300x158.png) ](https://www.precipiodx.com/precipio-restructures-capitalization-table/)\n\n#####  [Precipio Restructures Capitalization Table](https://www.precipiodx.com/precipio-restructures-capitalization-table/)\n\nMarch 22, 2018\n\nInvestors to convert preferred shares and exercise warrants NEW HAVEN, CT, (March 22nd, 2018) – Specialty cancer diagnostics company Precipio, Inc. (NASDAQ: PRPO), in an 8-K issued today [...] \n\n[ Read More ](https://www.precipiodx.com/precipio-restructures-capitalization-table/)\n\n[ ![Precipio Press Release](https://www.precipiodx.com/wp-content/uploads/2022/08/PressRelease-300x158.png) ](https://www.precipiodx.com/precipio-integrates-cost-reducing-and-fast-turnaround-high-resolution-melt-into-liquid-biopsy-platform/)\n\n#####  [Precipio Integrates Cost Reducing And Fast Turnaround “High Resolution Melt” Into Liquid Biopsy Platform](https://www.precipiodx.com/precipio-integrates-cost-reducing-and-fast-turnaround-high-resolution-melt-into-liquid-biopsy-platform/)\n\nMarch 20, 2018\n\nEnhances competitive advantage as industry’s most cost effective solution NEW HAVEN, CT, (March 20th, 2018) – Specialty cancer diagnostics company Precipio, Inc. (NASDAQ: PRPO), announced today it has [...] \n\n[ Read More ](https://www.precipiodx.com/precipio-integrates-cost-reducing-and-fast-turnaround-high-resolution-melt-into-liquid-biopsy-platform/)\n\n[ ![Precipio Press Release](https://www.precipiodx.com/wp-content/uploads/2022/08/PressRelease-300x158.png) ](https://www.precipiodx.com/precipio-settles-lawsuit-with-crede-capital/)\n\n#####  [Precipio Settles Lawsuit With Crede Capital](https://www.precipiodx.com/precipio-settles-lawsuit-with-crede-capital/)\n\nMarch 13, 2018\n\nCompletes Restructuring of close to 95% Transgenomic Liabilities NEW HAVEN, CT, (March 13th, 2018) – Specialty cancer diagnostics company Precipio, Inc. (NASDAQ: PRPO), announced today it has settled [...] \n\n[ Read More ](https://www.precipiodx.com/precipio-settles-lawsuit-with-crede-capital/)\n\n[ ![Precipio Press Release](https://www.precipiodx.com/wp-content/uploads/2022/08/PressRelease-300x158.png) ](https://www.precipiodx.com/key-measure-of-precipios-pathology-sales-growth-4x-prior-quarter/)\n\n#####  [Key Measure Of Precipio’s Pathology Sales Growth 4X Prior Quarter](https://www.precipiodx.com/key-measure-of-precipios-pathology-sales-growth-4x-prior-quarter/)\n\nFebruary 22, 2018\n\nStrong indications of academic-level pathology market adoption and sales uptake NEW HAVEN, CT, (February 22nd, 2018) – Specialty cancer diagnostics company Precipio, Inc. (NASDAQ: PRPO), announced today that [...] \n\n[ Read More ](https://www.precipiodx.com/key-measure-of-precipios-pathology-sales-growth-4x-prior-quarter/)\n\n[ ![Precipio Press Release](https://www.precipiodx.com/wp-content/uploads/2022/08/PressRelease-300x158.png) ](https://www.precipiodx.com/precipio-launches-unique-lung-cancer-monitoring-test-for-therapy-resistance/)\n\n#####  [Precipio Launches Unique Lung Cancer Monitoring Test For Therapy Resistance](https://www.precipiodx.com/precipio-launches-unique-lung-cancer-monitoring-test-for-therapy-resistance/)\n\nFebruary 15, 2018\n\nNew test fulfills promise of liquid biopsies to cost effectively monitor patients NEW HAVEN, CT, (February 15th, 2018) – Specialty cancer diagnostics company Precipio, Inc. (NASDAQ: PRPO), announced [...] \n\n[ Read More ](https://www.precipiodx.com/precipio-launches-unique-lung-cancer-monitoring-test-for-therapy-resistance/)\n\n[ ![Precipio Press Release](https://www.precipiodx.com/wp-content/uploads/2022/08/PressRelease-300x158.png) ](https://www.precipiodx.com/precipio-announces-q4-2017-revenue-at-350-of-previous-quarter/)\n\n#####  [Precipio Announces Q4 2017 Revenue At 350% Of Previous Quarter](https://www.precipiodx.com/precipio-announces-q4-2017-revenue-at-350-of-previous-quarter/)\n\nFebruary 9, 2018\n\nFirst post-merger quarter to turn the corner and demonstrate growth NEW HAVEN, CT, (February 09th, 2018) – Specialty cancer diagnostics company Precipio, Inc. (NASDAQ: PRPO), announces preliminary, unaudited [...] \n\n[ Read More ](https://www.precipiodx.com/precipio-announces-q4-2017-revenue-at-350-of-previous-quarter/)\n\n[ ![Precipio Press Release](https://www.precipiodx.com/wp-content/uploads/2022/08/PressRelease-300x158.png) ](https://www.precipiodx.com/precipio-enters-japanese-liquid-biopsy-market-with-first-hospital-sale/)\n\n#####  [Precipio Enters Japanese Liquid Biopsy Market With First Hospital Sale](https://www.precipiodx.com/precipio-enters-japanese-liquid-biopsy-market-with-first-hospital-sale/)\n\nFebruary 6, 2018\n\nFirst ICE-COLD PCR™ order generated from distribution partnership with Sowa Trading Company NEW HAVEN, CT, (February 06th, 2018) – Specialty cancer diagnostics company Precipio, Inc. (NASDAQ: PRPO), announces [...] \n\n[ Read More ](https://www.precipiodx.com/precipio-enters-japanese-liquid-biopsy-market-with-first-hospital-sale/)\n\n[ ![Precipio Press Release](https://www.precipiodx.com/wp-content/uploads/2022/08/PressRelease-300x158.png) ](https://www.precipiodx.com/precipio-commences-validation-study-of-proprietary-iv-cell-cytogenetics-media-at-university-of-pennsylvania/)\n\n#####  [Precipio Commences Validation Study Of Proprietary IV-Cell Cytogenetics Media At University Of Pennsylvania](https://www.precipiodx.com/precipio-commences-validation-study-of-proprietary-iv-cell-cytogenetics-media-at-university-of-pennsylvania/)\n\nJanuary 22, 2018\n\nNEW HAVEN, CT, (January 22nd, 2018) – Specialty cancer diagnostics company Precipio, Inc. (NASDAQ: PRPO), today announced it is collaborating with the cytogenetics laboratory at the University of [...] \n\n[ Read More ](https://www.precipiodx.com/precipio-commences-validation-study-of-proprietary-iv-cell-cytogenetics-media-at-university-of-pennsylvania/)\n\n[ ![Precipio Press Release](https://www.precipiodx.com/wp-content/uploads/2022/08/PressRelease-300x158.png) ](https://www.precipiodx.com/precipio-appoints-new-sales-vp-to-manage-diagnostics-sales-expansion/)\n\n#####  [Precipio Appoints New Sales VP To Manage Diagnostics Sales Expansion](https://www.precipiodx.com/precipio-appoints-new-sales-vp-to-manage-diagnostics-sales-expansion/)\n\nJanuary 16, 2018\n\nSales growth acceleration plan to triple size of oncologist/hospital sales team in 2018 NEW HAVEN, CT, (January 16th, 2018) – Specialty cancer diagnostics company Precipio, Inc. (NASDAQ: PRPO), [...] \n\n[ Read More ](https://www.precipiodx.com/precipio-appoints-new-sales-vp-to-manage-diagnostics-sales-expansion/)\n\n[ ![Precipio Press Release](https://www.precipiodx.com/wp-content/uploads/2022/08/PressRelease-300x158.png) ](https://www.precipiodx.com/yale-study-demonstrates-four-fold-superiority-of-academic-level-diagnostic-accuracy/)\n\n#####  [Yale Study Demonstrates Four-Fold Superiority Of Academic Level Diagnostic Accuracy](https://www.precipiodx.com/yale-study-demonstrates-four-fold-superiority-of-academic-level-diagnostic-accuracy/)\n\nJanuary 10, 2018\n\nStudy further shows ~73% of cases which academic pathologists determined were previously misdiagnosed, have definite or possible material impact on patient treatment plans NEW HAVEN, [...] \n\n[ Read More ](https://www.precipiodx.com/yale-study-demonstrates-four-fold-superiority-of-academic-level-diagnostic-accuracy/)\n\n  * [ $0.00 ](https://www.precipiodx.com/cart/ \"Cart\")\n    * Cart\n\nNo products in the cart.\n\n[ Return to shop ](https://www.precipiodx.com/shop/)\n\n  * Search for:\n\n  * [About Us](https://www.precipiodx.com/about/)\n    * [Our Culture](https://www.precipiodx.com/about/culture/)\n    * [News](https://www.precipiodx.com/about/news/)\n    * [Careers](https://www.precipiodx.com/about/careers/)\n    * [Scientific Advisors](https://www.precipiodx.com/about/scientific-advisors/)\n    * [Management Team](https://www.precipiodx.com/about/management-team/)\n    * [Board of Directors](https://www.precipiodx.com/about/board-of-directors/)\n  * [Products](https://www.precipiodx.com/products/)\n    * [Molecular Kits](https://www.precipiodx.com/products/molecular-kits/)\n      * [MPN Panel](https://www.precipiodx.com/products/bloodhound-mpn-panel/)\n      * [BCR-ABL1 Panel](https://www.precipiodx.com/products/bloodhound-bcr-abl1-molecular-panel/)\n      * [ABL1 Resistance Panel](https://www.precipiodx.com/products/bloodhound-abl1-resistance-panel/)\n      * [AML Panel](https://www.precipiodx.com/products/molecular-kits/acute-myeloid-leukemia-panel/)\n      * [CLL Panel](https://www.precipiodx.com/products/molecular-kits/cll-panel/)\n      * [Cytopenia Panel](https://www.precipiodx.com/products/molecular-kits/cytopenia-panel/)\n    * [IV-Cell Cytogenetics Media](https://www.precipiodx.com/products/iv-cell-cytogenetics-media/)\n  * [Clinical Services](https://www.precipiodx.com/clinical-services/)\n    * [Hematopathology Services](https://www.precipiodx.com/clinical-services/blood-cancer-testing/)\n    * [Sample Reports](https://www.precipiodx.com/sample-report/)\n    * [Proprietary Technologies](https://www.precipiodx.com/clinical-services/proprietary-technologies/)\n    * [Meet Our Hematopathologists](https://www.precipiodx.com/clinical-services/meet-our-pathologists/)\n  * [Resources](https://www.precipiodx.com/resources/)\n    * [FAQs](https://www.precipiodx.com/resources/faqs/)\n    * [Brochures](https://www.precipiodx.com/resources/brochures/)\n    * [Case Studies](https://www.precipiodx.com/resources/case-studies/)\n    * [Sample Reports](https://www.precipiodx.com/sample-report/)\n    * [Instructions For Use](https://www.precipiodx.com/resources/ifus/)\n    * [Instructions For Use – Non U.S. CE](https://www.precipiodx.com/resources/instructions-for-use-non-us-ce/)\n  * [Investors](https://www.precipiodx.com/investors/)\n    * [Press Releases](https://www.precipiodx.com/investors/press-releases/)\n    * [Media](https://www.precipiodx.com/investors/media/)\n    * [SEC Filings](https://www.precipiodx.com/investors/sec-filings/)\n    * [Subscription](https://www.precipiodx.com/investors/subscription/)\n    * [Investor FAQs](https://www.precipiodx.com/investors/investor-faqs/)\n    * [Corporate Governance](https://www.precipiodx.com/investors/corporate-governance/)\n    * [Business Update Calls](https://www.precipiodx.com/investors/business-update-calls/)\n  * [Contact](https://www.precipiodx.com/contact/)\n  * [My Account](https://www.precipiodx.com/login/)\n    * [![Login Icon](https://www.precipiodx.com/wp-content/uploads/2022/07/login-svgrepo-com.svg)CaseVu](https://www.casevu-lis.precipiodx.com/)\n    * [![Login Icon](https://www.precipiodx.com/wp-content/uploads/2022/07/login-svgrepo-com.svg)Shop](https://www.precipiodx.com/my-account/)\n    * [![Login Icon](https://www.precipiodx.com/wp-content/uploads/2022/07/login-svgrepo-com.svg)Patient Bill Pay](https://www.precipiodx.com/billing/)\n\n\n\n### Login\n\nUsername or email address *\n\nPassword *\n\nRemember me Log in\n\n[Lost your password?](https://www.precipiodx.com/my-account/lost-password/)\n"
        }
      ]
    },
    {
      "section_name": "Media",
      "links": [
        {
          "title": "Media",
          "url": "https://www.precipiodx.com/investors/media/",
          "content": "[Skip to content](#main)\n\n[ ![Precipio](https://www.precipiodx.com/wp-content/uploads/2022/07/logo.png) ![Precipio](https://www.precipiodx.com/wp-content/uploads/2022/07/logo.png) ](https://www.precipiodx.com/ \"Precipio - Expect More from the start.\")\n\n  * [ ](#)\n\n\n\n\n  * [About Us](https://www.precipiodx.com/about/)\n    * [Our Culture](https://www.precipiodx.com/about/culture/)\n    * [News](https://www.precipiodx.com/about/news/)\n    * [Careers](https://www.precipiodx.com/about/careers/)\n    * [Scientific Advisors](https://www.precipiodx.com/about/scientific-advisors/)\n    * [Management Team](https://www.precipiodx.com/about/management-team/)\n    * [Board of Directors](https://www.precipiodx.com/about/board-of-directors/)\n  * [Products](https://www.precipiodx.com/products/)\n    * [Molecular Kits](https://www.precipiodx.com/products/molecular-kits/)\n      * [MPN Panel](https://www.precipiodx.com/products/bloodhound-mpn-panel/)\n      * [BCR-ABL1 Panel](https://www.precipiodx.com/products/bloodhound-bcr-abl1-molecular-panel/)\n      * [ABL1 Resistance Panel](https://www.precipiodx.com/products/bloodhound-abl1-resistance-panel/)\n      * [AML Panel](https://www.precipiodx.com/products/molecular-kits/acute-myeloid-leukemia-panel/)\n      * [CLL Panel](https://www.precipiodx.com/products/molecular-kits/cll-panel/)\n      * [Cytopenia Panel](https://www.precipiodx.com/products/molecular-kits/cytopenia-panel/)\n    * [IV-Cell Cytogenetics Media](https://www.precipiodx.com/products/iv-cell-cytogenetics-media/)\n  * [Clinical Services](https://www.precipiodx.com/clinical-services/)\n    * [Hematopathology Services](https://www.precipiodx.com/clinical-services/blood-cancer-testing/)\n    * [Sample Reports](https://www.precipiodx.com/sample-report/)\n    * [Proprietary Technologies](https://www.precipiodx.com/clinical-services/proprietary-technologies/)\n    * [Meet Our Hematopathologists](https://www.precipiodx.com/clinical-services/meet-our-pathologists/)\n  * [Resources](https://www.precipiodx.com/resources/)\n    * [FAQs](https://www.precipiodx.com/resources/faqs/)\n    * [Brochures](https://www.precipiodx.com/resources/brochures/)\n    * [Case Studies](https://www.precipiodx.com/resources/case-studies/)\n    * [Sample Reports](https://www.precipiodx.com/sample-report/)\n    * [Instructions For Use](https://www.precipiodx.com/resources/ifus/)\n    * [Instructions For Use – Non U.S. CE](https://www.precipiodx.com/resources/instructions-for-use-non-us-ce/)\n  * [Investors](https://www.precipiodx.com/investors/)\n    * [Press Releases](https://www.precipiodx.com/investors/press-releases/)\n    * [Media](https://www.precipiodx.com/investors/media/)\n    * [SEC Filings](https://www.precipiodx.com/investors/sec-filings/)\n    * [Subscription](https://www.precipiodx.com/investors/subscription/)\n    * [Investor FAQs](https://www.precipiodx.com/investors/investor-faqs/)\n    * [Corporate Governance](https://www.precipiodx.com/investors/corporate-governance/)\n    * [Business Update Calls](https://www.precipiodx.com/investors/business-update-calls/)\n  * [Contact](https://www.precipiodx.com/contact/)\n  * [My Account](https://www.precipiodx.com/login/)\n    * [![Login Icon](https://www.precipiodx.com/wp-content/uploads/2022/07/login-svgrepo-com.svg)CaseVu](https://www.casevu-lis.precipiodx.com/)\n    * [![Login Icon](https://www.precipiodx.com/wp-content/uploads/2022/07/login-svgrepo-com.svg)Shop](https://www.precipiodx.com/my-account/)\n    * [![Login Icon](https://www.precipiodx.com/wp-content/uploads/2022/07/login-svgrepo-com.svg)Patient Bill Pay](https://www.precipiodx.com/billing/)\n  * [ $0.00 **0** ](https://www.precipiodx.com/cart/ \"Cart\")\n\nCart\n\n  * [](#)\n    * Search for:\n\n\n\n\n  * [ **0** ](https://www.precipiodx.com/cart/ \"Cart\")\n\n\n\n# Media\n\nSep 02, 2021 | [**New Haven Biz:** “Precipio seeks a better, more accurate way to diagnose cancer”](https://nebusinessmedia.uberflip.com/i/1407104-new-haven-biz-september-2021/17)  \n---|---  \nJun 09, 2021 | [**Dark Daily Webinar:** “HemeScreen® Operational & Financial Benefits”](https://register.gotowebinar.com/register/434194258829721616)  \nJun 08, 2021 | [**BioWorld:** “Precipio launches Hemescreen anemia panel”](https://www.precipiodx.com/investors/media/2021/0608/Precipio%20launches%20Hemescreen%20anemia%20panel.html)  \nJan 08, 2021 | [**ION Solutions:** “ION Solutions & Precipio introduce HemeScreen Program via the ION Oncology Newsletter”](https://www.iononline.com/publications)  \nAug 03, 2020 | [**Nasdaq:** “#TradeTalks: COVID-19 Antibody Testing News (PRPO)”](https://www.nasdaq.com/videos/tradetalks%3A-covid-19-antibody-testing-news-prpo)  \nApr 26, 2019 | [**Proactiveinvestors USA:** “Precipio in talks with international health care systems to expand reach”](https://www.proactiveinvestors.com/companies/stocktube/13118/precipio-in-talks-with-international-health-care-systems-to-expand-reach-13118.html)  \nDec 21, 2018 | [**Medical Laboratory Observer (MLO):** “The clinical impact of MDx economics”](https://www.mlo-online.com/the-clinical-impact-of-mdx-economics)  \nNov 27, 2018 | [**GenomeWeb:** “Lung Cancer Screening Study at UCMC to Utilize Precipio ICE-COLD PCR Tech”](https://www.genomeweb.com/molecular-diagnostics/lung-cancer-screening-study-ucmc-utilize-precipio-ice-cold-pcr-tech)  \nNov 23, 2018 | [**Your Family’s Health:** “Listen to Precipio’s CEO Discuss Liquid Biopsies and Second Opinions for a Cancer Diagnosis in a Radio Interview”](https://www.spreaker.com/user/whpc/fhelon)  \nNov 15, 2018 | [**PharmaVOICE:** “Trend: Advanced Diagnostics and Precision Medicine”](https://www.pharmavoice.com/article/2018-11-diagnostics/)  \nNov 01, 2018 | [**GenomeWeb:** “PerkinElmer, Precipio Collaborate On Liquid Biopsy Testing”](https://www.genomeweb.com/pcr/perkinelmer-precipio-collaborate-liquid-biopsy-testing)  \nOct 26, 2018 | [**Clinical Lab Products:** “Precipio Expands ICE-COLD PCR Lung Cancer Mutation Detection Offering”](http://www.clpmag.com/2018/10/precipio-expands-ice-cold-pcr-lung-cancer-mutation-detection-offering/)  \nOct 09, 2018 | [**EuroLab:** “Molecular test for hematologic cancers”](https://www.scientistlive.com/content/molecular-test-hematologic-cancers)  \nOct 05, 2018 | [**GenomeWeb:** “New Products Posted to GenomeWeb: Precipio, Seq2Know, Stratify Genomics”](https://www.genomeweb.com/new-products-posted-genomeweb-precipio-seq2know-stratify-genomics)  \nOct 03, 2018 | [**Laboratory Focus:** “Precipio launches promising assay for hematologic cancers”](https://laboratoryfocus.ca/precipio-launches-promising-assay-for-hematologic-cancers/)  \nSep 21, 2018 | [**MedGadget:** “Precipio Announces ICEme Reagent for Lung Cancer Mutation Detection”](https://www.medgadget.com/2018/09/precipio-announces-iceme-kit-for-lung-cancer-mutation-detection.html)  \nSep 21, 2018 | [**GenomeWeb:** “New Products Posted to GenomeWeb: Roche, Genomenon, Precipio, More”](https://www.genomeweb.com/new-products-posted-genomeweb-roche-genomenon-precipio-more)  \nSep 20, 2018 | [**BioSpace:** “As Liquid Biopsies Grow, Who’s Going to Pay?”](https://www.biospace.com/article/fd1a-as-liquid-biopsies-grow-who-s-going-to-pay-/)  \nSep 01, 2018 | [**Clinical Lab Products:** “Inside Track: In the Trenches”](http://www.clpmag.com/2018/09/inside-track-trenches/)  \nAug 24, 2018 | [**Drug Delivery Business News:** “Tracking tumors with Precipio’s liquid biopsy tech”](https://www.drugdeliverybusiness.com/tracking-tumors-with-precipios-liquid-biopsy-tech/)  \nAug 18, 2018 | [**The Pathologist:** “The Economics of Personalized Medicine”](https://www.drugdeliverybusiness.com/tracking-tumors-with-precipios-liquid-biopsy-tech/)  \nJul 02, 2018 | [**Clinical Lab Products:** “Precipio Launches Liquid Biopsy DNA Enrichment Sales in Europe”](http://www.clpmag.com/2018/07/precipio-launches-liquid-biopsy-dna-enrichment-sales-europe/)  \nJun 20, 2018 | [**MD & DI:** “Monitoring is Key in Precipio’s Liquid Biopsy Success”](https://www.mddionline.com/monitoring-key-precipio%E2%80%99s-liquid-biopsy-success)  \nMay 22, 2018 | [**BioWorld MedTech:** “Micro-cap Dx player Precipio launches pancreatic liquid biopsy from Dana-Farber”](http://www.bioworld.com/content/micro-cap-dx-player-precipio-launches-pancreatic-liquid-biopsy-dana-farber)  \nMay 18, 2018 | [**MedGadget:** “Advanced Cancer Diagnostics Reduce Frequency of Misdiagnoses: Interview with Precipio CEO Ilan Danieli”](https://www.medgadget.com/2018/05/advanced-cancer-diagnostics-reduce-frequency-of-misdiagnoses-interview-with-precipio-founder-and-ceo-ilan-danieli.html)  \nMay 17, 2018 | [**Reuters:** “Precipio Launches Ice Cold-Pcr™ Liquid Biopsy Reagent For Pancreatic Cancer”](https://www.reuters.com/article/brief-precipio-launches-ice-cold-pcr-liq/brief-precipio-launches-ice-cold-pcr-liquid-biopsy-kit-for-pancreatic-cancer-idUSFWN1SO0LJ)  \n  \n  * [ $0.00 ](https://www.precipiodx.com/cart/ \"Cart\")\n    * Cart\n\nNo products in the cart.\n\n[ Return to shop ](https://www.precipiodx.com/shop/)\n\n  * Search for:\n\n  * [About Us](https://www.precipiodx.com/about/)\n    * [Our Culture](https://www.precipiodx.com/about/culture/)\n    * [News](https://www.precipiodx.com/about/news/)\n    * [Careers](https://www.precipiodx.com/about/careers/)\n    * [Scientific Advisors](https://www.precipiodx.com/about/scientific-advisors/)\n    * [Management Team](https://www.precipiodx.com/about/management-team/)\n    * [Board of Directors](https://www.precipiodx.com/about/board-of-directors/)\n  * [Products](https://www.precipiodx.com/products/)\n    * [Molecular Kits](https://www.precipiodx.com/products/molecular-kits/)\n      * [MPN Panel](https://www.precipiodx.com/products/bloodhound-mpn-panel/)\n      * [BCR-ABL1 Panel](https://www.precipiodx.com/products/bloodhound-bcr-abl1-molecular-panel/)\n      * [ABL1 Resistance Panel](https://www.precipiodx.com/products/bloodhound-abl1-resistance-panel/)\n      * [AML Panel](https://www.precipiodx.com/products/molecular-kits/acute-myeloid-leukemia-panel/)\n      * [CLL Panel](https://www.precipiodx.com/products/molecular-kits/cll-panel/)\n      * [Cytopenia Panel](https://www.precipiodx.com/products/molecular-kits/cytopenia-panel/)\n    * [IV-Cell Cytogenetics Media](https://www.precipiodx.com/products/iv-cell-cytogenetics-media/)\n  * [Clinical Services](https://www.precipiodx.com/clinical-services/)\n    * [Hematopathology Services](https://www.precipiodx.com/clinical-services/blood-cancer-testing/)\n    * [Sample Reports](https://www.precipiodx.com/sample-report/)\n    * [Proprietary Technologies](https://www.precipiodx.com/clinical-services/proprietary-technologies/)\n    * [Meet Our Hematopathologists](https://www.precipiodx.com/clinical-services/meet-our-pathologists/)\n  * [Resources](https://www.precipiodx.com/resources/)\n    * [FAQs](https://www.precipiodx.com/resources/faqs/)\n    * [Brochures](https://www.precipiodx.com/resources/brochures/)\n    * [Case Studies](https://www.precipiodx.com/resources/case-studies/)\n    * [Sample Reports](https://www.precipiodx.com/sample-report/)\n    * [Instructions For Use](https://www.precipiodx.com/resources/ifus/)\n    * [Instructions For Use – Non U.S. CE](https://www.precipiodx.com/resources/instructions-for-use-non-us-ce/)\n  * [Investors](https://www.precipiodx.com/investors/)\n    * [Press Releases](https://www.precipiodx.com/investors/press-releases/)\n    * [Media](https://www.precipiodx.com/investors/media/)\n    * [SEC Filings](https://www.precipiodx.com/investors/sec-filings/)\n    * [Subscription](https://www.precipiodx.com/investors/subscription/)\n    * [Investor FAQs](https://www.precipiodx.com/investors/investor-faqs/)\n    * [Corporate Governance](https://www.precipiodx.com/investors/corporate-governance/)\n    * [Business Update Calls](https://www.precipiodx.com/investors/business-update-calls/)\n  * [Contact](https://www.precipiodx.com/contact/)\n  * [My Account](https://www.precipiodx.com/login/)\n    * [![Login Icon](https://www.precipiodx.com/wp-content/uploads/2022/07/login-svgrepo-com.svg)CaseVu](https://www.casevu-lis.precipiodx.com/)\n    * [![Login Icon](https://www.precipiodx.com/wp-content/uploads/2022/07/login-svgrepo-com.svg)Shop](https://www.precipiodx.com/my-account/)\n    * [![Login Icon](https://www.precipiodx.com/wp-content/uploads/2022/07/login-svgrepo-com.svg)Patient Bill Pay](https://www.precipiodx.com/billing/)\n\n\n\n### Login\n\nUsername or email address *\n\nPassword *\n\nRemember me Log in\n\n[Lost your password?](https://www.precipiodx.com/my-account/lost-password/)\n"
        }
      ]
    },
    {
      "section_name": "SEC Filings",
      "links": [
        {
          "title": "SEC Filings",
          "url": "https://www.precipiodx.com/investors/sec-filings/",
          "content": "[Skip to content](#main)\n\n[ ![Precipio](https://www.precipiodx.com/wp-content/uploads/2022/07/logo.png) ![Precipio](https://www.precipiodx.com/wp-content/uploads/2022/07/logo.png) ](https://www.precipiodx.com/ \"Precipio - Expect More from the start.\")\n\n  * [ ](#)\n\n\n\n\n  * [About Us](https://www.precipiodx.com/about/)\n    * [Our Culture](https://www.precipiodx.com/about/culture/)\n    * [News](https://www.precipiodx.com/about/news/)\n    * [Careers](https://www.precipiodx.com/about/careers/)\n    * [Scientific Advisors](https://www.precipiodx.com/about/scientific-advisors/)\n    * [Management Team](https://www.precipiodx.com/about/management-team/)\n    * [Board of Directors](https://www.precipiodx.com/about/board-of-directors/)\n  * [Products](https://www.precipiodx.com/products/)\n    * [Molecular Kits](https://www.precipiodx.com/products/molecular-kits/)\n      * [MPN Panel](https://www.precipiodx.com/products/bloodhound-mpn-panel/)\n      * [BCR-ABL1 Panel](https://www.precipiodx.com/products/bloodhound-bcr-abl1-molecular-panel/)\n      * [ABL1 Resistance Panel](https://www.precipiodx.com/products/bloodhound-abl1-resistance-panel/)\n      * [AML Panel](https://www.precipiodx.com/products/molecular-kits/acute-myeloid-leukemia-panel/)\n      * [CLL Panel](https://www.precipiodx.com/products/molecular-kits/cll-panel/)\n      * [Cytopenia Panel](https://www.precipiodx.com/products/molecular-kits/cytopenia-panel/)\n    * [IV-Cell Cytogenetics Media](https://www.precipiodx.com/products/iv-cell-cytogenetics-media/)\n  * [Clinical Services](https://www.precipiodx.com/clinical-services/)\n    * [Hematopathology Services](https://www.precipiodx.com/clinical-services/blood-cancer-testing/)\n    * [Sample Reports](https://www.precipiodx.com/sample-report/)\n    * [Proprietary Technologies](https://www.precipiodx.com/clinical-services/proprietary-technologies/)\n    * [Meet Our Hematopathologists](https://www.precipiodx.com/clinical-services/meet-our-pathologists/)\n  * [Resources](https://www.precipiodx.com/resources/)\n    * [FAQs](https://www.precipiodx.com/resources/faqs/)\n    * [Brochures](https://www.precipiodx.com/resources/brochures/)\n    * [Case Studies](https://www.precipiodx.com/resources/case-studies/)\n    * [Sample Reports](https://www.precipiodx.com/sample-report/)\n    * [Instructions For Use](https://www.precipiodx.com/resources/ifus/)\n    * [Instructions For Use – Non U.S. CE](https://www.precipiodx.com/resources/instructions-for-use-non-us-ce/)\n  * [Investors](https://www.precipiodx.com/investors/)\n    * [Press Releases](https://www.precipiodx.com/investors/press-releases/)\n    * [Media](https://www.precipiodx.com/investors/media/)\n    * [SEC Filings](https://www.precipiodx.com/investors/sec-filings/)\n    * [Subscription](https://www.precipiodx.com/investors/subscription/)\n    * [Investor FAQs](https://www.precipiodx.com/investors/investor-faqs/)\n    * [Corporate Governance](https://www.precipiodx.com/investors/corporate-governance/)\n    * [Business Update Calls](https://www.precipiodx.com/investors/business-update-calls/)\n  * [Contact](https://www.precipiodx.com/contact/)\n  * [My Account](https://www.precipiodx.com/login/)\n    * [![Login Icon](https://www.precipiodx.com/wp-content/uploads/2022/07/login-svgrepo-com.svg)CaseVu](https://www.casevu-lis.precipiodx.com/)\n    * [![Login Icon](https://www.precipiodx.com/wp-content/uploads/2022/07/login-svgrepo-com.svg)Shop](https://www.precipiodx.com/my-account/)\n    * [![Login Icon](https://www.precipiodx.com/wp-content/uploads/2022/07/login-svgrepo-com.svg)Patient Bill Pay](https://www.precipiodx.com/billing/)\n  * [ $0.00 **0** ](https://www.precipiodx.com/cart/ \"Cart\")\n\nCart\n\n  * [](#)\n    * Search for:\n\n\n\n\n  * [ **0** ](https://www.precipiodx.com/cart/ \"Cart\")\n\n\n\n# SEC Filings\n\nFiling Date| Filings| Description| Format  \n---|---|---|---  \nAug 15, 2024| 8-K| Current report, items 7.01, and 9.01| [ ![](/wp-content/uploads/2022/08/html.png) ](https://www.sec.gov/ix?doc=/Archives/edgar/data/1043961/000110465924090145/tm2421845d1_8k.htm)  \nAug 13, 2024| 10-Q| Quarterly report [Sections 13 or 15(d)]| [ ![](/wp-content/uploads/2022/08/html.png) ](https://www.sec.gov/ix?doc=/Archives/edgar/data/1043961/000155837024012053/prpo-20240630x10q.htm)  \nAug 02, 2024| SC 13G| Statement of Beneficial Ownership by Certain Investors| [ ![](/wp-content/uploads/2022/08/html.png) ](https://www.sec.gov/Archives/edgar/data/1043961/000089914024000797/e77479529.htm)  \nJun 25, 2024| 8-K| Current report, item 5.07| [ ![](/wp-content/uploads/2022/08/html.png) ](https://www.sec.gov/ix?doc=/Archives/edgar/data/1043961/000110465924074732/tm2418223d1_8k.htm)  \nJun 13, 2024| DEFA14A| Additional definitive proxy soliciting materials and Rule 14(a)(12) material| [ ![](/wp-content/uploads/2022/08/html.png) ](https://www.sec.gov/Archives/edgar/data/1043961/000110465924071331/tm2417251d2_defa14a.htm)  \nJun 13, 2024| DEFA14A| Additional definitive proxy soliciting materials and Rule 14(a)(12) material| [ ![](/wp-content/uploads/2022/08/html.png) ](https://www.sec.gov/Archives/edgar/data/1043961/000110465924071330/tm2417251d1_defa14a.htm)  \nMay 14, 2024| 10-Q| Quarterly report [Sections 13 or 15(d)]| [ ![](/wp-content/uploads/2022/08/html.png) ](https://www.sec.gov/ix?doc=/Archives/edgar/data/1043961/000155837024008128/prpo-20240331x10q.htm)  \nMay 06, 2024| 8-K| Current report, items 1.01, 2.03, 7.01, and 9.01| [ ![](/wp-content/uploads/2022/08/html.png) ](https://www.sec.gov/ix?doc=/Archives/edgar/data/1043961/000110465924057536/tm2413628d1_8k.htm)  \nMay 01, 2024| 8-K| Current report, item 1.02| [ ![](/wp-content/uploads/2022/08/html.png) ](https://www.sec.gov/ix?doc=/Archives/edgar/data/1043961/000110465924055829/tm2413231d1_8k.htm)  \nApr 29, 2024| ARS| Annual Report to Security Holders| [ ![](/wp-content/uploads/2022/08/html.png) ](https://www.sec.gov/Archives/edgar/data/1043961/000114036124022975/ny20024826x3_ars.pdf)  \nApr 29, 2024| DEFA14A| Additional definitive proxy soliciting materials and Rule 14(a)(12) material| [ ![](/wp-content/uploads/2022/08/html.png) ](https://www.sec.gov/Archives/edgar/data/1043961/000114036124022957/ny20024826x2_defa14a.htm)  \nApr 29, 2024| DEF 14A| Other definitive proxy statements| [ ![](/wp-content/uploads/2022/08/html.png) ](https://www.sec.gov/Archives/edgar/data/1043961/000114036124022948/ny20024826x1_def14a.htm)  \nApr 08, 2024| 424B5| Prospectus [Rule 424(b)(5)]| [ ![](/wp-content/uploads/2022/08/html.png) ](https://www.sec.gov/Archives/edgar/data/1043961/000110465924044788/tm2411360d1_424b5.htm)  \nMar 29, 2024| S-8| Securities to be offered to employees in employee benefit plans| [ ![](/wp-content/uploads/2022/08/html.png) ](https://www.sec.gov/Archives/edgar/data/1043961/000110465924041153/tm2410202d1_s8.htm)  \nMar 29, 2024| 10-K| Annual report [Section 13 and 15(d), not S-K Item 405]| [ ![](/wp-content/uploads/2022/08/html.png) ](https://www.sec.gov/ix?doc=/Archives/edgar/data/1043961/000155837024004365/prpo-20231231x10k.htm)  \nMar 26, 2024| 8-K| Current report, items 7.01 and 9.01| [ ![](/wp-content/uploads/2022/08/html.png) ](https://www.sec.gov/ix?doc=/Archives/edgar/data/1043961/000110465924039066/tm249884d1_8k.htm)  \nJan 19, 2024| 424B5| Prospectus [Rule 424(b)(5)]| [ ![](/wp-content/uploads/2022/08/html.png) ](https://www.sec.gov/Archives/edgar/data/1043961/000110465924005204/tm243323d1_424b5.htm)  \nJan 02, 2024| 8-K| Current report, items 7.01 and 9.01| [ ![](/wp-content/uploads/2022/08/html.png) ](https://www.sec.gov/ix?doc=/Archives/edgar/data/1043961/000110465924000386/tm241487d1_8k.htm)  \nDec 14, 2023| 8-K| Current report, items 7.01 and 9.01| [ ![](/wp-content/uploads/2022/08/html.png) ](https://www.sec.gov/ix?doc=/Archives/edgar/data/1043961/000110465923126061/tm2332910d1_8k.htm)  \nNov 16, 2023| 8-K| Current report, items 7.01 and 9.01| [ ![](/wp-content/uploads/2022/08/html.png) ](https://www.sec.gov/ix?doc=/Archives/edgar/data/1043961/000110465923119167/tm2330947d1_8k.htm)  \nNov 13, 2023| 10-Q| Quarterly report [Sections 13 or 15(d)]| [ ![](/wp-content/uploads/2022/08/html.png) ](https://www.sec.gov/ix?doc=/Archives/edgar/data/1043961/000155837023018820/prpo-20230930x10q.htm)  \nOct 06, 2023| 8-K| Current report, item 8.01| [ ![](/wp-content/uploads/2022/08/html.png) ](https://www.sec.gov/ix?doc=/Archives/edgar/data/1043961/000110465923107522/tm2328002d1_8k.htm)  \nSep 21, 2023| 8-K| Current report, items 5.03, 7.01, and 9.01| [ ![](/wp-content/uploads/2022/08/html.png) ](https://www.sec.gov/ix?doc=/Archives/edgar/data/1043961/000110465923102859/tm2326654d1_8k.htm)  \nAug 14, 2023| 8-K| Current report, items 7.01 and 9.01| [ ![](/wp-content/uploads/2022/08/html.png) ](https://www.sec.gov/ix?doc=/Archives/edgar/data/1043961/000110465923091283/tm2323703d1_8k.htm)  \nAug 11, 2023| 10-Q| Quarterly report [Sections 13 or 15(d)]| [ ![](/wp-content/uploads/2022/08/html.png) ](https://www.sec.gov/ix?doc=/Archives/edgar/data/1043961/000155837023014655/prpo-20230630x10q.htm)  \nJul 19, 2023| EFFECT| Notice of Effectiveness| [ ![](/wp-content/uploads/2022/08/html.png) ](https://www.sec.gov/Archives/edgar/data/1043961/999999999523002139/9999999995-23-002139-index.htm)  \nJul 07, 2023| S-1| General form for registration of securities under the Securities Act of 1933| [ ![](/wp-content/uploads/2022/08/html.png) ](https://www.sec.gov/Archives/edgar/data/1043961/000110465923079141/tm2320648d1_s1.htm)  \nJun 15, 2023| 8-K| Current report, items 5.07 and 9.01| [ ![](/wp-content/uploads/2022/08/html.png) ](https://www.sec.gov/ix?doc=/Archives/edgar/data/1043961/000110465923071658/tm2318854d1_8k.htm)  \nJun 12, 2023| 8-K| Current report, items 1.01, 3.02, 8.01, and 9.01| [ ![](/wp-content/uploads/2022/08/html.png) ](https://www.sec.gov/ix?doc=/Archives/edgar/data/1043961/000110465923070356/tm2318350d1_8k.htm)  \nJun 09, 2023| 424B5| Prospectus [Rule 424(b)(5)]| [ ![](/wp-content/uploads/2022/08/html.png) ](https://www.sec.gov/Archives/edgar/data/1043961/000110465923069888/tm2318272d1_424b5.htm)  \nMay 16, 2023| 8-K| Current report, items 7.01 and 9.01| [ ![](/wp-content/uploads/2022/08/html.png) ](https://www.sec.gov/ix?doc=/Archives/edgar/data/1043961/000110465923060979/tm2315868d1_8k.htm)  \nMay 12, 2023| 10-Q| Quarterly report [Sections 13 or 15(d)]| [ ![](/wp-content/uploads/2022/08/html.png) ](https://www.sec.gov/ix?doc=/Archives/edgar/data/1043961/000155837023009597/prpo-20230331x10q.htm)  \nApr 27, 2023| EFFECT| Notice of Effectiveness| [ ![](/wp-content/uploads/2022/08/html.png) ](https://www.sec.gov/Archives/edgar/data/1043961/999999999523001078/xslEFFECTX01/primary_doc.xml)  \nApr 27, 2023| 8-K| Current report, items 3.01 and 9.01| [ ![](/wp-content/uploads/2022/08/html.png) ](https://www.sec.gov/ix?doc=/Archives/edgar/data/1043961/000110465923051492/tm2314019d1_8k.htm)  \nApr 25, 2023| S-3/A| **[Amend]** Registration statement under Securities Act of 1933| [ ![](/wp-content/uploads/2022/08/html.png) ](https://www.sec.gov/Archives/edgar/data/1043961/000110465923049642/tm2313545d1_s3a.htm)  \nApr 25, 2023| DEFA14A| Additional definitive proxy soliciting materials and Rule 14(a)(12) material| [ ![](/wp-content/uploads/2022/08/html.png) ](https://www.sec.gov/Archives/edgar/data/1043961/000114036123020210/ny20008385x4_defa14a.htm)  \nApr 25, 2023| DEF 14A| Other definitive proxy statements| [ ![](/wp-content/uploads/2022/08/html.png) ](https://www.sec.gov/Archives/edgar/data/1043961/000114036123020203/ny20008385x3_def14a.htm)  \nApr 17, 2023| 8-K| Current report, items 1.01, 8.01, and 9.01| [ ![](/wp-content/uploads/2022/08/html.png) ](https://www.sec.gov/ix?doc=/Archives/edgar/data/1043961/000110465923045710/tm2312629d2_8k.htm)  \nApr 14, 2023| S-3| Registration statement under Securities Act of 1933| [ ![](/wp-content/uploads/2022/08/html.png) ](https://www.sec.gov/Archives/edgar/data/1043961/000110465923045647/tm2312629d1_s3.htm)  \nApr 14, 2023| ARS| Annual Report to Security Holders| [ ![](/wp-content/uploads/2022/08/html.png) ](https://www.sec.gov/Archives/edgar/data/1043961/000114036123018484/ny20008385x2_ars.pdf)  \nApr 14, 2023| PRE 14A| Other preliminary proxy statements| [ ![](/wp-content/uploads/2022/08/html.png) ](https://www.sec.gov/Archives/edgar/data/1043961/000114036123018482/ny20008385x1_pre14a.htm)  \nMar 30, 2023| S-8| Securities to be offered to employees in employee benefit plans| [ ![](/wp-content/uploads/2022/08/html.png) ](https://www.sec.gov/Archives/edgar/data/1043961/000110465923039240/tm2310893d1_s8.htm)  \nMar 30, 2023| 10-K| Annual report [Section 13 and 15(d), not S-K Item 405]| [ ![](/wp-content/uploads/2022/08/html.png) ](https://www.sec.gov/ix?doc=/Archives/edgar/data/1043961/000155837023005076/prpo-20221231x10k.htm)  \nMar 29, 2023| 8-K| Current report, items 7.01 and 9.01| [ ![](/wp-content/uploads/2022/08/html.png) ](https://www.sec.gov/ix?doc=/Archives/edgar/data/1043961/000110465923038295/tm2310887d1_8k.htm)  \nNov 21, 2022| 8-K| Current report, item 8.01| [ ![](/wp-content/uploads/2022/08/html.png) ](https://www.sec.gov/ix?doc=/Archives/edgar/data/1043961/000110465922120842/tm2231116d1_8k.htm)  \nNov 10, 2022| 10-Q| Quarterly report [Sections 13 or 15(d)]| [ ![](/wp-content/uploads/2022/08/html.png) ](https://www.sec.gov/ix?doc=/Archives/edgar/data/1043961/000155837022017400/prpo-20220930x10q.htm)  \nOct 31, 2022| 8-K| Current report, item 3.01| [ ![](/wp-content/uploads/2022/08/html.png) ](https://www.sec.gov/ix?doc=/Archives/edgar/data/1043961/000155837022017400/prpo-20220930x10q.htm)  \nSep 19, 2022| 8-K| Current report, item 8.01| [ ![](/wp-content/uploads/2022/08/html.png) ](https://www.sec.gov/Archives/edgar/data/1043961/000110465922101194/0001104659-22-101194-index.htm)  \nSep 19, 2022| 8-K| Current report, item 8.01| [ ![](/wp-content/uploads/2022/08/html.png) ](https://www.sec.gov/Archives/edgar/data/1043961/000110465922101191/0001104659-22-101191-index.htm)  \nAug 11, 2022| 10-Q| Quarterly report [Sections 13 or 15(d)]| [ ![](/wp-content/uploads/2022/08/html.png) ](https://www.sec.gov/Archives/edgar/data/1043961/000155837022013260/0001558370-22-013260-index.htm)  \nAug 08, 2022| 8-K| Current report, items 7.01 and 9.01| [ ![](/wp-content/uploads/2022/08/html.png) ](https://www.sec.gov/Archives/edgar/data/1043961/000110465922087281/0001104659-22-087281-index.htm)  \nJul 07, 2022| 8-K| Current report, items 7.01 and 9.01| [ ![](/wp-content/uploads/2022/08/html.png) ](https://www.sec.gov/Archives/edgar/data/1043961/000110465922081270/0001104659-22-081270-index.htm)  \nJul 06, 2022| 8-K | Current report, item 5.07 | [ ![](/wp-content/uploads/2022/08/html.png) ](https://www.sec.gov/Archives/edgar/data/1043961/000110465922077460/0001104659-22-077460-index.htm)  \nJun 15, 2022 | 8-K| Current report, items 8.01 and 9.01 | [ ![](/wp-content/uploads/2022/08/html.png) ](https://www.sec.gov/Archives/edgar/data/1043961/000110465922071248/0001104659-22-071248-index.htm)  \nJun 13, 2022 | 8-K| Current report, items 7.01 and 9.01 | [ ![](/wp-content/uploads/2022/08/html.png) ](https://www.sec.gov/Archives/edgar/data/1043961/000110465922070596/0001104659-22-070596-index.htm)  \nMay 11, 2022 | 10-Q| Quarterly report [Sections 13 or 15(d)] | [ ![](/wp-content/uploads/2022/08/html.png) ](https://www.sec.gov/Archives/edgar/data/1043961/000155837022008317/0001558370-22-008317-index.htm)  \nApr 28, 2022 | DEFA14A | Additional definitive proxy soliciting materials and Rule 14(a)(12) material | [ ![](/wp-content/uploads/2022/08/html.png) ](https://www.sec.gov/Archives/edgar/data/1043961/000114036122016618/0001140361-22-016618-index.htm)  \nApr 28, 2022 | DEF 14A | Other definitive proxy statements | [ ![](/wp-content/uploads/2022/08/html.png) ](https://www.sec.gov/Archives/edgar/data/1043961/000114036122016614/0001140361-22-016614-index.htm)  \nMar 30, 2022 | 3| Initial statement of beneficial ownership of securities | [ ![](/wp-content/uploads/2022/08/html.png) ](https://www.sec.gov/Archives/edgar/data/1043961/000155837022004774/0001558370-22-004774-index.htm)  \nMar 30, 2022 | 10-K| Annual report [Section 13 and 15(d), not S-K Item 405] | [ ![](/wp-content/uploads/2022/08/html.png) ](https://www.sec.gov/Archives/edgar/data/1043961/000155837022004774/0001558370-22-004774-index.htm)  \nMar 23, 2022 | 8-K| Current report, items 7.01 and 9.01 | [ ![](/wp-content/uploads/2022/08/html.png) ](https://www.sec.gov/Archives/edgar/data/1043961/000110465922036672/0001104659-22-036672-index.htm)  \nMar 21, 2022 | 8-K| Current report, items 5.02, 7.01, and 9.01 | [ ![](/wp-content/uploads/2022/08/html.png) ](https://www.sec.gov/Archives/edgar/data/1043961/000110465922036190/0001104659-22-036190-index.htm)  \nMar 01, 2022 | 4/A| [Amend] Statement of changes in beneficial ownership of securities | [ ![](/wp-content/uploads/2022/08/html.png) ](https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=0001043961&owner=exclude&count=40&hidefilings=0)  \nMar 01, 2022 | 4/A| [Amend] Statement of changes in beneficial ownership of securities | [ ![](/wp-content/uploads/2022/08/html.png) ](https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=0001043961&owner=exclude&count=40&hidefilings=0)  \nMar 01, 2022 | 4| Statement of changes in beneficial ownership of securities | [ ![](/wp-content/uploads/2022/08/html.png) ](https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=0001043961&owner=exclude&count=40&hidefilings=0)  \nMar 01, 2022 | 4| Statement of changes in beneficial ownership of securities | [ ![](/wp-content/uploads/2022/08/html.png) ](https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=0001043961&owner=exclude&count=40&hidefilings=0)  \nFeb 28, 2022 | 8-K| Current report, items 2.02 and 9.01 | [ ![](/wp-content/uploads/2022/08/html.png) ](https://www.sec.gov/Archives/edgar/data/1043961/000110465922027450/0001104659-22-027450-index.htm)  \nJan 13, 2022 | 4| Statement of changes in beneficial ownership of securities | [ ![](/wp-content/uploads/2022/08/html.png) ](https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=0001043961&owner=exclude&count=40&hidefilings=0)  \nJan 13, 2022 | 4| Statement of changes in beneficial ownership of securities | [ ![](/wp-content/uploads/2022/08/html.png) ](https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=0001043961&owner=exclude&count=40&hidefilings=0)  \nJan 13, 2022 | 4| Statement of changes in beneficial ownership of securities | [ ![](/wp-content/uploads/2022/08/html.png) ](https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=0001043961&owner=exclude&count=40&hidefilings=0)  \nJan 13, 2022 | 4| Statement of changes in beneficial ownership of securities | [ ![](/wp-content/uploads/2022/08/html.png) ](https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=0001043961&owner=exclude&count=40&hidefilings=0)  \nJan 13, 2022 | 4| Statement of changes in beneficial ownership of securities | [ ![](/wp-content/uploads/2022/08/html.png) ](https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=0001043961&owner=exclude&count=40&hidefilings=0)  \nJan 13, 2022 | 4| Statement of changes in beneficial ownership of securities | [ ![](/wp-content/uploads/2022/08/html.png) ](https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=0001043961&owner=exclude&count=40&hidefilings=0)  \nJan 13, 2022 | 4| Statement of changes in beneficial ownership of securities | [ ![](/wp-content/uploads/2022/08/html.png) ](https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=0001043961&owner=exclude&count=40&hidefilings=0)  \nJan 13, 2022 | 4| Statement of changes in beneficial ownership of securities | [ ![](/wp-content/uploads/2022/08/html.png) ](https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=0001043961&owner=exclude&count=40&hidefilings=0)  \nJan 13, 2022 | 4| Statement of changes in beneficial ownership of securities | [ ![](/wp-content/uploads/2022/08/html.png) ](https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=0001043961&owner=exclude&count=40&hidefilings=0)  \nDec 10, 2021 | 4| Statement of changes in beneficial ownership of securities | [ ![](/wp-content/uploads/2022/08/html.png) ](https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=0001043961&owner=exclude&count=40&hidefilings=0)  \nDec 10, 2021 | 4| Statement of changes in beneficial ownership of securities | [ ![](/wp-content/uploads/2022/08/html.png) ](https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=0001043961&owner=exclude&count=40&hidefilings=0)  \nNov 12, 2021 | 10-Q| Quarterly report [Sections 13 or 15(d)] | [ ![](/wp-content/uploads/2022/08/html.png) ](https://www.sec.gov/Archives/edgar/data/1043961/000155837021015776/0001558370-21-015776-index.htm)  \nNov 02, 2021 | 8-K| Current report, items 7.01 and 9.01 | [ ![](/wp-content/uploads/2022/08/html.png) ](https://www.sec.gov/Archives/edgar/data/1043961/000110465921132509/0001104659-21-132509-index.htm)  \nAug 23, 2021 | 8-K| Current report, items 7.01 and 9.01 | [ ![](/wp-content/uploads/2022/08/html.png) ](https://www.sec.gov/Archives/edgar/data/1043961/000110465921108274/0001104659-21-108274-index.htm)  \nAug 13, 2021 | 8-K| Current report, items 7.01 and 9.01 | [ ![](/wp-content/uploads/2022/08/html.png) ](https://www.sec.gov/Archives/edgar/data/1043961/000110465921104422/0001104659-21-104422-index.htm)  \nAug 12, 2021 | 10-Q| Quarterly report [Sections 13 or 15(d)]] | [ ![](/wp-content/uploads/2022/08/html.png) ](https://www.sec.gov/Archives/edgar/data/1043961/000155837021011475/0001558370-21-011475-index.htm)  \nAug 03, 2021 | 144| Report of proposed sale of securities | [ ![](/wp-content/uploads/2022/08/html.png) ](https://www.sec.gov/Archives/edgar/data/1043961/000155837021011475/0001558370-21-011475-index.htm)  \nJul 28, 2021 | 8-K| Current report, items 2.02 and 9.01 | [ ![](/wp-content/uploads/2022/08/html.png) ](https://www.sec.gov/Archives/edgar/data/1043961/000110465921096999/0001104659-21-096999-index.htm)  \nJun 21, 2021 | 8-K| Current report, item 5.07 | [ ![](/wp-content/uploads/2022/08/html.png) ](https://www.sec.gov/Archives/edgar/data/1043961/000110465921083527/0001104659-21-083527-index.htm)  \nJun 17, 2021 | 144| Report of proposed sale of securities | [ ![](/wp-content/uploads/2022/08/html.png) ](https://www.sec.gov/Archives/edgar/data/1043961/000110465921083527/0001104659-21-083527-index.htm)  \nJun 15, 2021 | 8-K| Current report, item 8.01 | [ ![](/wp-content/uploads/2022/08/html.png) ](https://www.sec.gov/Archives/edgar/data/1043961/000110465921081469/0001104659-21-081469-index.htm)  \nJun 15, 2021 | 8-K| Current report, item 1.02 | [ ![](/wp-content/uploads/2022/08/html.png) ](https://www.sec.gov/Archives/edgar/data/1043961/000110465921081468/0001104659-21-081468-index.htm)  \nMay 21, 2021 | DEFR14A | Revised definitive proxy soliciting materials | [ ![](/wp-content/uploads/2022/08/html.png) ](https://www.sec.gov/Archives/edgar/data/1043961/000110465921070510/0001104659-21-070510-index.htm)  \nMay 17, 2021 | 8-K| Current report, items 7.01 and 9.01 | [ ![](/wp-content/uploads/2022/08/html.png) ](https://www.sec.gov/Archives/edgar/data/1043961/000110465921067627/0001104659-21-067627-index.htm)  \nMay 14, 2021 | 10-Q| Quarterly report [Sections 13 or 15(d)] | [ ![](/wp-content/uploads/2022/08/html.png) ](https://www.sec.gov/Archives/edgar/data/1043961/000155837021007252/0001558370-21-007252-index.htm)  \nApr 29, 2021 | DEFA14A | Additional definitive proxy soliciting materials and Rule 14(a)(12) material | [ ![](/wp-content/uploads/2022/08/html.png) ](https://www.sec.gov/Archives/edgar/data/1043961/000114036121014976/0001140361-21-014976-index.htm)  \nApr 29, 2021 | DEF 14A | Other definitive proxy statements | [ ![](/wp-content/uploads/2022/08/html.png) ](https://www.sec.gov/Archives/edgar/data/1043961/000114036121014971/0001140361-21-014971-index.htm)  \nApr 02, 2021 | 8-K| Current report, items 1.01 and 9.01 | [ ![](/wp-content/uploads/2022/08/html.png) ](https://www.sec.gov/Archives/edgar/data/1043961/000110465921046029/0001104659-21-046029-index.htm)  \nApr 02, 2021 | 424B5 | Prospectus [Rule 424(b)(5)] | [ ![](/wp-content/uploads/2022/08/html.png) ](https://www.sec.gov/Archives/edgar/data/1043961/000110465921046001/0001104659-21-046001-index.htm)  \nMar 29, 2021 | 10-K| Annual report [Section 13 and 15(d), not S-K Item 405] | [ ![](/wp-content/uploads/2022/08/html.png) ](https://www.sec.gov/Archives/edgar/data/1043961/000155837021003619/0001558370-21-003619-index.htm)  \nMar 18, 2021 | 8-K| Current report, items 7.01 and 9.01 | [ ![](/wp-content/uploads/2022/08/html.png) ](https://www.sec.gov/Archives/edgar/data/1043961/000110465921038453/0001104659-21-038453-index.htm)  \nMar 03, 2021 | 8-K| Current report, items 5.02, 5.05, 8.01 and 9.01 | [ ![](/wp-content/uploads/2022/08/html.png) ](https://www.sec.gov/Archives/edgar/data/1043961/000110465921031474/0001104659-21-031474-index.htm)  \nNov 13, 2020 | 10-Q| Quarterly report [Sections 13 or 15(d)] | [ ![](/wp-content/uploads/2022/08/html.png) ](https://www.sec.gov/Archives/edgar/data/1043961/000155837020013815/0001558370-20-013815-index.htm)  \nNov 12, 2020 | 8-K| Current report, items 7.01 and 9.01 | [ ![](/wp-content/uploads/2022/08/html.png) ](https://www.sec.gov/Archives/edgar/data/1043961/000110465920123827/0001104659-20-123827-index.htm)  \nSep 04, 2020 | 8-K| Current report, items 7.01 and 9.01 | [ ![](/wp-content/uploads/2022/08/html.png) ](https://www.sec.gov/Archives/edgar/data/1043961/000110465920102604/0001104659-20-102604-index.htm)  \nAug 28, 2020 | 8-K| Current report, item 5.02 | [ ![](/wp-content/uploads/2022/08/html.png) ](https://www.sec.gov/Archives/edgar/data/1043961/000110465920100215/0001104659-20-100215-index.htm)  \nAug 13, 2020 | 10-K| Quarterly report [Sections 13 or 15(d)] | [ ![](/wp-content/uploads/2022/08/html.png) ](https://www.sec.gov/Archives/edgar/data/1043961/000155837020010522/0001558370-20-010522-index.htm)  \nAug 07, 2020 | 8-K| Current report, items 7.01 and 9.01| [ ![](/wp-content/uploads/2022/08/html.png) ](https://www.sec.gov/Archives/edgar/data/1043961/000110465920091988/0001104659-20-091988-index.htm)  \nJul 22, 2020 | 4/A| [Amend] Statement of changes in beneficial ownership of securities | [ ![](/wp-content/uploads/2022/08/html.png) ]()  \nJul 14, 2020 | 4/A| [Amend] Statement of changes in beneficial ownership of securities | [ ![](/wp-content/uploads/2022/08/html.png) ](https://www.sec.gov/Archives/edgar/data/1043961/000110465920085602/0001104659-20-085602-index.htm)  \nJul 22, 2020 | 8-K| Current report, items 2.02 and 9.01 | [ ![](/wp-content/uploads/2022/08/html.png) ](https://www.sec.gov/Archives/edgar/data/1043961/000110465920085602/0001104659-20-085602-index.htm)  \nJul 14, 2020 | 4| Statement of changes in beneficial ownership of securities | [ ![](/wp-content/uploads/2022/08/html.png) ](https://www.sec.gov/Archives/edgar/data/1043961/000110465920085602/0001104659-20-085602-index.htm)  \nJul 14, 2020 | 4| Statement of changes in beneficial ownership of securities | [ ![](/wp-content/uploads/2022/08/html.png) ](https://www.sec.gov/Archives/edgar/data/1043961/000110465920085602/0001104659-20-085602-index.htm)  \nJul 13, 2020 | 8-K| Current report, item 8.01 | [ ![](/wp-content/uploads/2022/08/html.png) ](https://www.sec.gov/Archives/edgar/data/1043961/000110465920083109/0001104659-20-083109-index.htm)  \nJul 07, 2020 | EFFECT| Notice of Effectiveness | [ ![](/wp-content/uploads/2022/08/html.png) ](https://www.sec.gov/Archives/edgar/data/1043961/999999999520001704/9999999995-20-001704-index.htm)  \nJul 07, 2020 | 424B3 | Prospectus [Rule 424(b)(3)] | [ ![](/wp-content/uploads/2022/08/html.png) ](https://www.sec.gov/Archives/edgar/data/1043961/000110465920081774/0001104659-20-081774-index.htm)  \nJul 07, 2020 | 4| Statement of changes in beneficial ownership of securities | [ ![](/wp-content/uploads/2022/08/html.png) ](https://www.sec.gov/Archives/edgar/data/1043961/000110465920081698/0001104659-20-081698-index.htm)  \nJul 07, 2020 | 4| Statement of changes in beneficial ownership of securities | [ ![](/wp-content/uploads/2022/08/html.png) ](https://www.sec.gov/Archives/edgar/data/1043961/000110465920081356/0001104659-20-081356-index.htm)  \nJul 07, 2020 | S-1/A | [Amend] General form for registration of securities under the Securities Act of 1933 | [ ![](/wp-content/uploads/2022/08/html.png) ](https://www.sec.gov/Archives/edgar/data/1043961/000110465920081698/0001104659-20-081698-index.htm)  \nJul 07, 2020 | S-1AA| [Amend] General form for registration of securities under the Securities Act of 1933 | [ ![](/wp-content/uploads/2022/08/html.png) ](https://www.sec.gov/Archives/edgar/data/1043961/000110465920081356/0001104659-20-081356-index.htm)  \nJul 06, 2020 | 4| Statement of changes in beneficial ownership of securities | [ ![](/wp-content/uploads/2022/08/html.png) ](https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=0001043961&type=&dateb=&owner=exclude&start=40&count=40)  \nJul 02, 2020 | CORRESP | [Cover] Correspondence | [ ![](/wp-content/uploads/2022/08/html.png) ](https://www.sec.gov/Archives/edgar/data/1043961/000110465920080602/0001104659-20-080602-index.htm)  \nJul 02, 2020 | UPLOAD| [Cover] SEC-generated letter | [ ![](/wp-content/uploads/2022/08/html.png) ](https://www.sec.gov/Archives/edgar/data/1043961/000000000020005963/0000000000-20-005963-index.htm)  \nJun 30, 2020 | 8-K| Current report, item 8.01 | [ ![](/wp-content/uploads/2022/08/html.png) ](https://www.sec.gov/Archives/edgar/data/1043961/000110465920078955/0001104659-20-078955-index.htm)  \nJun 26, 2020 | 8-K| Current report, item 5.07 | [ ![](/wp-content/uploads/2022/08/html.png) ](https://www.sec.gov/Archives/edgar/data/1043961/000110465920077549/0001104659-20-077549-index.htm)  \nJun 26, 2020 | S-1| General form for registration of securities under the Securities Act of 1933 | [ ![](/wp-content/uploads/2022/08/html.png) ](https://www.sec.gov/Archives/edgar/data/1043961/000110465920077541/0001104659-20-077541-index.htm)  \nJun 03, 2020 | 8-K| Current report, item 8.01 | [ ![](/wp-content/uploads/2022/08/html.png) ](https://www.sec.gov/Archives/edgar/data/1043961/000110465920069479/0001104659-20-069479-index.htm)  \nJun 03, 2019 | 10-Q| Quarterly report [Sections 13 or 15(d)] | [ ![](/wp-content/uploads/2022/08/html.png) ](https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=0001043961&type=&dateb=&owner=exclude&start=40&count=40)  \nMay 13, 2020 | 8-K| Current report, items 7.01 and 9.01 | [ ![](/wp-content/uploads/2022/08/html.png) ](https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=0001043961&type=&dateb=&owner=exclude&start=40&count=40)  \nMay 01, 2020 | 8-K| Current report, item 3.01 | [ ![](/wp-content/uploads/2022/08/html.png) ](https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=0001043961&type=&dateb=&owner=exclude&start=40&count=40)  \nApr 29, 2020 | DEFA14A | Additional definitive proxy soliciting materials and Rule 14(a)(12) material | [ ![](/wp-content/uploads/2022/08/html.png) ](https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=0001043961&type=&dateb=&owner=exclude&start=40&count=40)  \nApr 29, 2020 | DEF 14A | Other definitive proxy statements | [ ![](/wp-content/uploads/2022/08/html.png) ](https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=0001043961&type=&dateb=&owner=exclude&start=40&count=40)  \nApr 24, 2020 | 8-K| Current report, items 1.01, 2.03, 8.01, and 9.01 | [ ![](/wp-content/uploads/2022/08/html.png) ](https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=0001043961&type=&dateb=&owner=exclude&start=40&count=40)  \nApr 13, 2020 | EFFECT| Notice of Effectiveness | [ ![](/wp-content/uploads/2022/08/html.png) ](https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=0001043961&type=&dateb=&owner=exclude&start=40&count=40)  \nApr 13, 2020 | EFFECT | Notice of Effectiveness | [ ![](/wp-content/uploads/2022/08/html.png) ](https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=0001043961&type=&dateb=&owner=exclude&start=40&count=40)  \nApr 13, 2020 | 424B3| Prospectus [Rule 424(b)(3)] | [ ![](/wp-content/uploads/2022/08/html.png) ](https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=0001043961&type=&dateb=&owner=exclude&start=40&count=40)  \nApr 09, 2020 | S-3/A | [Amend] Registration statement under Securities Act of 1933 | [ ![](/wp-content/uploads/2022/08/html.png) ](https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=0001043961&type=&dateb=&owner=exclude&start=40&count=40)  \nApr 08, 2020 | S-1/A | [Amend] General form for registration of securities under the Securities Act of 1933 | [ ![](/wp-content/uploads/2022/08/html.png) ](https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=0001043961&type=&dateb=&owner=exclude&start=40&count=40)  \nApr 07, 2020 | 8-K| Current report, item 5.02 | [ ![](/wp-content/uploads/2022/08/html.png) ](https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=0001043961&type=&dateb=&owner=exclude&start=40&count=40)  \nApr 07, 2020 | 10-K/A | [Amend] Annual report [Section 13 and 15(d), not S-K Item 405] | [ ![](/wp-content/uploads/2022/08/html.png) ](https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=0001043961&type=&dateb=&owner=exclude&start=40&count=40)  \nMar 27, 2020 | S-3| Registration statement under Securities Act of 1933 | [ ![](/wp-content/uploads/2022/08/html.png) ](https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=0001043961&type=&dateb=&owner=exclude&start=40&count=40)  \nMar 27, 2020 | S-1| General form for registration of securities under the Securities Act of 1933 | [ ![](/wp-content/uploads/2022/08/html.png) ](https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=0001043961&type=&dateb=&owner=exclude&start=40&count=40)  \nMar 27, 2020 | 8-K| Current report, items 1.01, 3.02, and 9.01 | [ ![](/wp-content/uploads/2022/08/html.png) ](https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=0001043961&type=&dateb=&owner=exclude&start=40&count=40)  \nMar 27, 2020| 10-K| Annual report [Section 13 and 15(d), not S-K Item 405] | [ ![](/wp-content/uploads/2022/08/html.png) ](https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=0001043961&type=&dateb=&owner=exclude&start=40&count=40)  \nMar 16, 2020 | 8-K| Current report, items 7.01 and 9.01 | [ ![](/wp-content/uploads/2022/08/html.png) ](https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=0001043961&type=&dateb=&owner=exclude&start=40&count=40)  \nFeb 18, 2020 | 8-K| Current report, items 7.01 and 9.01 | [ ![](/wp-content/uploads/2022/08/html.png) ](https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=0001043961&type=&dateb=&owner=exclude&start=40&count=40)  \nJan 14, 2020 | S-1| General form for registration of securities under the Securities Act of 1933 | [ ![](/wp-content/uploads/2022/08/html.png) ](https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=0001043961&type=&dateb=&owner=exclude&start=40&count=40)  \nJan 14, 2020 | 8-K| Current report, items 7.01 and 9.01 | [ ![](/wp-content/uploads/2022/08/html.png) ](https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=0001043961&type=&dateb=&owner=exclude&start=40&count=40)  \nDec 04, 2019 | 8-K| Current report, items 5.02, 8.01, and 9.01 | [ ![](/wp-content/uploads/2022/08/html.png) ](https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=0001043961&type=&dateb=&owner=exclude&start=80&count=40)  \nNov 26, 2019 | 8-K| Current report, item 8.01 | [ ![](/wp-content/uploads/2022/08/html.png) ](https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=0001043961&type=&dateb=&owner=exclude&start=80&count=40)  \nNov 13, 2019 | 10-Q| Quarterly report [Sections 13 or 15(d)] | [](https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=0001043961&type=&dateb=&owner=exclude&start=80&count=40)  \nNov 05, 2019 | 8-K| Current report, items 7.01 and 9.01 | [](https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=0001043961&type=&dateb=&owner=exclude&start=80&count=40)  \nOct 03, 2019 | 8-K| Current report, items 7.01 and 9.01 | [](https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=0001043961&type=&dateb=&owner=exclude&start=80&count=40)  \nSep 26, 2019 | 8-K| Current report, item 7.01 | [](https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=0001043961&type=&dateb=&owner=exclude&start=80&count=40)  \nAug 21, 2019 | 424B3 | Prospectus [Rule 424(b)(3)] | [](https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=0001043961&type=&dateb=&owner=exclude&start=80&count=40)  \nAug 09, 2019 | S-1| General form for registration of securities under the Securities Act of 1933 | [](https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=0001043961&type=&dateb=&owner=exclude&start=80&count=40)  \nAug 09, 2019 | 10-Q| Quarterly report [Sections 13 or 15(d)] | [](https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=0001043961&type=&dateb=&owner=exclude&start=80&count=40)  \nJun 20, 2019 | 8-K| Current report, items 7.01 and 9.01 | [](https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=0001043961&type=&dateb=&owner=exclude&start=80&count=40)  \nJun 19, 2019 | 8-K| Current report, item 5.07 | [](https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=0001043961&type=&dateb=&owner=exclude&start=80&count=40)  \nJun 10, 2019 | 8-K| Current report, item 8.01 | [](https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=0001043961&type=&dateb=&owner=exclude&start=80&count=40)  \nMay 23, 2019 | 8-K| Current report, item 8.01 | [](https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=0001043961&type=&dateb=&owner=exclude&start=80&count=40)  \nMay 16, 2019 | 10-Q| Quarterly report [Sections 13 or 15(d)] | [](https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=0001043961&type=&dateb=&owner=exclude&start=80&count=40)  \nMay 15, 2019 | NT 10-Q | Notification of inability to timely file Form 10-Q or 10-QSB | [](https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=0001043961&type=&dateb=&owner=exclude&start=80&count=40)  \nMay 15, 2019 | 8-K| Current report, items 8.01 and 9.01 | [](https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=0001043961&type=&dateb=&owner=exclude&start=80&count=40)  \nApr 29, 2019 | DEFA14A | Additional definitive proxy soliciting materials and Rule 14(a)(12) material | [](https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=0001043961&type=&dateb=&owner=exclude&start=80&count=40)  \nApr 29, 2019 | DEF 14A | Other definitive proxy statements | [](https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=0001043961&type=&dateb=&owner=exclude&start=80&count=40)  \nApr 26, 2019 | 8-K| Current report, items 5.03, 7.01, and 9.01 | [](https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=0001043961&type=&dateb=&owner=exclude&start=80&count=40)  \nApr 16, 2019 | 10-K| Annual report [Section 13 and 15(d), not S-K Item 405] | [](https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=0001043961&type=&dateb=&owner=exclude&start=80&count=40)  \nMar 29, 2019 | NT 10-K | Notice of late filing of Form 10-K | [](https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=0001043961&type=&dateb=&owner=exclude&start=80&count=40)  \nMar 27, 2019 | 8-K| Current report, item 3.01 | [](https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=0001043961&type=&dateb=&owner=exclude&start=80&count=40)  \nMar 11, 2019 | 8-K| Current report, items 7.01 and 9.01 | [](https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=0001043961&type=&dateb=&owner=exclude&start=80&count=40)  \nFeb 14, 2019 | 8-K| Current report, items 2.02 and 9.01 | [](https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=0001043961&type=&dateb=&owner=exclude&start=80&count=40)  \nFeb 13, 2019 | EFFECT | Notice of Effectiveness | [](https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=0001043961&type=&dateb=&owner=exclude&start=80&count=40)  \nFeb 13, 2019 | 424B3 | Prospectus [Rule 424(b)(3)] | [](https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=0001043961&type=&dateb=&owner=exclude&start=80&count=40)  \nFeb 13, 2019 | 424B3 | Prospectus [Rule 424(b)(3)] | [](https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=0001043961&type=&dateb=&owner=exclude&start=80&count=40)  \nFeb 12, 2019 | EFFECT | Notice of Effectiveness | [](https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=0001043961&type=&dateb=&owner=exclude&start=80&count=40)  \nFeb 06, 2019 | S-3| Registration statement under Securities Act of 1933 | [](https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=0001043961&type=&dateb=&owner=exclude&start=80&count=40)  \nFeb 01, 2019 | S-1| General form for registration of securities under the Securities Act of 1933 | [](https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=0001043961&type=&dateb=&owner=exclude&start=80&count=40)  \nJan 30, 2019 | 8-K| Current report, items 1.01, 1.02, 3.02, and 9.01 | [](https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=0001043961&type=&dateb=&owner=exclude&start=80&count=40)  \nJan 22, 2019 | 8-K| Unregistered Sales of Equity Securities to Crede Capital Group LLC | [](https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=0001043961&type=&dateb=&owner=exclude&start=80&count=40)  \nJan 07, 2019 | 8-K| Settlement Agreement with a Third Party Service Provider | [](https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=0001043961&type=&dateb=&owner=exclude&start=80&count=40)  \nDec 20, 2018 | 8-K| Submission of Matters to a Vote of Security Holders | [](https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=0001043961&type=&dateb=&owner=exclude&start=80&count=40)  \nDec 03, 2018 | 8-K| Amendment to Security Purchase Agreement of April 20, 2018 | [](https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=0001043961&type=&dateb=&owner=exclude&start=80&count=40)  \nNov 19, 2018 | 10-Q| Quarterly report [Sections 13 or 15(d)] | [](https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=0001043961&type=&dateb=&owner=exclude&start=80&count=40)  \nNov 15, 2018 | PRE 14A | Preliminary proxy statement | [](https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=0001043961&type=&dateb=&owner=exclude&start=80&count=40)  \nNov 15, 2018 | NT 10-Q | Notice of late filing of 10-Q form 12-b 25 | [](https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=0001043961&type=&dateb=&owner=exclude&start=80&count=40)  \nOct 16, 2018 | 8-K| Current report, items 2.02 and 9.01 | [](https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=0001043961&type=&dateb=&owner=exclude&start=80&count=40)  \nOct 01, 2018 | 424B3| Prospectus [Rule 424(b)(3)] | [](https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=0001043961&type=&dateb=&owner=exclude&start=80&count=40)  \nSep 28, 2018 | EFFECT| Notice of Effectiveness | [](https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=0001043961&type=&dateb=&owner=exclude&start=80&count=40)  \nSep 27, 2018 | 8-K| Current report, items 3.01 and 9.01 | [](https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=0001043961&type=&dateb=&owner=exclude&start=80&count=40)  \nSep 25, 2018 | 8-K| Current report, items 1.01 and 9.01 | [](https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=0001043961&type=&dateb=&owner=exclude&start=80&count=40)  \nSep 25, 2018 | S-1/A | [Amend] General form for registration of securities under the Securities Act of 1933 | [](https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=0001043961&type=&dateb=&owner=exclude&start=80&count=40)  \nSep 20, 2018 | 8-K| Current report, items 1.01 and 9.01 | [](https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=0001043961&type=&dateb=&owner=exclude&start=80&count=40)  \nSep 14, 2018 | S-1| General form for registration of securities under the Securities Act of 1933 | [](https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=0001043961&type=&dateb=&owner=exclude&start=80&count=40)  \nSep 14, 2018 | SC 13D/A | [Amend] General statement of acquisition of beneficial ownership | [](https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=0001043961&type=&dateb=&owner=exclude&start=80&count=40)  \nSep 13, 2018 | 8-K| Current report, items 1.01, 3.02, 8.01, and 9.01 | [](https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=0001043961&type=&dateb=&owner=exclude&start=80&count=40)  \nAug 22, 2018 | 8-K| Current report, items 7.01 and 9.01 | [](https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=0001043961&type=&dateb=&owner=exclude&start=80&count=40)  \nAug 16, 2018 | 10-Q| Quarterly report [Sections 13 or 15(d)] | [](https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=0001043961&type=&dateb=&owner=exclude&start=80&count=40)  \nAug 15, 2018 | NT 10-Q | Notice of late filing of 10-Q form 12-b 25 | [](https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=0001043961&type=&dateb=&owner=exclude&start=80&count=40)  \nAug 10, 2018 | RW| Registration Withdrawal Request | [](https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=0001043961&type=&dateb=&owner=exclude&start=80&count=40)  \nAug 09, 2018 | 8-K| Current report, items 5.02 and 9.01 | [](https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=0001043961&type=&dateb=&owner=exclude&start=80&count=40)  \nJul 18, 2018 | 8-K| Current report, items 2.02 and 9.01 | [](https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=0001043961&type=&dateb=&owner=exclude&start=80&count=40)  \nJul 06, 2018 | 8-K| Current report, item 5.07 | [](https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=0001043961&type=&dateb=&owner=exclude&start=80&count=40)  \nJun 15, 2018 | DEFA14A| Additional definitive proxy soliciting materials and Rule 14(a)(12) material | [](https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=0001043961&type=&dateb=&owner=exclude&start=80&count=40)  \nJun 15, 2018 | 8-K| Current report, items 8.01 and 9.01 | [](https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=0001043961&type=&dateb=&owner=exclude&start=80&count=40)  \nJun 14, 2018 | S-1/A | [Amend] General form for registration of securities under the Securities Act of 1933 | [](https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=0001043961&type=&dateb=&owner=exclude&start=80&count=40)  \nJun 04, 2018 | 8-K| Current report, item 8.01 | [](https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=0001043961&type=&dateb=&owner=exclude&start=80&count=40)  \nMay 29, 2018 | DEF 14A | Other definitive proxy statements | [](https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=0001043961&type=&dateb=&owner=exclude&start=80&count=40)  \nMay 21, 2018 | 10-Q| Quarterly report [Sections 13 or 15(d)] | [](https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=0001043961&type=&dateb=&owner=exclude&start=80&count=40)  \nMay 18, 2018 | PRE 14A | Preliminary proxy statement | [](https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=0001043961&type=&dateb=&owner=exclude&start=80&count=40)  \nMay 15, 2018 | NT 10-Q | Notice of late filing of 10-Q form 12-b 25 | [](https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=0001043961&type=&dateb=&owner=exclude&start=80&count=40)  \nMay 14, 2018 | 8-K| Current report, items 2.02 and 9.01 | [](https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=0001043961&type=&dateb=&owner=exclude&start=80&count=40)  \nApr 26, 2018 | 8-K| Current report, items 7.01 and 9.01 | [](https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=0001043961&type=&dateb=&owner=exclude&start=80&count=40)  \nApr 26, 2018 | 8-K/A| [Amend] Current report, items 1.01, 3.02, 7.01, and 9.01 | [](https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=0001043961&type=&dateb=&owner=exclude&start=80&count=40)  \nApr 23, 2018 | 8-K| Current report, items 1.01, 3.02, 7.01, and 9.01 | [](https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=0001043961&type=&dateb=&owner=exclude&start=80&count=40)  \nApr 16, 2018 | S-1| General form for registration of securities under the Securities Act of 1933 | [](https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=0001043961&type=&dateb=&owner=exclude&start=80&count=40)  \nApr 13, 2018 | 10-K| Annual report [Section 13 and 15(d), not S-K Item 405] | [](https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=0001043961&type=&dateb=&owner=exclude&start=80&count=40)  \nApr 02, 2018 | NT 10-K | Notice of late filing of Form 10-K | [](https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=0001043961&type=&dateb=&owner=exclude&start=80&count=40)  \nMar 30, 2018 | 8-K| Current report, item 3.01 | [](https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=0001043961&type=&dateb=&owner=exclude&start=80&count=40)  \nMar 21, 2018 | 8-K| Current report, items 1.01, 3.03, and 9.01 | [](https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=0001043961&type=&dateb=&owner=exclude&start=80&count=40)  \nMar 14, 2018 | 8-K| Current report, item 8.01 | [](https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=0001043961&type=&dateb=&owner=exclude&start=80&count=40)  \nFeb 27, 2018 | SC 13G/A | [Amend] Statement of acquisition of beneficial ownership by individuals | [](https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=0001043961&type=&dateb=&owner=exclude&start=80&count=40)  \nFeb 26, 2018 | 8-K| Current report, item 8.01 | [](https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=0001043961&type=&dateb=&owner=exclude&start=80&count=40)  \nFeb 14, 2018 | SC 13G | Statement of acquisition of beneficial ownership by individuals | [](https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=0001043961&type=&dateb=&owner=exclude&start=80&count=40)  \nFeb 13, 2018 | 8-K| Current report, item 8.01 | [](https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=0001043961&type=&dateb=&owner=exclude&start=80&count=40)  \nFeb 12, 2018 | 424B5 | Prospectus [Rule 424(b)(5)] | [](https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=0001043961&type=&dateb=&owner=exclude&start=80&count=40)  \nFeb 09, 2018 | 424B5 | Prospectus [Rule 424(b)(5)] | [](https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=0001043961&type=&dateb=&owner=exclude&start=80&count=40)  \nFeb 09, 2018 | 8-K| Current report, items 1.01, 2.02, 3.03, and 9.01 | [](https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=0001043961&type=&dateb=&owner=exclude&start=80&count=40)  \nFeb 01, 2018 | S-8| Securities to be offered to employees in employee benefit plans | [](https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=0001043961&type=&dateb=&owner=exclude&start=80&count=40)  \nJan 31, 2018 | 8-K| Current report, items 5.07 and 8.01 | [](https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=0001043961&type=&dateb=&owner=exclude&start=80&count=40)  \n[ View All Filings ](https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=0001043961&type=&dateb=&owner=exclude&start=0&count=40)\n\n  * [ $0.00 ](https://www.precipiodx.com/cart/ \"Cart\")\n    * Cart\n\nNo products in the cart.\n\n[ Return to shop ](https://www.precipiodx.com/shop/)\n\n  * Search for:\n\n  * [About Us](https://www.precipiodx.com/about/)\n    * [Our Culture](https://www.precipiodx.com/about/culture/)\n    * [News](https://www.precipiodx.com/about/news/)\n    * [Careers](https://www.precipiodx.com/about/careers/)\n    * [Scientific Advisors](https://www.precipiodx.com/about/scientific-advisors/)\n    * [Management Team](https://www.precipiodx.com/about/management-team/)\n    * [Board of Directors](https://www.precipiodx.com/about/board-of-directors/)\n  * [Products](https://www.precipiodx.com/products/)\n    * [Molecular Kits](https://www.precipiodx.com/products/molecular-kits/)\n      * [MPN Panel](https://www.precipiodx.com/products/bloodhound-mpn-panel/)\n      * [BCR-ABL1 Panel](https://www.precipiodx.com/products/bloodhound-bcr-abl1-molecular-panel/)\n      * [ABL1 Resistance Panel](https://www.precipiodx.com/products/bloodhound-abl1-resistance-panel/)\n      * [AML Panel](https://www.precipiodx.com/products/molecular-kits/acute-myeloid-leukemia-panel/)\n      * [CLL Panel](https://www.precipiodx.com/products/molecular-kits/cll-panel/)\n      * [Cytopenia Panel](https://www.precipiodx.com/products/molecular-kits/cytopenia-panel/)\n    * [IV-Cell Cytogenetics Media](https://www.precipiodx.com/products/iv-cell-cytogenetics-media/)\n  * [Clinical Services](https://www.precipiodx.com/clinical-services/)\n    * [Hematopathology Services](https://www.precipiodx.com/clinical-services/blood-cancer-testing/)\n    * [Sample Reports](https://www.precipiodx.com/sample-report/)\n    * [Proprietary Technologies](https://www.precipiodx.com/clinical-services/proprietary-technologies/)\n    * [Meet Our Hematopathologists](https://www.precipiodx.com/clinical-services/meet-our-pathologists/)\n  * [Resources](https://www.precipiodx.com/resources/)\n    * [FAQs](https://www.precipiodx.com/resources/faqs/)\n    * [Brochures](https://www.precipiodx.com/resources/brochures/)\n    * [Case Studies](https://www.precipiodx.com/resources/case-studies/)\n    * [Sample Reports](https://www.precipiodx.com/sample-report/)\n    * [Instructions For Use](https://www.precipiodx.com/resources/ifus/)\n    * [Instructions For Use – Non U.S. CE](https://www.precipiodx.com/resources/instructions-for-use-non-us-ce/)\n  * [Investors](https://www.precipiodx.com/investors/)\n    * [Press Releases](https://www.precipiodx.com/investors/press-releases/)\n    * [Media](https://www.precipiodx.com/investors/media/)\n    * [SEC Filings](https://www.precipiodx.com/investors/sec-filings/)\n    * [Subscription](https://www.precipiodx.com/investors/subscription/)\n    * [Investor FAQs](https://www.precipiodx.com/investors/investor-faqs/)\n    * [Corporate Governance](https://www.precipiodx.com/investors/corporate-governance/)\n    * [Business Update Calls](https://www.precipiodx.com/investors/business-update-calls/)\n  * [Contact](https://www.precipiodx.com/contact/)\n  * [My Account](https://www.precipiodx.com/login/)\n    * [![Login Icon](https://www.precipiodx.com/wp-content/uploads/2022/07/login-svgrepo-com.svg)CaseVu](https://www.casevu-lis.precipiodx.com/)\n    * [![Login Icon](https://www.precipiodx.com/wp-content/uploads/2022/07/login-svgrepo-com.svg)Shop](https://www.precipiodx.com/my-account/)\n    * [![Login Icon](https://www.precipiodx.com/wp-content/uploads/2022/07/login-svgrepo-com.svg)Patient Bill Pay](https://www.precipiodx.com/billing/)\n\n\n\n### Login\n\nUsername or email address *\n\nPassword *\n\nRemember me Log in\n\n[Lost your password?](https://www.precipiodx.com/my-account/lost-password/)\n"
        }
      ]
    },
    {
      "section_name": "Subscription",
      "links": [
        {
          "title": "Subscription",
          "url": "https://www.precipiodx.com/investors/subscription/",
          "content": "[Skip to content](#main)\n\n[ ![Precipio](https://www.precipiodx.com/wp-content/uploads/2022/07/logo.png) ![Precipio](https://www.precipiodx.com/wp-content/uploads/2022/07/logo.png) ](https://www.precipiodx.com/ \"Precipio - Expect More from the start.\")\n\n  * [ ](#)\n\n\n\n\n  * [About Us](https://www.precipiodx.com/about/)\n    * [Our Culture](https://www.precipiodx.com/about/culture/)\n    * [News](https://www.precipiodx.com/about/news/)\n    * [Careers](https://www.precipiodx.com/about/careers/)\n    * [Scientific Advisors](https://www.precipiodx.com/about/scientific-advisors/)\n    * [Management Team](https://www.precipiodx.com/about/management-team/)\n    * [Board of Directors](https://www.precipiodx.com/about/board-of-directors/)\n  * [Products](https://www.precipiodx.com/products/)\n    * [Molecular Kits](https://www.precipiodx.com/products/molecular-kits/)\n      * [MPN Panel](https://www.precipiodx.com/products/bloodhound-mpn-panel/)\n      * [BCR-ABL1 Panel](https://www.precipiodx.com/products/bloodhound-bcr-abl1-molecular-panel/)\n      * [ABL1 Resistance Panel](https://www.precipiodx.com/products/bloodhound-abl1-resistance-panel/)\n      * [AML Panel](https://www.precipiodx.com/products/molecular-kits/acute-myeloid-leukemia-panel/)\n      * [CLL Panel](https://www.precipiodx.com/products/molecular-kits/cll-panel/)\n      * [Cytopenia Panel](https://www.precipiodx.com/products/molecular-kits/cytopenia-panel/)\n    * [IV-Cell Cytogenetics Media](https://www.precipiodx.com/products/iv-cell-cytogenetics-media/)\n  * [Clinical Services](https://www.precipiodx.com/clinical-services/)\n    * [Hematopathology Services](https://www.precipiodx.com/clinical-services/blood-cancer-testing/)\n    * [Sample Reports](https://www.precipiodx.com/sample-report/)\n    * [Proprietary Technologies](https://www.precipiodx.com/clinical-services/proprietary-technologies/)\n    * [Meet Our Hematopathologists](https://www.precipiodx.com/clinical-services/meet-our-pathologists/)\n  * [Resources](https://www.precipiodx.com/resources/)\n    * [FAQs](https://www.precipiodx.com/resources/faqs/)\n    * [Brochures](https://www.precipiodx.com/resources/brochures/)\n    * [Case Studies](https://www.precipiodx.com/resources/case-studies/)\n    * [Sample Reports](https://www.precipiodx.com/sample-report/)\n    * [Instructions For Use](https://www.precipiodx.com/resources/ifus/)\n    * [Instructions For Use – Non U.S. CE](https://www.precipiodx.com/resources/instructions-for-use-non-us-ce/)\n  * [Investors](https://www.precipiodx.com/investors/)\n    * [Press Releases](https://www.precipiodx.com/investors/press-releases/)\n    * [Media](https://www.precipiodx.com/investors/media/)\n    * [SEC Filings](https://www.precipiodx.com/investors/sec-filings/)\n    * [Subscription](https://www.precipiodx.com/investors/subscription/)\n    * [Investor FAQs](https://www.precipiodx.com/investors/investor-faqs/)\n    * [Corporate Governance](https://www.precipiodx.com/investors/corporate-governance/)\n    * [Business Update Calls](https://www.precipiodx.com/investors/business-update-calls/)\n  * [Contact](https://www.precipiodx.com/contact/)\n  * [My Account](https://www.precipiodx.com/login/)\n    * [![Login Icon](https://www.precipiodx.com/wp-content/uploads/2022/07/login-svgrepo-com.svg)CaseVu](https://www.casevu-lis.precipiodx.com/)\n    * [![Login Icon](https://www.precipiodx.com/wp-content/uploads/2022/07/login-svgrepo-com.svg)Shop](https://www.precipiodx.com/my-account/)\n    * [![Login Icon](https://www.precipiodx.com/wp-content/uploads/2022/07/login-svgrepo-com.svg)Patient Bill Pay](https://www.precipiodx.com/billing/)\n  * [ $0.00 **0** ](https://www.precipiodx.com/cart/ \"Cart\")\n\nCart\n\n  * [](#)\n    * Search for:\n\n\n\n\n  * [ **0** ](https://www.precipiodx.com/cart/ \"Cart\")\n\n\n\n# Subscription\n\n## Subscribe to our mailing list\n\n* indicates required\n\nFirst Name \n\nLast Name \n\nCompany \n\nTitle \n\nEmail Address *\n\nPhone Number \n\nAddress \n\nAddress Line 2\n\nCity\n\nState/Province/Region\n\nPostal / Zip Code\n\nCountry USAAaland IslandsAfghanistanAlbaniaAlgeriaAmerican SamoaAndorraAngolaAnguillaAntigua And BarbudaArgentinaArmeniaArubaAustraliaAustriaAzerbaijanBahamasBahrainBangladeshBarbadosBelarusBelgiumBelizeBeninBermudaBhutanBoliviaBonaire, Saint Eustatius and SabaBosnia and HerzegovinaBotswanaBouvet IslandBrazilBrunei DarussalamBulgariaBurkina FasoBurundiCambodiaCameroonCanadaCape VerdeCayman IslandsCentral African RepublicChadChileChinaChristmas IslandColombiaComorosCongoCook IslandsCosta RicaCote D’IvoireCroatiaCubaCuracaoCyprusCzech RepublicDemocratic Republic of the CongoDenmarkDjiboutiDominicaDominican RepublicEcuadorEgyptEl SalvadorEquatorial GuineaEritreaEstoniaEthiopiaFalkland IslandsFaroe IslandsFijiFinlandFranceFrench GuianaFrench PolynesiaGabonGambiaGeorgiaGermanyGhanaGibraltarGreeceGreenlandGrenadaGuadeloupeGuamGuatemalaGuernseyGuineaGuyanaHaitiHondurasHong KongHungaryIcelandIndiaIndonesiaIranIraqIrelandIsle of ManIsraelItalyJamaicaJapanJersey (Channel Islands)JordanKazakhstanKenyaKiribatiKuwaitKyrgyzstanLao People’s Democratic RepublicLatviaLebanonLesothoLiberiaLibyaLiechtensteinLithuaniaLuxembourgMacauMacedoniaMadagascarMalawiMalaysiaMaldivesMaliMaltaMarshall IslandsMartiniqueMauritaniaMauritiusMayotteMexicoMoldova, Republic ofMonacoMongoliaMontenegroMontserratMoroccoMozambiqueMyanmarNamibiaNepalNetherlandsNetherlands AntillesNew CaledoniaNew ZealandNicaraguaNigerNigeriaNiueNorfolk IslandNorth KoreaNorwayOmanPakistanPalauPalestinePanamaPapua New GuineaParaguayPeruPhilippinesPitcairnPolandPortugalQatarRepublic of KosovoReunionRomaniaRussiaRwandaSaint Kitts and NevisSaint LuciaSaint MartinSaint Vincent and the GrenadinesSamoa (Independent)San MarinoSao Tome and PrincipeSaudi ArabiaSenegalSerbiaSeychellesSierra LeoneSingaporeSint MaartenSlovakiaSloveniaSolomon IslandsSomaliaSouth AfricaSouth Georgia and the South Sandwich IslandsSouth KoreaSouth SudanSpainSri LankaSudanSurinameSvalbard and Jan Mayen IslandsSwazilandSwedenSwitzerlandSyriaTaiwanTajikistanTanzaniaThailandTimor-LesteTogoTongaTrinidad and TobagoTunisiaTurkeyTurkmenistanTurks & Caicos IslandsUgandaUkraineUnited Arab EmiratesUnited KingdomUruguayUzbekistanVanuatuVatican City State (Holy See)VenezuelaVietnamVirgin Islands (British)Virgin Islands (U.S.)Western SaharaYemenZambiaZimbabwe\n\n**Subscription alerts**\n\n  * Email me company news.\n  * Email me all SEC filings.\n  * Investor Relations representatives can contact me.\n\n\n\n  * [ $0.00 ](https://www.precipiodx.com/cart/ \"Cart\")\n    * Cart\n\nNo products in the cart.\n\n[ Return to shop ](https://www.precipiodx.com/shop/)\n\n  * Search for:\n\n  * [About Us](https://www.precipiodx.com/about/)\n    * [Our Culture](https://www.precipiodx.com/about/culture/)\n    * [News](https://www.precipiodx.com/about/news/)\n    * [Careers](https://www.precipiodx.com/about/careers/)\n    * [Scientific Advisors](https://www.precipiodx.com/about/scientific-advisors/)\n    * [Management Team](https://www.precipiodx.com/about/management-team/)\n    * [Board of Directors](https://www.precipiodx.com/about/board-of-directors/)\n  * [Products](https://www.precipiodx.com/products/)\n    * [Molecular Kits](https://www.precipiodx.com/products/molecular-kits/)\n      * [MPN Panel](https://www.precipiodx.com/products/bloodhound-mpn-panel/)\n      * [BCR-ABL1 Panel](https://www.precipiodx.com/products/bloodhound-bcr-abl1-molecular-panel/)\n      * [ABL1 Resistance Panel](https://www.precipiodx.com/products/bloodhound-abl1-resistance-panel/)\n      * [AML Panel](https://www.precipiodx.com/products/molecular-kits/acute-myeloid-leukemia-panel/)\n      * [CLL Panel](https://www.precipiodx.com/products/molecular-kits/cll-panel/)\n      * [Cytopenia Panel](https://www.precipiodx.com/products/molecular-kits/cytopenia-panel/)\n    * [IV-Cell Cytogenetics Media](https://www.precipiodx.com/products/iv-cell-cytogenetics-media/)\n  * [Clinical Services](https://www.precipiodx.com/clinical-services/)\n    * [Hematopathology Services](https://www.precipiodx.com/clinical-services/blood-cancer-testing/)\n    * [Sample Reports](https://www.precipiodx.com/sample-report/)\n    * [Proprietary Technologies](https://www.precipiodx.com/clinical-services/proprietary-technologies/)\n    * [Meet Our Hematopathologists](https://www.precipiodx.com/clinical-services/meet-our-pathologists/)\n  * [Resources](https://www.precipiodx.com/resources/)\n    * [FAQs](https://www.precipiodx.com/resources/faqs/)\n    * [Brochures](https://www.precipiodx.com/resources/brochures/)\n    * [Case Studies](https://www.precipiodx.com/resources/case-studies/)\n    * [Sample Reports](https://www.precipiodx.com/sample-report/)\n    * [Instructions For Use](https://www.precipiodx.com/resources/ifus/)\n    * [Instructions For Use – Non U.S. CE](https://www.precipiodx.com/resources/instructions-for-use-non-us-ce/)\n  * [Investors](https://www.precipiodx.com/investors/)\n    * [Press Releases](https://www.precipiodx.com/investors/press-releases/)\n    * [Media](https://www.precipiodx.com/investors/media/)\n    * [SEC Filings](https://www.precipiodx.com/investors/sec-filings/)\n    * [Subscription](https://www.precipiodx.com/investors/subscription/)\n    * [Investor FAQs](https://www.precipiodx.com/investors/investor-faqs/)\n    * [Corporate Governance](https://www.precipiodx.com/investors/corporate-governance/)\n    * [Business Update Calls](https://www.precipiodx.com/investors/business-update-calls/)\n  * [Contact](https://www.precipiodx.com/contact/)\n  * [My Account](https://www.precipiodx.com/login/)\n    * [![Login Icon](https://www.precipiodx.com/wp-content/uploads/2022/07/login-svgrepo-com.svg)CaseVu](https://www.casevu-lis.precipiodx.com/)\n    * [![Login Icon](https://www.precipiodx.com/wp-content/uploads/2022/07/login-svgrepo-com.svg)Shop](https://www.precipiodx.com/my-account/)\n    * [![Login Icon](https://www.precipiodx.com/wp-content/uploads/2022/07/login-svgrepo-com.svg)Patient Bill Pay](https://www.precipiodx.com/billing/)\n\n\n\n### Login\n\nUsername or email address *\n\nPassword *\n\nRemember me Log in\n\n[Lost your password?](https://www.precipiodx.com/my-account/lost-password/)\n"
        }
      ]
    },
    {
      "section_name": "Investor FAQs",
      "links": [
        {
          "title": "Investor FAQs",
          "url": "https://www.precipiodx.com/investors/investor-faqs/",
          "content": "[Skip to content](#main)\n\n[ ![Precipio](https://www.precipiodx.com/wp-content/uploads/2022/07/logo.png) ![Precipio](https://www.precipiodx.com/wp-content/uploads/2022/07/logo.png) ](https://www.precipiodx.com/ \"Precipio - Expect More from the start.\")\n\n  * [ ](#)\n\n\n\n\n  * [About Us](https://www.precipiodx.com/about/)\n    * [Our Culture](https://www.precipiodx.com/about/culture/)\n    * [News](https://www.precipiodx.com/about/news/)\n    * [Careers](https://www.precipiodx.com/about/careers/)\n    * [Scientific Advisors](https://www.precipiodx.com/about/scientific-advisors/)\n    * [Management Team](https://www.precipiodx.com/about/management-team/)\n    * [Board of Directors](https://www.precipiodx.com/about/board-of-directors/)\n  * [Products](https://www.precipiodx.com/products/)\n    * [Molecular Kits](https://www.precipiodx.com/products/molecular-kits/)\n      * [MPN Panel](https://www.precipiodx.com/products/bloodhound-mpn-panel/)\n      * [BCR-ABL1 Panel](https://www.precipiodx.com/products/bloodhound-bcr-abl1-molecular-panel/)\n      * [ABL1 Resistance Panel](https://www.precipiodx.com/products/bloodhound-abl1-resistance-panel/)\n      * [AML Panel](https://www.precipiodx.com/products/molecular-kits/acute-myeloid-leukemia-panel/)\n      * [CLL Panel](https://www.precipiodx.com/products/molecular-kits/cll-panel/)\n      * [Cytopenia Panel](https://www.precipiodx.com/products/molecular-kits/cytopenia-panel/)\n    * [IV-Cell Cytogenetics Media](https://www.precipiodx.com/products/iv-cell-cytogenetics-media/)\n  * [Clinical Services](https://www.precipiodx.com/clinical-services/)\n    * [Hematopathology Services](https://www.precipiodx.com/clinical-services/blood-cancer-testing/)\n    * [Sample Reports](https://www.precipiodx.com/sample-report/)\n    * [Proprietary Technologies](https://www.precipiodx.com/clinical-services/proprietary-technologies/)\n    * [Meet Our Hematopathologists](https://www.precipiodx.com/clinical-services/meet-our-pathologists/)\n  * [Resources](https://www.precipiodx.com/resources/)\n    * [FAQs](https://www.precipiodx.com/resources/faqs/)\n    * [Brochures](https://www.precipiodx.com/resources/brochures/)\n    * [Case Studies](https://www.precipiodx.com/resources/case-studies/)\n    * [Sample Reports](https://www.precipiodx.com/sample-report/)\n    * [Instructions For Use](https://www.precipiodx.com/resources/ifus/)\n    * [Instructions For Use – Non U.S. CE](https://www.precipiodx.com/resources/instructions-for-use-non-us-ce/)\n  * [Investors](https://www.precipiodx.com/investors/)\n    * [Press Releases](https://www.precipiodx.com/investors/press-releases/)\n    * [Media](https://www.precipiodx.com/investors/media/)\n    * [SEC Filings](https://www.precipiodx.com/investors/sec-filings/)\n    * [Subscription](https://www.precipiodx.com/investors/subscription/)\n    * [Investor FAQs](https://www.precipiodx.com/investors/investor-faqs/)\n    * [Corporate Governance](https://www.precipiodx.com/investors/corporate-governance/)\n    * [Business Update Calls](https://www.precipiodx.com/investors/business-update-calls/)\n  * [Contact](https://www.precipiodx.com/contact/)\n  * [My Account](https://www.precipiodx.com/login/)\n    * [![Login Icon](https://www.precipiodx.com/wp-content/uploads/2022/07/login-svgrepo-com.svg)CaseVu](https://www.casevu-lis.precipiodx.com/)\n    * [![Login Icon](https://www.precipiodx.com/wp-content/uploads/2022/07/login-svgrepo-com.svg)Shop](https://www.precipiodx.com/my-account/)\n    * [![Login Icon](https://www.precipiodx.com/wp-content/uploads/2022/07/login-svgrepo-com.svg)Patient Bill Pay](https://www.precipiodx.com/billing/)\n  * [ $0.00 **0** ](https://www.precipiodx.com/cart/ \"Cart\")\n\nCart\n\n  * [](#)\n    * Search for:\n\n\n\n\n  * [ **0** ](https://www.precipiodx.com/cart/ \"Cart\")\n\n\n\n# Frequently Asked Questions\n\n[ When was Precipio, Inc. founded? ](#accordion-item-when-was-precipio,-inc.-founded?)\n\nPrecipio, Inc. was founded in 2017 as a result of the merger with Transgenomic, Inc.\n\n[ Where is your corporate headquarters located? ](#accordion-item-where-is-your-corporate-headquarters-located?)\n\nOur corporate headquarters are located at 4 Science Park, New Haven, CT 06511.\n\n[ Is Precipio, Inc. a public company? ](#accordion-item-is-precipio,-inc.-a-public-company?)\n\nYes. Precipio, Inc. is a public company traded on the NASDAQ CM under the symbol PRPO.\n\n[ What is Precipio, Inc.’s Cusip number? ](#accordion-item-what-is-precipio,-inc.’s-cusip-number?)\n\nThe Cusip for Precipio, Inc. 74019L602.\n\n[ How can I buy Precipio, Inc. stock? ](#accordion-item-how-can-i-buy-precipio,-inc.-stock?)\n\nPlease contact a licensed stockbroker or use an online trading account. You can also contact us for additional information.\n\n[ What is the fiscal year for Precipio, Inc.? ](#accordion-item-what-is-the-fiscal-year-for-precipio,-inc.?)\n\nOur fiscal year ends on December 31st.\n\n[ How do I contact Precipio, Inc. Investor Relations department? ](#accordion-item-how-do-i-contact-precipio,-inc.-investor-relations-department?)\n\nPlease contact: Precipio Inc., 4 Science Park, New Haven, CT 06511. investors@precipiodx.com [1.203.787.7888](tel:12037877888)\n\n  * [ $0.00 ](https://www.precipiodx.com/cart/ \"Cart\")\n    * Cart\n\nNo products in the cart.\n\n[ Return to shop ](https://www.precipiodx.com/shop/)\n\n  * Search for:\n\n  * [About Us](https://www.precipiodx.com/about/)\n    * [Our Culture](https://www.precipiodx.com/about/culture/)\n    * [News](https://www.precipiodx.com/about/news/)\n    * [Careers](https://www.precipiodx.com/about/careers/)\n    * [Scientific Advisors](https://www.precipiodx.com/about/scientific-advisors/)\n    * [Management Team](https://www.precipiodx.com/about/management-team/)\n    * [Board of Directors](https://www.precipiodx.com/about/board-of-directors/)\n  * [Products](https://www.precipiodx.com/products/)\n    * [Molecular Kits](https://www.precipiodx.com/products/molecular-kits/)\n      * [MPN Panel](https://www.precipiodx.com/products/bloodhound-mpn-panel/)\n      * [BCR-ABL1 Panel](https://www.precipiodx.com/products/bloodhound-bcr-abl1-molecular-panel/)\n      * [ABL1 Resistance Panel](https://www.precipiodx.com/products/bloodhound-abl1-resistance-panel/)\n      * [AML Panel](https://www.precipiodx.com/products/molecular-kits/acute-myeloid-leukemia-panel/)\n      * [CLL Panel](https://www.precipiodx.com/products/molecular-kits/cll-panel/)\n      * [Cytopenia Panel](https://www.precipiodx.com/products/molecular-kits/cytopenia-panel/)\n    * [IV-Cell Cytogenetics Media](https://www.precipiodx.com/products/iv-cell-cytogenetics-media/)\n  * [Clinical Services](https://www.precipiodx.com/clinical-services/)\n    * [Hematopathology Services](https://www.precipiodx.com/clinical-services/blood-cancer-testing/)\n    * [Sample Reports](https://www.precipiodx.com/sample-report/)\n    * [Proprietary Technologies](https://www.precipiodx.com/clinical-services/proprietary-technologies/)\n    * [Meet Our Hematopathologists](https://www.precipiodx.com/clinical-services/meet-our-pathologists/)\n  * [Resources](https://www.precipiodx.com/resources/)\n    * [FAQs](https://www.precipiodx.com/resources/faqs/)\n    * [Brochures](https://www.precipiodx.com/resources/brochures/)\n    * [Case Studies](https://www.precipiodx.com/resources/case-studies/)\n    * [Sample Reports](https://www.precipiodx.com/sample-report/)\n    * [Instructions For Use](https://www.precipiodx.com/resources/ifus/)\n    * [Instructions For Use – Non U.S. CE](https://www.precipiodx.com/resources/instructions-for-use-non-us-ce/)\n  * [Investors](https://www.precipiodx.com/investors/)\n    * [Press Releases](https://www.precipiodx.com/investors/press-releases/)\n    * [Media](https://www.precipiodx.com/investors/media/)\n    * [SEC Filings](https://www.precipiodx.com/investors/sec-filings/)\n    * [Subscription](https://www.precipiodx.com/investors/subscription/)\n    * [Investor FAQs](https://www.precipiodx.com/investors/investor-faqs/)\n    * [Corporate Governance](https://www.precipiodx.com/investors/corporate-governance/)\n    * [Business Update Calls](https://www.precipiodx.com/investors/business-update-calls/)\n  * [Contact](https://www.precipiodx.com/contact/)\n  * [My Account](https://www.precipiodx.com/login/)\n    * [![Login Icon](https://www.precipiodx.com/wp-content/uploads/2022/07/login-svgrepo-com.svg)CaseVu](https://www.casevu-lis.precipiodx.com/)\n    * [![Login Icon](https://www.precipiodx.com/wp-content/uploads/2022/07/login-svgrepo-com.svg)Shop](https://www.precipiodx.com/my-account/)\n    * [![Login Icon](https://www.precipiodx.com/wp-content/uploads/2022/07/login-svgrepo-com.svg)Patient Bill Pay](https://www.precipiodx.com/billing/)\n\n\n\n### Login\n\nUsername or email address *\n\nPassword *\n\nRemember me Log in\n\n[Lost your password?](https://www.precipiodx.com/my-account/lost-password/)\n"
        }
      ]
    },
    {
      "section_name": "Corporate Governance",
      "links": [
        {
          "title": "Corporate Governance",
          "url": "https://www.precipiodx.com/investors/corporate-governance/",
          "content": "[Skip to content](#main)\n\n[ ![Precipio](https://www.precipiodx.com/wp-content/uploads/2022/07/logo.png) ![Precipio](https://www.precipiodx.com/wp-content/uploads/2022/07/logo.png) ](https://www.precipiodx.com/ \"Precipio - Expect More from the start.\")\n\n  * [ ](#)\n\n\n\n\n  * [About Us](https://www.precipiodx.com/about/)\n    * [Our Culture](https://www.precipiodx.com/about/culture/)\n    * [News](https://www.precipiodx.com/about/news/)\n    * [Careers](https://www.precipiodx.com/about/careers/)\n    * [Scientific Advisors](https://www.precipiodx.com/about/scientific-advisors/)\n    * [Management Team](https://www.precipiodx.com/about/management-team/)\n    * [Board of Directors](https://www.precipiodx.com/about/board-of-directors/)\n  * [Products](https://www.precipiodx.com/products/)\n    * [Molecular Kits](https://www.precipiodx.com/products/molecular-kits/)\n      * [MPN Panel](https://www.precipiodx.com/products/bloodhound-mpn-panel/)\n      * [BCR-ABL1 Panel](https://www.precipiodx.com/products/bloodhound-bcr-abl1-molecular-panel/)\n      * [ABL1 Resistance Panel](https://www.precipiodx.com/products/bloodhound-abl1-resistance-panel/)\n      * [AML Panel](https://www.precipiodx.com/products/molecular-kits/acute-myeloid-leukemia-panel/)\n      * [CLL Panel](https://www.precipiodx.com/products/molecular-kits/cll-panel/)\n      * [Cytopenia Panel](https://www.precipiodx.com/products/molecular-kits/cytopenia-panel/)\n    * [IV-Cell Cytogenetics Media](https://www.precipiodx.com/products/iv-cell-cytogenetics-media/)\n  * [Clinical Services](https://www.precipiodx.com/clinical-services/)\n    * [Hematopathology Services](https://www.precipiodx.com/clinical-services/blood-cancer-testing/)\n    * [Sample Reports](https://www.precipiodx.com/sample-report/)\n    * [Proprietary Technologies](https://www.precipiodx.com/clinical-services/proprietary-technologies/)\n    * [Meet Our Hematopathologists](https://www.precipiodx.com/clinical-services/meet-our-pathologists/)\n  * [Resources](https://www.precipiodx.com/resources/)\n    * [FAQs](https://www.precipiodx.com/resources/faqs/)\n    * [Brochures](https://www.precipiodx.com/resources/brochures/)\n    * [Case Studies](https://www.precipiodx.com/resources/case-studies/)\n    * [Sample Reports](https://www.precipiodx.com/sample-report/)\n    * [Instructions For Use](https://www.precipiodx.com/resources/ifus/)\n    * [Instructions For Use – Non U.S. CE](https://www.precipiodx.com/resources/instructions-for-use-non-us-ce/)\n  * [Investors](https://www.precipiodx.com/investors/)\n    * [Press Releases](https://www.precipiodx.com/investors/press-releases/)\n    * [Media](https://www.precipiodx.com/investors/media/)\n    * [SEC Filings](https://www.precipiodx.com/investors/sec-filings/)\n    * [Subscription](https://www.precipiodx.com/investors/subscription/)\n    * [Investor FAQs](https://www.precipiodx.com/investors/investor-faqs/)\n    * [Corporate Governance](https://www.precipiodx.com/investors/corporate-governance/)\n    * [Business Update Calls](https://www.precipiodx.com/investors/business-update-calls/)\n  * [Contact](https://www.precipiodx.com/contact/)\n  * [My Account](https://www.precipiodx.com/login/)\n    * [![Login Icon](https://www.precipiodx.com/wp-content/uploads/2022/07/login-svgrepo-com.svg)CaseVu](https://www.casevu-lis.precipiodx.com/)\n    * [![Login Icon](https://www.precipiodx.com/wp-content/uploads/2022/07/login-svgrepo-com.svg)Shop](https://www.precipiodx.com/my-account/)\n    * [![Login Icon](https://www.precipiodx.com/wp-content/uploads/2022/07/login-svgrepo-com.svg)Patient Bill Pay](https://www.precipiodx.com/billing/)\n  * [ $0.00 **0** ](https://www.precipiodx.com/cart/ \"Cart\")\n\nCart\n\n  * [](#)\n    * Search for:\n\n\n\n\n  * [ **0** ](https://www.precipiodx.com/cart/ \"Cart\")\n\n\n\n# Corporate Governance\n\n[Policy regarding securityholder recommendations of director nominees](/wp-content/uploads/2022/08/Policy-Regarding-Securityholder-Recommendations-of-Director-Nominees.pdf)\n\n[ Policy regarding securityholder communications](/wp-content/uploads/2022/08/Policy-regarding-securityholder-communications.pdf)\n\n[Description of amendments to Precipio, Inc. code of business conduct and ethics](/wp-content/uploads/2022/08/Description-of-Amendments-to-Precipio-Code-of-Business-Conduct-and-Ethics.pdf)\n\n[ Code of business conduct and ethics](/wp-content/uploads/2022/08/Code-of-Business-Conduct.pdf)\n\n[Whistleblower policy hotline 1-844-703-8157](/wp-content/uploads/2022/08/PRPO-Whistleblower-Policy.pdf)\n\n[ Charter of the nominating and corporate governance committee](/wp-content/uploads/2022/08/Charter-of-the-Nominating-and-Corporate-Governance-Committee.pdf)\n\n[ Charter of the compensation committee](/wp-content/uploads/2022/08/Charter-of-the-Compensation-Committee.pdf)\n\n[ Charter of the audit committee](/wp-content/uploads/2022/08/Charter-of-the-Audit-Committee.pdf)\n\n[ Board of directors ](/about/board-of-directors/)\n\n  * [ $0.00 ](https://www.precipiodx.com/cart/ \"Cart\")\n    * Cart\n\nNo products in the cart.\n\n[ Return to shop ](https://www.precipiodx.com/shop/)\n\n  * Search for:\n\n  * [About Us](https://www.precipiodx.com/about/)\n    * [Our Culture](https://www.precipiodx.com/about/culture/)\n    * [News](https://www.precipiodx.com/about/news/)\n    * [Careers](https://www.precipiodx.com/about/careers/)\n    * [Scientific Advisors](https://www.precipiodx.com/about/scientific-advisors/)\n    * [Management Team](https://www.precipiodx.com/about/management-team/)\n    * [Board of Directors](https://www.precipiodx.com/about/board-of-directors/)\n  * [Products](https://www.precipiodx.com/products/)\n    * [Molecular Kits](https://www.precipiodx.com/products/molecular-kits/)\n      * [MPN Panel](https://www.precipiodx.com/products/bloodhound-mpn-panel/)\n      * [BCR-ABL1 Panel](https://www.precipiodx.com/products/bloodhound-bcr-abl1-molecular-panel/)\n      * [ABL1 Resistance Panel](https://www.precipiodx.com/products/bloodhound-abl1-resistance-panel/)\n      * [AML Panel](https://www.precipiodx.com/products/molecular-kits/acute-myeloid-leukemia-panel/)\n      * [CLL Panel](https://www.precipiodx.com/products/molecular-kits/cll-panel/)\n      * [Cytopenia Panel](https://www.precipiodx.com/products/molecular-kits/cytopenia-panel/)\n    * [IV-Cell Cytogenetics Media](https://www.precipiodx.com/products/iv-cell-cytogenetics-media/)\n  * [Clinical Services](https://www.precipiodx.com/clinical-services/)\n    * [Hematopathology Services](https://www.precipiodx.com/clinical-services/blood-cancer-testing/)\n    * [Sample Reports](https://www.precipiodx.com/sample-report/)\n    * [Proprietary Technologies](https://www.precipiodx.com/clinical-services/proprietary-technologies/)\n    * [Meet Our Hematopathologists](https://www.precipiodx.com/clinical-services/meet-our-pathologists/)\n  * [Resources](https://www.precipiodx.com/resources/)\n    * [FAQs](https://www.precipiodx.com/resources/faqs/)\n    * [Brochures](https://www.precipiodx.com/resources/brochures/)\n    * [Case Studies](https://www.precipiodx.com/resources/case-studies/)\n    * [Sample Reports](https://www.precipiodx.com/sample-report/)\n    * [Instructions For Use](https://www.precipiodx.com/resources/ifus/)\n    * [Instructions For Use – Non U.S. CE](https://www.precipiodx.com/resources/instructions-for-use-non-us-ce/)\n  * [Investors](https://www.precipiodx.com/investors/)\n    * [Press Releases](https://www.precipiodx.com/investors/press-releases/)\n    * [Media](https://www.precipiodx.com/investors/media/)\n    * [SEC Filings](https://www.precipiodx.com/investors/sec-filings/)\n    * [Subscription](https://www.precipiodx.com/investors/subscription/)\n    * [Investor FAQs](https://www.precipiodx.com/investors/investor-faqs/)\n    * [Corporate Governance](https://www.precipiodx.com/investors/corporate-governance/)\n    * [Business Update Calls](https://www.precipiodx.com/investors/business-update-calls/)\n  * [Contact](https://www.precipiodx.com/contact/)\n  * [My Account](https://www.precipiodx.com/login/)\n    * [![Login Icon](https://www.precipiodx.com/wp-content/uploads/2022/07/login-svgrepo-com.svg)CaseVu](https://www.casevu-lis.precipiodx.com/)\n    * [![Login Icon](https://www.precipiodx.com/wp-content/uploads/2022/07/login-svgrepo-com.svg)Shop](https://www.precipiodx.com/my-account/)\n    * [![Login Icon](https://www.precipiodx.com/wp-content/uploads/2022/07/login-svgrepo-com.svg)Patient Bill Pay](https://www.precipiodx.com/billing/)\n\n\n\n### Login\n\nUsername or email address *\n\nPassword *\n\nRemember me Log in\n\n[Lost your password?](https://www.precipiodx.com/my-account/lost-password/)\n"
        }
      ]
    },
    {
      "section_name": "Business Update Calls",
      "links": [
        {
          "title": "Business Update Calls",
          "url": "https://www.precipiodx.com/investors/business-update-calls/",
          "content": "[Skip to content](#main)\n\n[ ![Precipio](https://www.precipiodx.com/wp-content/uploads/2022/07/logo.png) ![Precipio](https://www.precipiodx.com/wp-content/uploads/2022/07/logo.png) ](https://www.precipiodx.com/ \"Precipio - Expect More from the start.\")\n\n  * [ ](#)\n\n\n\n\n  * [About Us](https://www.precipiodx.com/about/)\n    * [Our Culture](https://www.precipiodx.com/about/culture/)\n    * [News](https://www.precipiodx.com/about/news/)\n    * [Careers](https://www.precipiodx.com/about/careers/)\n    * [Scientific Advisors](https://www.precipiodx.com/about/scientific-advisors/)\n    * [Management Team](https://www.precipiodx.com/about/management-team/)\n    * [Board of Directors](https://www.precipiodx.com/about/board-of-directors/)\n  * [Products](https://www.precipiodx.com/products/)\n    * [Molecular Kits](https://www.precipiodx.com/products/molecular-kits/)\n      * [MPN Panel](https://www.precipiodx.com/products/bloodhound-mpn-panel/)\n      * [BCR-ABL1 Panel](https://www.precipiodx.com/products/bloodhound-bcr-abl1-molecular-panel/)\n      * [ABL1 Resistance Panel](https://www.precipiodx.com/products/bloodhound-abl1-resistance-panel/)\n      * [AML Panel](https://www.precipiodx.com/products/molecular-kits/acute-myeloid-leukemia-panel/)\n      * [CLL Panel](https://www.precipiodx.com/products/molecular-kits/cll-panel/)\n      * [Cytopenia Panel](https://www.precipiodx.com/products/molecular-kits/cytopenia-panel/)\n    * [IV-Cell Cytogenetics Media](https://www.precipiodx.com/products/iv-cell-cytogenetics-media/)\n  * [Clinical Services](https://www.precipiodx.com/clinical-services/)\n    * [Hematopathology Services](https://www.precipiodx.com/clinical-services/blood-cancer-testing/)\n    * [Sample Reports](https://www.precipiodx.com/sample-report/)\n    * [Proprietary Technologies](https://www.precipiodx.com/clinical-services/proprietary-technologies/)\n    * [Meet Our Hematopathologists](https://www.precipiodx.com/clinical-services/meet-our-pathologists/)\n  * [Resources](https://www.precipiodx.com/resources/)\n    * [FAQs](https://www.precipiodx.com/resources/faqs/)\n    * [Brochures](https://www.precipiodx.com/resources/brochures/)\n    * [Case Studies](https://www.precipiodx.com/resources/case-studies/)\n    * [Sample Reports](https://www.precipiodx.com/sample-report/)\n    * [Instructions For Use](https://www.precipiodx.com/resources/ifus/)\n    * [Instructions For Use – Non U.S. CE](https://www.precipiodx.com/resources/instructions-for-use-non-us-ce/)\n  * [Investors](https://www.precipiodx.com/investors/)\n    * [Press Releases](https://www.precipiodx.com/investors/press-releases/)\n    * [Media](https://www.precipiodx.com/investors/media/)\n    * [SEC Filings](https://www.precipiodx.com/investors/sec-filings/)\n    * [Subscription](https://www.precipiodx.com/investors/subscription/)\n    * [Investor FAQs](https://www.precipiodx.com/investors/investor-faqs/)\n    * [Corporate Governance](https://www.precipiodx.com/investors/corporate-governance/)\n    * [Business Update Calls](https://www.precipiodx.com/investors/business-update-calls/)\n  * [Contact](https://www.precipiodx.com/contact/)\n  * [My Account](https://www.precipiodx.com/login/)\n    * [![Login Icon](https://www.precipiodx.com/wp-content/uploads/2022/07/login-svgrepo-com.svg)CaseVu](https://www.casevu-lis.precipiodx.com/)\n    * [![Login Icon](https://www.precipiodx.com/wp-content/uploads/2022/07/login-svgrepo-com.svg)Shop](https://www.precipiodx.com/my-account/)\n    * [![Login Icon](https://www.precipiodx.com/wp-content/uploads/2022/07/login-svgrepo-com.svg)Patient Bill Pay](https://www.precipiodx.com/billing/)\n  * [ $0.00 **0** ](https://www.precipiodx.com/cart/ \"Cart\")\n\nCart\n\n  * [](#)\n    * Search for:\n\n\n\n\n  * [ **0** ](https://www.precipiodx.com/cart/ \"Cart\")\n\n\n\n# business update calls\n\n[ ![Precipio Logo](https://www.precipiodx.com/wp-content/uploads/2022/11/PRPO-logo-circle-transparent-300x249.png) 2024 Q3 Shareholder Update Call – November 18, 2024 ](/wp-content/uploads/2024/11/Precipio_20241118_500PME.mp3) [ ![Precipio Logo](https://www.precipiodx.com/wp-content/uploads/2022/11/PRPO-logo-circle-transparent-300x249.png) 2024 Q2 Shareholder Update Call – August 19, 2024 ](/wp-content/uploads/2024/08/Precipio_20240819_500PME.mp3) [ ![Precipio Logo](https://www.precipiodx.com/wp-content/uploads/2022/11/PRPO-logo-circle-transparent-300x249.png) 2023 Q4 Shareholder Update Call – April 1, 2024 ](/wp-content/uploads/2024/04/Precipio_20240401_500PME.mp3) [ ![Precipio Logo](https://www.precipiodx.com/wp-content/uploads/2022/11/PRPO-logo-circle-transparent-300x249.png) 2023 Q3 Shareholder Update Call – November 20, 2023 ](/wp-content/uploads/2023/11/Precipio_20231120_500PME.mp3) [ ![Precipio Logo](https://www.precipiodx.com/wp-content/uploads/2022/11/PRPO-logo-circle-transparent-300x249.png) 2023 Q2 Shareholder Update Call – August 17, 2023 ](/wp-content/uploads/2023/08/Precipio_20230817_500PME.mp3) [ ![Precipio Logo](https://www.precipiodx.com/wp-content/uploads/2022/11/PRPO-logo-circle-transparent-300x249.png) 2023 Q1 Shareholder Update Call – May 17, 2023 ](/wp-content/uploads/2023/05/Precipio_20230517_500PME.mp3) [ ![Precipio Logo](https://www.precipiodx.com/wp-content/uploads/2022/11/PRPO-logo-circle-transparent-300x249.png) 2022 Q4 Shareholder Update Call – April 3, 2023 ](/wp-content/uploads/2023/04/Precipio_20230403_500PME.mp3) [ ![Precipio Logo](https://www.precipiodx.com/wp-content/uploads/2022/11/PRPO-logo-circle-transparent-300x249.png) 2022 Q3 Shareholder Update Call – November 14, 2022 ](/wp-content/uploads/2022/11/PrecipioInc_20221114_500PME.mp3) [ ![Precipio Logo](https://www.precipiodx.com/wp-content/uploads/2022/11/PRPO-logo-circle-transparent-300x249.png) 2022 Q2 Shareholder Update Call – August 15, 2022 ](https://www.precipiodx.com/wp-content/uploads/2022/11/Precipio_20220815_500PME.mp3) [ ![Precipio Logo](https://www.precipiodx.com/wp-content/uploads/2022/11/PRPO-logo-circle-transparent-300x249.png) 2021 Q4 Shareholder Update Call – April 4, 2022 ](https://www.precipiodx.com/wp-content/uploads/2022/11/Precipio_20220404_500PME.mp3) [ ![Precipio Logo](https://www.precipiodx.com/wp-content/uploads/2022/11/PRPO-logo-circle-transparent-300x249.png) 2021 Q3 Shareholder Update Call – November 15, 2021 ](https://www.precipiodx.com/wp-content/uploads/2022/11/Precipio_20211115_500PME.mp3) [ ![Precipio Logo](https://www.precipiodx.com/wp-content/uploads/2022/11/PRPO-logo-circle-transparent-300x249.png) 2021 Q2 Shareholder Update Call – August 26, 2021 ](https://www.precipiodx.com/wp-content/uploads/2022/11/Precipio_20210826_500PME.mp3) [ ![Precipio Logo](https://www.precipiodx.com/wp-content/uploads/2022/11/PRPO-logo-circle-transparent-300x249.png) 2021 Q1 Shareholder Update Call – May 20, 2021 ](https://www.precipiodx.com/wp-content/uploads/2022/11/Precipio_20210520_500PME.mp3) [ ![Precipio Logo](https://www.precipiodx.com/wp-content/uploads/2022/11/PRPO-logo-circle-transparent-300x249.png) 2020 Q4 Shareholder Update Call – March 31, 2021 ](https://www.precipiodx.com/wp-content/uploads/2022/11/Precipio_20210331_500PME.mp3) [ ![Precipio Logo](https://www.precipiodx.com/wp-content/uploads/2022/11/PRPO-logo-circle-transparent-300x249.png) 2020 Shareholder Update Call – November 19, 2020 ](https://www.precipiodx.com/wp-content/uploads/2022/11/Precipio_20201119_500PME.mp3) [ ![Precipio Logo](https://www.precipiodx.com/wp-content/uploads/2022/11/PRPO-logo-circle-transparent-300x249.png) 2020 Shareholder Update Call – September 09, 2020 ](https://www.precipiodx.com/wp-content/uploads/2022/11/Precipio_20200909_500PME.mp3) [ ![Precipio Logo](https://www.precipiodx.com/wp-content/uploads/2022/11/PRPO-logo-circle-transparent-300x249.png) 2020 Shareholder Update Call – August 17, 2020 ](https://www.precipiodx.com/wp-content/uploads/2022/11/Precipio_20200817_500PME.mp3) [ ![Precipio Logo](https://www.precipiodx.com/wp-content/uploads/2022/11/PRPO-logo-circle-transparent-300x249.png) 2020 Shareholder Update Call – May 19, 2020 ](https://www.precipiodx.com/wp-content/uploads/2022/11/Precipio_20200519_500PME.mp3) [ ![Precipio Logo](https://www.precipiodx.com/wp-content/uploads/2022/11/PRPO-logo-circle-transparent-300x249.png) 2020 Shareholder Update Call – January 20, 2020 ](https://www.precipiodx.com/wp-content/uploads/2022/11/Precipio_20200120_500PME.mp3) [ ![Precipio Logo](https://www.precipiodx.com/wp-content/uploads/2022/11/PRPO-logo-circle-transparent-300x249.png) 2019 Q3 Commercial Update Call – November 13, 2019 ](https://www.precipiodx.com/wp-content/uploads/2022/11/Precipio_20191113_530PME.mp3) [ ![Precipio Logo](https://www.precipiodx.com/wp-content/uploads/2022/11/PRPO-logo-circle-transparent-300x249.png) Precipio Commercial Update Call – October 10, 2019 ](https://www.precipiodx.com/wp-content/uploads/2022/11/Precipio_20191010_500PME.mp3) [ ![Precipio Logo](https://www.precipiodx.com/wp-content/uploads/2022/11/PRPO-logo-circle-transparent-300x249.png) 2019 Q2 Shareholder Update Call – August 21, 2019 ](https://www.precipiodx.com/wp-content/uploads/2022/11/Precipio_20190821_500PME.mp3)\n\n  * [ $0.00 ](https://www.precipiodx.com/cart/ \"Cart\")\n    * Cart\n\nNo products in the cart.\n\n[ Return to shop ](https://www.precipiodx.com/shop/)\n\n  * Search for:\n\n  * [About Us](https://www.precipiodx.com/about/)\n    * [Our Culture](https://www.precipiodx.com/about/culture/)\n    * [News](https://www.precipiodx.com/about/news/)\n    * [Careers](https://www.precipiodx.com/about/careers/)\n    * [Scientific Advisors](https://www.precipiodx.com/about/scientific-advisors/)\n    * [Management Team](https://www.precipiodx.com/about/management-team/)\n    * [Board of Directors](https://www.precipiodx.com/about/board-of-directors/)\n  * [Products](https://www.precipiodx.com/products/)\n    * [Molecular Kits](https://www.precipiodx.com/products/molecular-kits/)\n      * [MPN Panel](https://www.precipiodx.com/products/bloodhound-mpn-panel/)\n      * [BCR-ABL1 Panel](https://www.precipiodx.com/products/bloodhound-bcr-abl1-molecular-panel/)\n      * [ABL1 Resistance Panel](https://www.precipiodx.com/products/bloodhound-abl1-resistance-panel/)\n      * [AML Panel](https://www.precipiodx.com/products/molecular-kits/acute-myeloid-leukemia-panel/)\n      * [CLL Panel](https://www.precipiodx.com/products/molecular-kits/cll-panel/)\n      * [Cytopenia Panel](https://www.precipiodx.com/products/molecular-kits/cytopenia-panel/)\n    * [IV-Cell Cytogenetics Media](https://www.precipiodx.com/products/iv-cell-cytogenetics-media/)\n  * [Clinical Services](https://www.precipiodx.com/clinical-services/)\n    * [Hematopathology Services](https://www.precipiodx.com/clinical-services/blood-cancer-testing/)\n    * [Sample Reports](https://www.precipiodx.com/sample-report/)\n    * [Proprietary Technologies](https://www.precipiodx.com/clinical-services/proprietary-technologies/)\n    * [Meet Our Hematopathologists](https://www.precipiodx.com/clinical-services/meet-our-pathologists/)\n  * [Resources](https://www.precipiodx.com/resources/)\n    * [FAQs](https://www.precipiodx.com/resources/faqs/)\n    * [Brochures](https://www.precipiodx.com/resources/brochures/)\n    * [Case Studies](https://www.precipiodx.com/resources/case-studies/)\n    * [Sample Reports](https://www.precipiodx.com/sample-report/)\n    * [Instructions For Use](https://www.precipiodx.com/resources/ifus/)\n    * [Instructions For Use – Non U.S. CE](https://www.precipiodx.com/resources/instructions-for-use-non-us-ce/)\n  * [Investors](https://www.precipiodx.com/investors/)\n    * [Press Releases](https://www.precipiodx.com/investors/press-releases/)\n    * [Media](https://www.precipiodx.com/investors/media/)\n    * [SEC Filings](https://www.precipiodx.com/investors/sec-filings/)\n    * [Subscription](https://www.precipiodx.com/investors/subscription/)\n    * [Investor FAQs](https://www.precipiodx.com/investors/investor-faqs/)\n    * [Corporate Governance](https://www.precipiodx.com/investors/corporate-governance/)\n    * [Business Update Calls](https://www.precipiodx.com/investors/business-update-calls/)\n  * [Contact](https://www.precipiodx.com/contact/)\n  * [My Account](https://www.precipiodx.com/login/)\n    * [![Login Icon](https://www.precipiodx.com/wp-content/uploads/2022/07/login-svgrepo-com.svg)CaseVu](https://www.casevu-lis.precipiodx.com/)\n    * [![Login Icon](https://www.precipiodx.com/wp-content/uploads/2022/07/login-svgrepo-com.svg)Shop](https://www.precipiodx.com/my-account/)\n    * [![Login Icon](https://www.precipiodx.com/wp-content/uploads/2022/07/login-svgrepo-com.svg)Patient Bill Pay](https://www.precipiodx.com/billing/)\n\n\n\n### Login\n\nUsername or email address *\n\nPassword *\n\nRemember me Log in\n\n[Lost your password?](https://www.precipiodx.com/my-account/lost-password/)\n"
        }
      ]
    },
    {
      "section_name": "Corporate Deck",
      "links": [
        {
          "title": "Corporate Deck",
          "url": "https://www.precipiodx.com/wp-content/uploads/2022/08/Precipio-2022-Corp-Presentation2.pdf",
          "content": "(NASDAQ: PRPO)\nA Cancer Diagnostics Solutions Company\n2022 Corporate Presentation\nDISCLAIMER\nThispresentationhasbeenpreparedbyPrecipioInc.(the“Company”)andisgeneralbackgroundinformationabouttheCompany’sactivitiesasofthedateofthispresentation.Byacceptingthispresentation,therecipientacknowledgesandagreesthatalloftheinformationcontainedhereinisconfidential,thattherecipientwilldistribute,disclose,andusesuchinformationonlyforsuchpurposeandthattherecipientshallnotdistribute,discloseoruse\nsuchinformationinanywaydetrimentaltotheCompany.TheinformationcontainedhereindoesnotpurporttobeallinclusiveandtheCompanynoranyofitsrespectiveaffiliatesnoranyofitsortheircontrollingpersons,officers,directors,employeesorrepresentativesmakesanyrepresentationorwarranty,expressorimplied,astotheaccuracy,completenessorreliabilityoftheinformationcontainedinthispresentation.Thispresentationdoesnot\ncontainalltheinformationthatisormaybematerialtoinvestorsorpotentialinvestorsandshouldnotbeconsideredasadviceorarecommendationtoinvestorsorpotentialinvestorsinrespectoftheholding,purchasingorsellingofsecuritiesorotherfinancialinstrumentsanddoesnottakeintoaccountanyinvestor’sparticularobjectives,financialsituationorneeds.Certainstatementsinthispresentationmayconstitute“forward-looking\nstatements”withinthemeaningofSection27AoftheSecuritiesActof1933,asamended,andSection21EoftheSecuritiesExchangeActof1934,asamended,whichinvolveknownandunknownrisks,uncertaintiesandotherfactorsthatmaycauseactualresultstobemateriallydifferentfromanyanticipated/forecastedresults,performanceorachievementsexpressedorimpliedbysuchstatements.Forward-lookingstatementsinclude,butarenot\nlimitedto,thosewithrespecttomanagement’scurrentviewsandestimatesoffutureeconomiccircumstances,industryconditions,companyperformance,financialresults,includingtheabilityofthecompanytoincreaseitspresence/impact/marketshareinthediagnosticproductsandservicesmarkets,andregulatorymatters.Theseforward-lookingstatementsarebaseduponestimatesandassumptionsthat,whileconsideredreasonablebythe\nCompanyanditsmanagement,asthecasemaybe,areinherentlyuncertain.Newrisksanduncertaintiesmayemergefromtimetotime,anditisnotpossibletopredictallrisksanduncertainties.Theknownrisks,uncertaintiesandotherfactorsaffectingtheseforward-lookingstatementsaredescribedfromtimetotimeintheCompany’sfilingswiththeSecuritiesandExchangeCommission,includingtheCompany’smostrecentAnnualReporton\nForm10-Qand10-K.Anychangeinsuchfactors,risksanduncertaintiesmaycausetheactualresults,eventsandperformancetodiffermateriallyfromthosereferredtoinsuchstatements.Factorsthatmaycauseactualresultstodiffermateriallyfromcurrentexpectationsinclude,butarenotlimitedto,variousfactorsbeyondmanagement’scontrolincludinggeneraleconomicconditionsandotherrisks,aswellasfactorsassociatedwithcompanies,\nsuchasPrecipio,thatareengagedindiagnosticsandotherresearchanddevelopmentactivitiesinthebiotechnologyindustry,includinguncertaintyinproductacceptanceand/orreceiptofregulatoryapprovalsforproductcandidates,includinganydelaysandotherimpactsfromtheCOVID19pandemic.Accordingly,theCompanyclaimstheprotectionofthesafeharbourforforward-lookingstatementscontainedintheSecuritiesActwithrespecttoall\nstatementscontainedinthispresentation.AllinformationinthispresentationisasofthedatewhenthispresentationwasprovidedtotherecipientbyPrecipioandPrecipiodoesnotundertakeanydutytoupdatethisinformation,includinganyforward-lookingstatements,unlessrequiredbylaw.Norepresentationorwarranty,expressorimplied,ismadeastothefairness,accuracyorcompletenessofthepresentationandtheinformationcontained\nhereinandnorelianceshouldbeplacedonit.Informationinthispresentation(includingmarketdataandstatisticalinformation)hasbeenobtainedfromvarioussources(includingthird-partysources)andtheCompanydoesnotguaranteetheaccuracyorcompletenessofsuchinformation.WhiletheCompanybelievesitsinternalresearchisreliable,suchresearchhasnotbeenverifiedbyanyindependentsource.Allprojections,valuationsand\nstatisticalanalysesareprovidedforinformationpurposesonly.Thecontentsofthispresentationshouldnotbeconsideredtobelegal,tax,investmentorotheradvice,andanyinvestororprospectiveinvestorconsideringthepurchaseordisposalofanysecuritiesoftheCompanyshouldconsultwithitsowncounselandadvisersastoalllegal,tax,regulatory,financialandrelatedmattersconcerninganinvestmentinordisposalofsuchsecuritiesandasto\ntheirsuitabilityforsuchinvestororprospectiveinvestorThispresentationanditscontentsareconfidentialandproprietarytotheCompany,andnopartofitoritssubjectmattermaybereproduced,redistributed,passedon,orthecontentsotherwisedivulged,directlyorindirectly,toanyotherperson(excludingtherelevantperson’sprofessionaladvisers)orpublishedinwholeorinpartforanypurposewithoutthepriorwrittenconsentoftheCompany.\nPage 1\n2202 .v 6eR\n-0\nMarket problem\nDiagnostic errors cost $750B*\nannually in the US market\nAnd countless lives.\nPage 2\n* Patient Safety Learning White paper publication by PinnacleCare\nCompany Vision\nCreating clinically significant,\ncost-effective cancer diagnostic\ntechnologies to eliminate\nlaboratory errors\nPage 3\nUnique Business Model\nSolving Clinical, Operational, & Economic Challenges for Diagnostic Laboratories\nClinical Laboratory R&D\n• Precipio identifies clinical and • Collaborates with the\noperational challenges clinical laboratory\n• Facilitates the development, • Develop & test new\ntesting and implementations technologies clinically and\nof new technologies operationally in the lab\nPipeline\nProduct Product Product\nProduct\ncommercializati\non\nCommercialization Commercialization Commercialization\nPage 4\nHemescreen™ - Molecular Assays solving economic, workflow, & accuracy deficiencies\n(patent pending)\nSolution\nCommercial status\nTAM\nA set of proprietary\n5 commercial panels\nreagents using a $500M in the US\n3 panels in development\nsingle-platform, $1B worldwide\nYE2021 RR: ~$2M\ndelivering faster and\nest. 25% QoQ growth\nmore accurate\nresults\nPage 5\nHemeScreen delivered benefits to a large customer in Florida\nCase Study\nHemeScreen Benefits\n18 days TAT (send-out) reduced to\nTurnaround Time (TAT)\n1-2 days (in house)\nBroad panel enables more precise, targeted treatments\nPatient Impact\nShorter TAT drives a faster response and better patient care\nCustomer Economics Zero revenues, to ~$1M/year in operating profit\n(currently one panel only)\nPage 6\nIV-Cell™ Cytogenetics Cell Culture Media\nDelivering improved accuracy, operational simplicity and cost benefit\nSolution\nTAM Commercial status\nA proprietary media (chemical)\n$100M in the US Products for hematologic cancers\nused to simultaneously culture\n$250M worldwide available. Products for prenatal\nmultiple types of suspected\ntesting under development.\ncancer cells, eliminating\nMedia is commercial and being\ndiagnostic errors due to pre-\nused by several laboratories\nselection\n2022 RR: < $1M\nPage 7\nChannel Distribution Strategy\nLeveraging existing channel distributors\nBenefits:\nRapid direct access to target market Reduces time to market Avoids costly sales team\nHemeScreen Segments: IV-Cell Segments:\n70%\n5%\n10% 90%\n25%\nTAM: TAM:\n$500M US $100M US\n$1B Globally $250M Globally\nReference laboratories Reference laboratories\nHospital laboratories Academic center laboratories\nPhysician owned laboratories\nPage 8\nR&D Product Pipeline\n2 examples\nClinical Lab R&D\nProduct 3: QNS Product 4: Cancer MRD\nProduct Enriches target DNA in samples to A novel technology enabling accurate assessment\ndescription significantly reduce biopsy rejection rate of Minimal Residual Disease on limited samples\nTAM $0.5B Annually $3B Annually\nDevelopment\nIn process – expected completion Q1-2023 In process – expected completion Q2-2023\nStatus\nPage 9\nManagement Team\nIlan Danieli, Chief Executive Officer Keith Meadors, Sr. VP of Products Division\nHaving served asco-founder and CEO since2011, Ilan bringsover 25yearsof Keith Meadors has 38+ years of sales, marketing, leadership, and laboratory\nexperience managing small and medium-size companies. Past experiences diagnostics experience. Previously, Keith was VP of Sales & Marketing at Fresenius\nincludeCOOofOsiris,VPofOperationsatLaurusCapitalManagement,amulti KabiandheldseveralrolesatHospiraandBectonDickinsonDiagnostics. Keithhasan\nbillion-dollarhedgefund,aswellasinvariousotherentrepreneurialventures. MBAfrom TexasChristian University and hascompleted Medical Technology training\nat Rex Hospital School of Medical Technology. He holds Executive Certificates in\nLeadership,Sales,&MarketingManagementfromKelloggandisASCPBoardCertified.\nMatt Gage, Interim Chief Financial Officer Ahmed Zaki Sabet, Chief Operating Officer\nMattwasappointedtoInterimChiefFinancialOfficerofPrecipio,Inc.inMarch\nZaki has been the Company’s Chief Operating Officer since inception as its co-\n2022.HeservedasDirectorofFinancialReportingandAnalysisofPrecipio,Inc.\nfounder. He holds over 15 years of experience in laboratory management spanning\nsince joining the Company in June 2017 following its acquisition of\nallfieldsofreferencelaboratoryoperationsprimarilyfocusingoncancerdiagnostics.\nTransgenomic Inc., where Matt was the Director of Financial Reporting and\nPrior to Precipio, Zaki has served as a consultant with the College of American\nAnalysissince2014.Matthasover30yearsofexperienceincorporatefinance\nPathologists (CAP) for many years as well asseveral diagnostic companies in setting\nforprivateandpubliccompanies.\nuptheirspecializedcancertestingoperations.\nAyman Mohamed, MD, Chief Technology Officer\nMiri Chiko-Radomski, Legal Counsel, Chief People Officer\nAsco-founderofPrecipio,AymancurrentlyservesasthecompanyCTO,aswell\nMiri is an advocate with extensive international legal experience from Sweden,\nasthelaboratory’sTechnicalDirector.Inthisdualrole,Aymanisresponsiblefor\nEngland and Israel specializing in advising on equity capital markets matters,\nthe entire process from conceptualization and invention of proprietary\ngeneralcorporatematters,corporaterestructurings,corporategovernance,day-to-\ntechnologies for Precipio. Prior to Precipio, Ayman served in various technical\ndaysecuritieslawandcompanylawissuesandM&Atransactions.\nand research positions in both commercial diagnostic companies as well as\nacademiccenterssuchasColumbiaandYaleUniversities.\nPage 10\nBoard Of Directors\nRichard Sandberg, Chairman of the Board Ronald Andrews, Director\nRichard is a seasoned diagnostics executive with a substantial track record in Ronnie is a seasoned diagnostics executive who is currently CEO of Oncocyte\nfield. Having served and acted in multiple roles at Dianon Systems, Inc., a (NASDAQ: OCX). Ronnie brings a wealth of experience in the diagnostics world,\ndiagnosticscompanythatwasacquiredbyLabCorpfor$650M,alongwithOxford andspecificallyintheareasofproductdevelopment&commercialization.Someof\nImmunotec, acquired by PerkinElmer for $550M, his depth and expertise is a his past experiences includes CMO at Roche Molecular; President of Genetic\ntremendousvaluetothePrecipioteam. Science Division at Thermo Fisher Scientific; President of the Medical Sciences\nVenture at Life Technologies Corporation; and CEO of Clarient, which was\nacquiredbyGEHealthcarefor$580Min2010.\nJeffrey Cossman, MD, Director Kathy Laporte, Director\nJeffrey is a Hematopathologist and former Chair of Pathology Department at Kathy brings over 30 years of experience as a venture and angel investor and\nGeorgetownUniversity.HewastheCEOandChairmanatUnitedStatesDiagnostics builder of healthcare technology companies. She has extensive Board experience\nStandard Inc. and is a co-founder of the Association for Molecular Pathology and currently serves on the Boards of Bolt Biotherapeutics (NASDAQ: BOLT), and\n(AMP). His career path includes: CSO and director of The Critical Path Institute, Phoenix Biotech Acquisition Corporation (NASDAQ: PBAXU). Additionally, she has\nMedical Director of Gene Logic, Inc. He also served as Senior Investigator in served on multiple boards including Onyx Pharmaceuticals (NASDAQ: ONXX),\nHematopathology at the National Cancer Institute. He is currently a medical Affymax(NASDAQ:AFFY),andISTAPharmaceuticals(NASDAQ:ISTA).\nadvisortoEpigenomicsAG.\nDouglas Fisher, MD, Director\nDavid Cohen, Director\nDoug is currently a Partner at Revelation Partners, and joined the healthcare team\nDavid is currently the EVP and co-owner of Standard Oil of Connecticut, Inc., the\nfocusing on biopharmaceutical, diagnostic & medical device investments for\nlargest independently-owned energy retailing company in Connecticut. David has\nInterWest Partners, a venture capital firm. Doug served as Vice President of New\nalsofoundedanumberofhighlysuccessfulventures,includingMyGeneCounsel,a\nLeaf Venture Partners LLC, a private equity and venture capital firm, and prior to\ncancer bioinformatics company. David currently serves on the boards of the\njoining New Leaf, he was a project leader with The Boston Consulting Group, Inc.,\nfollowing companies: eBrevia, Emme Controls, My Gene Counsel, Sirona Medical\nwherehewasamemberoftheHealthCarePracticeArea.\nTechnologies,andThePlatt&LaBoniaCompany.\nPage 11\nSummary\nEstablished R&D Two commercially Revenue-generating Robust R&D pipeline\nplatform to develop available, revenue clinical lab creates a of impactful cancer\npractical, efficient generating products self-funded R&D diagnostic products,\ndiagnostic solutions center each with billion\ndollar TAMs\nFor more information please contact:\nIlan Danieli, CEO\nPrecipio, Inc. (NASDAQ: PRPO)\nidanieli@precipiodx.com\nTel: 203.787.7888 ex. 536 Page 12"
        }
      ]
    }
  ]
}